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Summary
This research has investigated the role of CD28 in T cell activation. These 
studies have clearly demonstrated that CD28 plays a major role in providing 
signals to T cells which in conjunction with the T cell receptor (TCR) result 
in interleukin -2 (IL-2) production and T cell proliferation. Kinetic analysis 
revealed that costimulatory signals through CD28 are required within 6 hours 
of TCR engagement and T ceils were unresponsive after this time. The surface 
expression o f CD28 was found to be downregulated following ligation by 
CD80 but was re-expresssed following T cell activation. CD28 ligation by 
CD80 on previously activated T cells resulted in augm ented T cell 
proliferation suggesting that CD28 signalling may prolong and/or enhance T 
cell responses, however this enhancement did not appear to involve IL-2 
production.
S tudies o f CD28 s ignalling  was found to involve the enzym e 
phosphatidylinositol 3-kinase (PI3-kinase) and inhibition o f this enzyme by 
wortm annin prevented IL-2 production and T cell proliferation. This 
inhibitory effect was not due to inhibiting IL-2R signalling. In contrast, the 
augmented proliferation by previously activated T cells, in response to CD28 
ligation was found be insensitive to wortmannin suggesting PI3-kinase was 
not required.
Comparison of the functional effects o f the two CD28 ligands, CD80 and 
CD86  showed that both ligands could costimulate T cell proliferation in 
conjunction with an anti-CD3 mAb and similarly both ligands augmented 
proliferation of activated T cells. These studies highlight the role of CD28 in T 
cell function and suggest that signals through CD28 may differ depending on 
the state of T cell activation.
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The ability of an organism to defend itself from infectious attack is essential 
for its survival. Defence mechanisms can operate at a number of different 
levels with the key component being the immune system. The first line of 
defence is the skin and other, mainly internal, surfaces which act as a barrier to 
invasion by potentially toxic substances/organisms. The next level of 
protection is the innate immune system made up of phagocytic cells which can 
engulf and eliminate any foreign substances (harmful or not) they come into 
contact with. The most sophisticated defence mechanism is the acquired 
immune system which is capable of detecting and destroying foreign invaders 
o f the host but which has a memory component to ensure future attacks are 
repelled more quickly. The complexity of the immune system ensures that an 
appropriate response both in intensity and duration is mounted against 
potential pathogens.
Unfortunately the immune system is not foolproof and there are many 
examples of diseases which involve its malfunction. The most obvious are the 
autoimmune diseases such as rheumatoid arthritis and multiple sclerosis where 
one of the clinical symptoms is the attack of healthy host cells by their own 
immune system. Other diseases, such as cancer, show the immune system 
failing to detect and subsequently destroy infected/abnormal cells. Sometimes 
even the immune system is unable to protect itself, as in Acquired Immune 
Deficiency Syndrome (AIDS) where CD4 T cells are the target cells o f the 
human immunodeficiency virus (HIV) virus. An efficiently functioning 
immune system can also, in exceptional circumstances, be deleterious. For 
example, tissue/organ transplantation is often used to prolong the survival of 
an individual. However, an efficient immune system will reject the foreign 
tissue counteracting the benefits gained by the surgical intervention.
All the above diseases/disorders have a common factor - an inappropriately 
functioning acquired immune system. By determining how the acquired 
immune system functions under normal circumstances it may be possible to 
use the knowledge gained to manipulate the immune system. Immunotherapy 
could then be used as a potential treatment of such diseases. However 
determining how the highly complex acquired immune system functions 
normally is an immense task.
The acquired immune system can mount an appropriate response both in terms 
of duration and intensity depending on the seriousness of the attack on the 
organism. It is this ability to determine the correct response to individual
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circumstances which makes this a highly complex defence system requiring 
tight control mechanisms to ensure proper functioning. However only a few 
different types of cells are involved - T lymphocytes (T cells), B lymphocytes 
(B cells) and a number of different antigen presenting cells (APCs) such as 
monocytes/macrophages and dendritic cells. All these cells have different 
functions and interactions between these cells are required to ensure a 
successful response by the immune system.
The ability to recognise foreign antigen is a function of both B cells and T 
cells. B cells are able to recognise foreign antigen directly via the specific 
antibody expressed on the B cell surface. In contrast T cells require interaction 
with antigen presenting cells which display foreign antigen on their surface for 
recognition to occur. There are also interactions between T cells and B cells 
with B cells requiring "T cell help" to mount a full B cell immune response. 
Since the aims of this research were to study the role of CD28 in T cell 
activation, the role of B cells in the immune system will not be considered 
further.
T lymphocytes and their receptors.
T cells play an important role in the acquired immune response by being able 
to recognise foreign antigen and initiate a cascade of events which results in 
the elimination of the antigen (Ashwell, 1990). It is essential that T cells 
perform their recognition function correctly. Failure to detect a foreign 
pathogen or recognition of a self antigen could have deleterious consequences. 
How T cells function under normal circumstances is still the subject of 
research but considerable information is available about T cell recognition of 
foreign antigen.
The T cell receptor (TCR).
(reviewed by Ashwell, 1990; Lefranc, 1990)
The site of foreign antigenic recognition on T cells is the T cell receptor 
(TCR) which is a heterodimeric structure of disulphide linked a  and p chains 
(or 8 and y chains in approximately 3% of T cells) with a single antigen 
recognition site (Figure 1.1a). The overall structure of the TCR on each T cell 
is similar but the TCR on an individual T cell has its own unique antigen
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binding specificity. In order to generate these two requirements (similar 
overall structure but unique binding site) the a  and P chains of the TCR are 
encoded by a number of genes. The constant region genes are responsible for 
the overall similarity in structure of the TCR. The variable and junction genes 
are responsible for generating the unique binding site of the TCR. The number 
of variable and junction genes for each of the TCR chains is large (60 variable 
genes and 15 junction genes for the P chain and 80 variable and 80 junction 
genes for the a  chain) (Wilson et al., 1988, Lai et al., 1988). The various 
combination of these genes for each chain (approximately 1500 for the P chain 
and 6400 for the a  chain) and the combinations of a  and p chains which can 
associate will generate a large range of TCRs with different antigen binding 
sites. However the overall diversity of the TCR required to ensure that all 
potential antigens can be recognised could not be generated solely by the 
different combinations of these genes. Additional diversity is generated by 
variable splicing of the junction and variable genes.
The TCR does not exist in isolation on the T cell surface. It is associated non- 
:ovalently with a number of invariant chains ( y, 6 , e, £ and rj ) which make 
jp  the CD3 complex (Figure 1.1b) (Clevers et al., 1988). Although all these 
:hains are associated with the TCR they play no role in determining antigen 
specificity - this is determined by the a p  chains. However the CD3 complex 
loes have an important role to play in T cell function - it is essential for 









Figure 1.1. T cell receptor structure.
a) The TCR consists of a heterodimeric structure of disulphide linked a  and p 
chains composed of constant, junction and variable domains.
b) The TCR/CD3 complex comprises the TCR non-covalently linked to at 
least four different invariant chains.
(From Lefranc 1990).
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Unlike B cells, T cells are unable to interact directly with antigen - the foreign 
antigen must be "presented" to them by antigen presenting cells (Grey and 
Chesnut, 1985). It is essential that T cells only interact with foreign antigen 
and do not generate an immune response to self antigens. An understanding of 
how APCs process and present antigen on their surface has provided insights 
into how T cells are able to distinguish between foreign and self antigens.
Antigen processing and presentation
The interaction between T cells and APCs requires both cells to come into 
close contact to allow the TCR of the T cell to recognise the foreign antigen 
expressed on the surface of the APC. As the foreign antigen may be large, this 
close contact is achieved by the APCs engulfing the foreign antigen, 
processing it internally, and displaying antigenic peptide on their surface. In 
order for the T cell to be able to recognise "foreign" antigens it has to be able 
to recognise " self'. This is achieved by the TCR of the T cell interacting with 
an antigen-Major Histocompatibility complex (MHC) complex on the surface 
of the APC.
MHC molecules are important surface markers which identify all host cells 
as "self". There are two types of MHC molecules, involved in antigen 
presentation, known as Class I and Class II (Hood et al., 1983). The 
distribution of these molecules is distinct with Class I found on all nucleated 
cells whereas MHC Class II is restricted to APCs and induced on activated T 
cells. Both Class I and Class II MHC molecules are each composed of two 
polypeptide chains (a  and P) which show some sequence homology but 
have major differences in their structure. In Class I MHC molecules the a  
chain is much larger (molecular weight of 44kDa) than the P chain (known as 
p2 - microglobulin with a molecular weight of 12kDa) whereas the a  and P 
chains in Class II MHC molecules are similar in size (molecular weights of 34 
and 29 kDa respectively). However both MHC molecules have a similar 3- 
dimensional structure composed of two alpha helices above a beta pleated 
sheet with a cleft being formed between the alpha helices (Bjorkman et al., 
1987a; Bjorkman et al., 1987b; Brown et al., 1988). It is within this cleft that 
antigenic peptide binds and is presented for recognition by T cells. The size of 
this cleft differs between Class I and Class II MHC molecules with the cleft in 
Class I MHCs being "closed" at both ends whereas in Class II MHCs one end 
is "open". This difference affects the ability of the two types of MHC to bind
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antigenic peptide - with MHC Class I binding peptides of 8 -10 amino acids 
whereas MHC Class II can bind larger peptides (15 - 24 amino acids) 
(Bjorkman et al., 1987a; Bjorkman et al., 1987b; Brown et al., 1988).
The antigenic peptides presented in Class I and Class II MHCs differ both in 
the source of the antigen and in the processing of the antigen to form peptides. 
Antigens presented in the context of MHC Class I molecules are derived from 
endogenous sources and are degraded by the large multifunctional proteinase 
(LMP) complex. The resulting peptides are delivered to the transporter 
associated with antigen processing (TAP) complex in the endoplasmic 
reticulum (ER) which transports them into the ER lumen where they bind to 
MHC Class I molecules and are exported to the cell surface ( reviewed by 
Monaco, 1992). The peptides presented on MHC Class II are derived from 
extracellular sources and are endocytosed and degraded within endosomes and 
lysosomes. The MHC Class II molecules are synthesised within the ER but do 
not bind endogenous antigenic peptide (which is presented in the context of 
MHC Class I molecules) due to the presence of the invariant chain which 
loosely associates with the MHC a  (3 heterodimer. Binding of the peptide 
occurs somewhere on the endocytic processing pathway and may differ 
depending on the cell type (reviewed by Neefjes and Ploegh, 1992).
As the TCR on the T cell interacts with both the MHC molecule and the 
antigen presented within the MHC, T cells are able to distinguish between 
cells which express "self' MHC containing self peptide and those expressing 
either foreign antigenic peptide within the self MHC or totally foreign cells 
which express "non-self MHCs (as in organ transplantation) and respond 
appropriately. This ability of T cells to respond only to the presence of 
foreign antigen (either foreign antigenic peptide within self MHC or foreign 
MHC molecules) is a result of selection of T cells during development. The 
selection process results in the development of T cells which can recognise 
self MHC but are not self-reactive. The exact mechanism of this selection 
process is still being determined but considerable insight into the selection 
process during T cell development has been achieved.
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T cell development.
(reviewed by Nikolic-Zugic, 1991).
T cells play a crucial role in the recognition of foreign antigen and the 
initiation of a cascade of events which eventually result in the destruction of 
the foreign pathogen. It is essential that the T cells which develop in the 
thym us and are transported to the periphery to carry out their 
immunosurveillance task are capable of detecting foreign antigens and are not 
self reactive. Failure of the selection process during T cell development could 
have disastrous consequences - pathogens which were not recognised could 
cause major damage and recognition of self antigens could result in an 
inappropriate immune response to host cells.
T cell development is a complex process in which more than 90% of the 
thymocytes are eliminated and do not mature into T cells. The T cell 
precursors are transported from the bone marrow to the thymus where a 
developm ental process occurs. The most critical event in thymocyte 
maturation is the expression of the TCR which will recognise a specific 
antigen in the context of either MHC Class I or Class II. The co-receptors CD4 
and CD8 are also both expressed on the thymocytes which are subject to 
intrathymic selection.
As the TCR is generated by random rearrangements of the numerous constant 
and variable genes of the a  and p chains as well as variable splicing of these 
genes, the number of potential TCRs produced is enormous. Some of the 
TCRs generated may not be functional and some may be self - reactive. It is 
essential that thymocytes bearing these TCRs are eliminated. Although the 
exact mechanism of T cell selection is unknown it is thought to occur in two 
distinct stages - positive and negative selection - which occur in different 
regions o f the thymus.
Positive selection is thought to occur via the cortical epithelial cells within the 
thymus which express an MHC - peptide complex. As the TCR expressed on 
each thymocyte will only recognise a specific MHC - peptide complex, it 
seems likely that only those thymocytes which recognise and bind to a 
particular MHC - peptide complex expressed by the cortical cells will be 
positively selected (Lo & Sprent 1986, Benoist & Mathis 1989). Those 
thymocytes which are unable to recognise and bind to a specific MHC-
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peptide complex or do not express a functional TCR will be rejected and 
undergo programmed cell death (apoptosis).
Negative selection is thought to occur in the medulla of the thymus where the 
thymocytes interact with haemopoetic and possibly medullary epithelial cells 
(Lo & Spent 1986, Benoist & Mathis 1989). The T cells again interact with 
MHC - peptide complexes which may not necessarily be the same as during 
positive selection. Due to the specificity of the TCR for a particular MHC - 
peptide complex an inappropriate interaction with an another MHC - peptide 
complex or a high affinity interaction with the correct MHC- peptide complex 
is thought to lead to clonal deletion (Smith et al., 1989). This selection process 
which results in the elimination of self-reacting T cells is known as central 
tolerance.
The expression of CD4 and CD8 on the developing T cells is also considered 
to be involved in T cell selection. The differentiation of the developing 
thymocytes into either CD4 or CD8 T cells occurs in the thymus. There are 
two models of selection - the instructive model and the selective model. The 
instructive model suggests that the MHC restriction of the TCR expressed on 
the developing thymocyte determines the function of the T cell. This is 
thought to occur early in positive selection when the thymocyte expresses 
both CD4 and CD8 . The extraneous CD4 or CD8 receptor is switched off 
following interaction of the thymocyte with a thymic stromal cell bearing the 
appropriate MHC restriction. The selective model suggests that positive 
selection occurs later when the thymocytes express either CD4 or CD8 . 
Thymocytes only continue to develop if they interact with their appropriate 
thymic stromal cells with both the TCR and the correct co-receptor. There is 
evidence to support both models of selection and research suggesting that 
both processes may be involved (Chan et al., 1993).
Although the exact mechanism of T cell selection is still to be elucidated, the 
end result of T cell development in the thymus is the production of mature T 
cells. These T cells are then transported to the periphery where they carry out 
their immunological surveillance functions. A critical component of the 
immunosurveillance function of peripheral T cells is recognition of foreign 
antigens. This involves recognition of the foreign antigen presented by the 
MHC on the surface of the APC by the TCR of the T cell. The interaction 
between the TCR on the T cell and the MHC-antigen complex on the APC 
will now be examined.
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TCR - MHC-antigen interactions
The interaction between the MHC/peptide complex and the TCR usually 
results in the antigenic fragment within the MHC cleft interacting with both 
the TCR a  and P chains. As the number of T cells with the specific TCR 
recognition site for each antigen will be small, this will lead to a low 
frequency response - approximately 1 in 10,000 T cells will respond (Davis 
and Bjorkman, 1988). However there are occasions when a large T cell 
response can be generated. This occurs when "superantigens" (e.g. 
staphylococcal enterotoxins) are presented by the MHC to the T cells. The 
ability of "superantigens" to generate a large immune response is due to the 
way they bind to the MHC molecules and their interaction with the TCR. The 
superantigen is not processed by the APC to produce antigenic peptide - the 
whole protein binds to the MHC, probably to the outer surface and not in the 
normal binding cleft. This results in the interaction between the MHC/antigen 
complex and the TCR/CD3 complex occurring primarily with the VP region of 
the TCR (Dellabonna et al., 1990). The superantigen can therefore interact 
with all the TCRs bearing the appropriate VP region regardless of their other 
components. As there are a limited number of VP elements, this interaction 
results in a large proportion (5% - 40%) of the total T cell population being 
stimulated (Janeway et al., 1989).
CD4 T cells play an essential role in the initial recognition of foreign antigenic 
peptide. Interaction between the CD4 T cells and APCs results in the 
transcription of over 100 genes in the 2-3 weeks duration of the immune 
response (Ullman et al., 1990). The stimulation of CD4 T helper (Th) cells 
results in their differentiation into two distinct sub populations - Type 1 Th 
(T h l)  and Type 2 Th (Th2) cells each of which produces its own set of 
cytokines and mediate separate effector functions. (Mosmann and Coffman, 
1989; Seder et al., 1994). Thl cells produce IL-2 and also y-interferon which 
leads to the activation of granulocytes and macrophages and the induction of 
their phagocytic activity. Th2 cells produce cytokines such as interleukin - 4 
(IL-4), interleukin - 5 (IL-5) and interleukin - 10 (IL-10) which stimulate 
production of mast cells and eosinophils and in conjunction with antigen 
activate B cells to proliferate, differentiate and produce immunoglobulin. This 
activation of the immune defence system results ultimately in the destruction 
of the foreign antigen and the attainment of immunological memory so that if 




Activation of T cells can only occur if sufficient TCRs on the cell surface 
become occupied with antigen. Antigen independent assistance given by a 
number of surface molecules on T cells is essential to establish contact 
between the T cells and the APCs (Figure 1.2). This adhesive function is 
necessary to bring the plasma membranes of the two cells in close contact. It 
also allows the T cell time to bring the TCR (by membrane diffusion) into 
contact with the antigen/MHC complex which may be present at low 
concentrations and stabilises this low affinity interaction (Makgoba et al.,
1989). It has been demonstrated using human cytolytic T lymphocytes (CTL) 
that antigen -independent adhesion precedes antigen-specific recognition and 
T cell activation. By using blocking mAbs, it was possible to show that such 
adhesion is regulated by the cell surface molecules CD2, LFA-3 (CD58) and 
LFA-1 (CD1 la/18) (Shaw et al., 1986).
CD2/CD58
CD2 is found on 95% of all T cells and its ligand CD58 is widely expressed. 
There is the possibility of a second ligand for CD2, as two mAbs are required 
to stimulate CD2 (Olive et al., 1986). It has been shown that CD59 which is 
widely expressed on both haemopoetic and non-haemopoetic human cells 
can bind to CD2 and may act as a second ligand for CD2 in humans (Hahn et 
al., 1992) whereas in mice CD48 has been identified as the possible second 
ligand (Kato et al., 1992). CD2 has been shown to stimulate T cells in 
conjunction with a primary signal via the TCR using monoclonal antibodies 
(mAbs) to CD2 or LFA3- Ig chimeric molecules to stimulate the CD2 on T 
cells (Carrera et al., 1988, Damle et al., 1992). However closer examination of 
the T cells stimulated by CD2 (in conjunction with TCR stimulation) showed 
that the T cells were predominantly memory cells and not naive T cells. CD2 
may play a role in restimulation of T cells and not the primary activation of 
naive T cells. This may be due to the way CD2 signals. CD2 itself has no 
intrinsic signalling mechanism and has been shown to signal via the £ chain of 
the TCR/CD3 complex (Howard et al., 1992). Activation of CD2 using either 
crosslinked CD58/Ig fusion proteins or anti-CD2 mAbs results in 
phospholipase Oyl (PLC) tyrosine phosphorylation and increased intracellular 
calcium concentrations (Kanner et al., 1992). This augmentation of the TCR 
signalling mechanism may be able to activate memory T cells but may be 
insufficient to fully activate naive T cells .
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LFA-1/ICAM1
LFA-1 (CD 11 a/CD 18) has also been shown to be involved in adhesion 
between T cells and APCs. There are three known ligands for LFA-1 i.e. 
ICAM -1(CD54), ICAM-2 (CD102) and ICAM-3 (CD 50) (M arlin and 
Springer, 1987; Fawcett et al., 1992). Interactions between LFA-1 and ICAM- 
1 have been shown to provide costimulatory signals which synergise with that 
provided via the TCR/CD3 complex (van Noesel et al., 1988; Van Seventer et 
al., 1992). However, as ICAM-1 is expressed at low levels on resting white 
blood cells, this interaction may not play a major part in T cell activation. 
ICAM-3 on the other hand is constitutively expressed on all leukocytes with 
the highest concentrations of mRNA found in antigen presenting cells such as 
monocytes/macrophages and B cells. As ICAM-3 is closely related to ICAM- 
1, with key residues in the LFA-1 binding site being conserved, it may be that 
ICAM-3 /LFA-1 interactions have an important role to play in T cell 
activation (Fawcett et al., 1992). However there is some evidence to suggest 
that LFA-l/ICAM -1 and CD2/LFA-3 may be able to augment cytotoxicity by 
CD8 CTLs (de Waal Malefyt et al., 1993) and so play a role in the effector 
rather than the initiation phase of the immune response.
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Figure 1.2 T Cell -APC Interaction
The interaction between the TCR on T cells and the MHC-antigen complex 
appears to involve other cell surface molecules such as CD2, LFA-3 and LFA- 
1 which help increase adhesion between the two cells and aid the TCR - MHC 
interaction. There is evidence to show that TCR only signalling in response to 
MHC-antigen ligation is insufficient to activate T cells and initiate T cell 
proliferation. This inability of T cells to respond to TCR only signalling can be 
beneficial to the individual as a means of controlling potentially inappropriate 
T cell responses. This is known as peripheral tolerance.
Peripheral tolerance
Although it is essential that the T cells circulating in the periphery are capable 
of detecting foreign antigen and are not self reactive, the selection process that 
takes place during T cell development in the thymus is not foolproof. Failure 
of this selection process can be seen by the presence of auto-reactive T cells in 
auto immune diseases and by the failure of T cells to detect cancerous cells 
which often express inappropriate antigens on their surface.
Because of the large number of TCRs produced by TCR gene rearrangements, 
it is likely that some of the TCRs will be able to recognise self antigens 
despite thymic selection. Mechanisms for switching off these self-reacting T 
cells are known as peripheral tolerance. Evidence for the existence of 
peripheral tolerance has been demonstrated using transgenic mice with thymic 
defects in negative selection during T cell development. Lack of negative 
selection would result in the generation of autoreactive T cells but the mice 
showed no overt signs of autoimmunity (Amakawa et al., 1996). However 
when transgenic mice with defective peripheral tolerance mechanisms were 
examined the mice died as a result of autoimmune syndromes (Sadlack et al., 
1995, Tivol et al., 1995 and Parijs et al., 1996). Thus peripheral tolerance may 
be a major mechanism for controlling self-reactive T cells.
There are both in vitro and in vivo models for peripheral tolerance. Studies by 
Jenkins & Schwartz (1987) used an in vitro model of T cell tolerance to 
examine IL-2 driven proliferation of CD4 T cells clones in response to 
antigenic peptide presented by syngeneic APCs. If the APCs were pre-treated 
with chemical fixative prior to presentation of the antigenic peptide the T cell 
clones became unresponsive (anergic). This suggested that the fixed APCs, 
although able to present the antigenic peptide to the T cell clones, were unable
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to provide all the necessary signals required for T cell activation. This would 
suggest that self-reactive T cells which interact with self antigen on cells 
which could not provide all the required stimuli for T cell activation (i.e. non 
professional APCs) could be tolerised. The induction of anergy in T cells 
given insufficient stimuli has also been demonstrated using anti-CD3 mAbs 
only to stimulate T cells. The T cells were found to be insensitive to 
restimulation (Wolf et al., 1994).
In vivo evidence for peripheral tolerance has been demonstrated in mice 
(Ramensee et al., 1989). Most murine T cells that express the V p6 TCR gene 
segment are reactive against the M is-la antigen. M is-lb  mice were made 
unresponsive to M is-la  antigens following intravenous immunisations of the 
M is-la  antigen. It was thought that as the M is-la antigen was found on resting 
B cells in the Mis - lb  mice, the Mls-Ia antigen was presented to the T cells by 
the B cells , a non- professional APC. The unresponsiveness of the M is-lb  
mice was not due to clonal deletion of T cells expressing V p6 TCRs but was 
due to anergy of the normally reactive Vp6 TCR expressing T cells. The lack 
of sufficient stimulatory signals by the APCs resulting in peripheral tolerance 
of T cells suggests that T cell interactions with APCs require additional 
stimuli to those produced by TCR-MHC interactions.
Induction of anergy in T cells by TCR only stimulation is not the only possible 
outcome of insufficient stimulation of the T cells. Clonal deletion is also 
possible following TCR only stimulation. In vitro studies using superantigens 
such as staphylococcal entertoxin B (SEB) have shown that clonal deletion of 
SEB- specific murine thymocytes and murine peripheral T cells occurred in 
response to stimulation by SEB (D'Adamio et al., 1993). However not all the 
SEB specific T cells were deleted and those remaining SEB-specific T cells 
could proliferate in response to SEB. Human thymocytes and peripheral T 
cells have also been shown to undergo activation induced cell death 
(apoptosis) when stimulated through the TCR using SEB in the absence of 
accessory cells (Groux et al., 1993). Apoptosis has also been demonstrated in 
T cell lines using superantigens (Damle et al., 1993). This activation induced 
cell death could be inhibited by the use of mAbs to LFA-1. The T cells used in 
this case had already been primed with antigen and the induction of apoptosis 
occurred when the cells were restimulated with superantigens. This suggests 
that this may be a mechanism for preventing repeated stimulation of T cells 
and allowing an immune response to subside. The blocking of apoptosis using 
mAbs to LFA-1 suggests a role for LFA-1 in the control of the immune
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response. In vivo data using mice have also shown that superantigens are able 
to induce apoptosis (Wahl et al., 1993). As in the in vitro experiments, the 
initial clonal deletion of T cells was followed by clonal expansion of the 
remaining superantigen - specific T cells.
The results of all these experiments suggest that TCR interaction with MHC- 
antigen complexes on APCs can induce three possible outcomes - T cells are 
rendered unresponsive, the T cells undergo programmed cell death (apoptosis) 
or T cells can be activated if sufficient signals are supplied i.e. the T cells are 
costimulated.
CD28 and T cell costimulation
Peripheral tolerance is a way of ensuring that self -reactive T cells can be 
inactivated and the potentially deleterious consequence of their activation is 
prevented. However peripheral tolerance also gives an insight into the signals 
required for T cell activation. TCR only signalling has been shown to result in 
either anergy or programmed cell death for the T cells. This suggests that for T 
cells to be activated additional signals are required. The induction of anergy 
by using chemically fixed APCs demonstrated by Jenkins & Schwartz (1987) 
suggested that the APCs could no longer provide all the signals required for 
T cell activation even though they could still present antigen to the T cells. 
Without costim ulatory signals the T cells were not activated and as a 
consequence the T cells were unable to clonally expand and generate the 
signals required to activate the other components of the immune response. As 
induction o f T cell proliferation is a key feature of the initiation of an immune 
response, the costimulatory signals required to induce T cell activation are a 
critical component of the initiation phase of an immune response.
Although other surface molecules (e.g. CD2, CD58) have been shown to 
provide help to T cells by increasing adhesion between the T cells and the 
APCs they are unable to provide the necessary costimulatory signals for T 
cell activation. However there is evidence that CD28 which is expressed on 
the T cell surface is able to provide the necessary costimulatory signals for T 
cell activation. Before examining the evidence for CD28 involvement in T cell 
activation, a review of the data known about CD28 and its ligands will be 
given.
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The CD28 family of receptors
There are two known members of the CD28 " family" of receptors - CD28 and 
CTLA-4. Both receptors have been cloned and analysed in some detail at both 
the DNA and protein level. The genes for both receptors are closely linked on 
human chromosome 2 (2q33-34) and share the same genomic organisation, 
suggesting a common evolutionary origin (Harper et al., 1991). However there 
is only 30% homology between the genes.
CD28 is a homodimer composed of two glycosylated 44kDa chains and is a 
member of the immunoglobulin superfamily. Each chain contains a single 
disulphide - linked extracellular "Ig - like" domain linked via transmembrane 
region to a short cytoplasmic tail of 41 amino acids (figure 1.3) (Aruffo and 
Seed 1987). This cytoplasmic domain is thought to be responsible for 
generating costimulatory signals.
CTLA-4 is also a disulphide - linked homodimer comprising two glycosylated 
20kDa chains. The single disulphide- linked extracellular domain is linked via 
a short amino acid stretch to a transmembrane region and short cytoplasmic 
domain of 36 amino acids (figure 1.3) (Linsley et al., 1991b). Although there 
is 100% conservation between the cytoplasmic domains of mouse and human 
CTLA-4 , suggesting a strongly conserved function, homology between 
human CD28 and CTLA-4 is as low as 30% (Harper et al., 1991). This 
suggests the possibility that the signals generated by these two receptors are 
different and may produce very different responses.
Expression of the two proteins on T cells is markedly different. CD28 is 
expressed at low levels on CD4+CD8+ thymocytes, with increasing 
expression occurring as the thymocytes mature. Peripheral T cells have similar 
levels of expression to the maturing thymocytes with 95% of CD4+ and 50% 
of CD8+ T cells expressing high levels of CD28 on their surface. Unlike 
CD28, CTLA-4 is not constitutively expressed and is only expressed on T 
cells after they have been activated via TCR/CD3 and CD28 ligation. The 
level of CTLA-4 expression on the T cells is only 1-2% of that of CD28 
(Freeman et al., 1992; Linsley et al., 1992a).
Although CD28 and CTLA-4 are members of the same "family" of receptors 
there are a num ber of differences - both in their homology and their
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expression. Despite these differences they have both been shown to bind the 
same ligands.
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Figure 1.3 CD28 receptor family 
The B7 family of ligands.
CD28 was shown to play an important role in T cell activation as long ago as 
the 1980s. However it was not until 1990 that a natural ligand for CD28 was 
discovered (Linsley et al., 1990).
B7, a B cell activation antigen (designated CD80 at the 5th International 
Workshop on Human Leukocyte Differentiation Antigens) was found to bind 
to CD28 and mediate adhesion between B cells and T cells (Linsley et al.,
1990). In 1993, a second ligand was discovered by two groups of researchers 
working independently. B7-2 (originally known as GL1) was discovered using 
mAbs generated in rats immunised with activated mouse B cells and was 
distinct from CD80 (Hathcock et al., 1993; Freeman et al., 1993). Using a 
monoclonal antibody that blocked lymphocyte costimulatory signals but did
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not bind to CD80, the second ligand, B70, was discovered which could bind to 
both CD28 and CTLA-4 (Azuma et al., 1993a).
The genes for B7-2 and B70 have been isolated and comparison of their 
nucleotide sequence reveals they are the same gene. However the published 
protein sequences of B7-2 and B70 show an additional six amino acids at the 
amino terminal of the B7-2 sequence which may be due to an alternative 
initiation site. B7-2 and B70 are considered to be the same and the second 
ligand for CD28 (Azuma et al., 1993a, Freeman et al., 1993). They were 
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Figure 1.4 Schematic representation of B7 family of ligands showing similar 
overall domain structure. CD86 has an extended cytoplasmic domain which 
may be involved in signalling (Freeman et al., 1989, Azuma et al., 1993a, 
Freeman et al., 1993).
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Both CD80 and CD86  are members of the Ig gene superfamily and comprise 
a single Ig V- like and single Ig C2- like extracellular domain (Figure 1.4) 
(Freeman et al., 1989, Azuma et al., 1993, Freeman et al., 1993). Comparison 
of the predicted amino acid sequences shows only 25% homology between 
CD80 and CD86 . If homology between mouse and human CD80 and between 
mouse and human CD86  is examined, overall homology is much higher at 
45% and 50%. This homology is concentrated in the extracellular domains of 
the proteins with their cytoplasmic sequences showing a much reduced 
homology (23% and 10% respectively). There are differences in the 
cytoplasmic domains with CD80 having a short 19 amino acid cytoplasmic tail 
whereas CD86  has an extended cytoplasmic domain which contains 
phosphorylation sites for protein kinase C (Azuma et al., 1993, Freeman et al., 
1993). This would suggest that CD86 but not CD80 may have a signalling 
function in the APCs it is expressed on.
Like their counter-receptors CD28 and CTLA-4, there are differences in the 
surface expression of CD80 and CD86 . Although both CD80 and CD86  are 
expressed on activated monocytes, activated B and T cells, CD86  is also 
expressed on resting monocytes. In addition, CD86 expression is upregulated 
early during B cell activation (expressed after 6 hours with maximal 
expression 24 hours) whereas CD80 is not detected until much later (24 hours 
after activation and reaches maximal levels after 48 hours). There is also a 
difference in the duration of expression of CD80 and CD86 on activated B 
cells with levels of CD86  remaining high 96 hours after stimulation whereas 
expression of CD80 has rapidly declined by that time (Hathcock et al., 1994). 
In addition not all activation signals resulted in upregulation o f CD80 
expression on B cells e.g. anti-Ig stimulation of B cells resulted in 
upregulation of CD86  but not CD80 (Lenschow et al., 1994). These results 
suggest that CD80 and CD86 expression may be regulated independently.
An examination of the receptor binding characteristics of both CD80 and 
CD86  (Linsley et al., 1994) shows that both bind CTLA-4 with 100 fold 
higher affinity than they bind CD28. The binding site on CD28 and CTLA-4 
for CD80 is a conserved hexapeptide m otif in the com plem entarity 
determining region 3 (CDR3). However, the greater binding characteristics of 
CTLA-4 has been shown to be due to non - conserved residues in the CDR-1 
and CDR-3 regions (Peach et al., 1994). Although both ligands bind CD28, 
CD86  has slightly lower ( 2 - 3  -fold) overall receptor binding properties. In 
contrast, binding to a mutant form of CTLA-4 (mutated in the hexapeptide
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binding motif) showed a significant difference with CD80 binding being >200 
- fold better than CD86 . This suggests that CD80 and CD86  may interact 
differently with the CDR-3 region of CTLA-4. Both CD80 and CD86  have 
similar binding kinetics but their rates of dissociation are markedly different 
with CD86  dissociating from CTLA-4-Ig 5 - 8  fold faster than CD80 (Linsley 
et al., 1994). Although there are differences in both the binding determinants 
used by CD80 and CD86  and the kinetics of their association with CD28 and 
CTLA-4 their ability to maintain similar binding avidity to their ligands 
suggests that they are not redundant molecules but have distinct functions.
CD28 costimulation of T cells.
Initial studies in the 1980s showed that ligation of CD28 using anti-CD28 
mAbs greatly enhanced T cell proliferation when T cells were stimulated with 
polyclonal T cell activators such as phorbol myristate acetate (PMA), 
phytohaemagglutinin (PHA), anti-CD3 and anti-CD2 mAbs (reviewed by 
June et al., 1990). This suggested that CD28 could provide costimulatory 
signals which would induce T cell activation. More recent in vitro studies 
have examined the effect of lack of CD28 costimulation on T cell activation. 
Human tetanus-toxoid specific clones were rendered non-responsive to 
secondary stimulation by costimulation-competent APCs if initially activated 
by CD80-deficient APCs (Gimmi CD et al., 1993). Similarly interruption of 
CD28 -CD80 signalling by anti-CD28 Fab fragments or the chimeric molecule 
CTLA-4-Ig (comprising the extracellular domain of CTLA-4 which includes 
the CD80 binding site fused to the constant region of an IgG antibody) 
resulted in peripheral blood T cells being hyporesponsive to secondary 
stimulation by specific alloantigens (Tan et al., 1993).
This important role of CD28 has also been demonstrated in vivo using 
knockout mice. In CD28 "knockout" mice, although T cell development and 
negative selection occurred normally, the animal's ability to produce IL-2 in 
response to mitogenic stimulation was diminished (Shahinian et al., 1993). 
Antibody production in these mice was also reduced. However, T cell 
responses were not totally absent as CTLs were able to respond to 
lymphochoriomeningitis virus (LCMV). This response may be due to the 
CTLs being mediated by cytokines other than IL-2 and not regulated by CD28 
(Shahinian et al., 1993). Further studies with CD28-deficient mice have shown 
that T cell responses to staphylococcal enterotoxins B were impaired 
(Mittrucker et al., 1996) and that the presence of CTLA-4 ( a counter receptor
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to CD80) on CD28-deficient mice T cells did not result in T cell activation 
when costimulated by CD80 transfectants indicating that CTLA-4 ligation was 
not costimulatory.
Not only has lack of CD28 costim ulation been shown to induce 
unresponsiveness in T cells but it has also be demonstrated that CD28 ligation 
can in fact reverse the induction of antigen - specific unresponsiveness. T hl T 
cells encountering antigen - MHC complexes in the absence of costimulation 
were rendered anergic and were unresponsive to restimulation. However this 
anergic state could be reversed by the addition of exogenous IL-2 or more 
importantly by ligation of CD28 during the initial stimulation of the T cells 
(Jenkins et al., 1991; Harding et al., 1992). The necessity for CD28 ligation to 
overcome T cell anergy helps to explain the lack of T cell stimulation in 
CD28 deficient mice despite the presence of CTLA-4 (which can also bind 
CD28 ligands).
The evidence from both in vitro and in vivo studies demonstrate that lack of 
costimulation through CD28 resulted in T cell hyporesponsiveness. When 
these data are coupled with the mAb data showing enhanced T cell 
proliferation using anti-CD28 mAbs in conjunction with mitogens or anti-CD3 
and CD2 mAbs, this suggests an essential requirement for CD28 costimulation 
in T cell activation.
With the discovery of the natural ligand for CD28 (CD80) it was possible to 
examine the effect of ligand binding to CD28 on T cell activation. CD28 
expressed on CHO cells was shown to bind to lymphoblastoid and leukaemic 
B cell lines. This adhesive function was CD80 specific as it could be inhibited 
by anti-CD80 mAbs (Linsley et al., 1990). Further research demonstrated that 
CD80 could costimulate T cells in conjunction with anti - CD3 mAbs resulting 
in T cell proliferation and IL-2 secretion. This interaction was also shown to 
be CD80 specific as it could be abrogated with anti- CD80 mAb (Gimmi et 
al., 1991; Linsley et al., 1991a). Although CD80 was able to bind to CD28 
and initiate T cell activation, it was observed that addition of the chimeric 
molecule CTLA4-Ig could abrogate CD28 - CD80 costimulation of T cells 
(Linsley et al., 1991b). As CD80 has a higher affinity for CTLA-4 than CD28, 
preferential binding of CD80 to CTLA-4 would prevent the essential 
costim ulation of the T cells by CD28 resulting in abrogation of T cell 
proliferation. CD80 ligation of CD28 has also been shown to provide the 
costimulatory signal required for alloactivation of CD4 T cells (Koulova et al.,
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1991). Alloactivation required both TCR binding and CD28 costimulation as 
mAbs to CD3, MHC Class II, CD28 and CD80 could inhibit T cell 
proliferation. All these experiments demonstrated that T cell activation 
required two signals - one generated via the TCR and the second through 
ligation of CD28.
The generation of the chimeric protein CTLA4-Ig meant that the role of CD28 
- CD80 costimulation could be examined indirectly in vivo. Treatment of mice 
with CTLA4-Ig resulted in long term acceptance of pancreatic islet cell 
xenografts (Lenschow et al., 1992) and the inhibition o f T cell dependant 
antibody responses (Linsley et al., 1992b). The results of the xenograft 
experiments suggests an essential role for CD28 in the generation of an 
immune response, in this case, to foreign tissue. The inhibition of antibody 
responses suggests that CD28 may also be involved in the later immune 
events such as T cell dependant B cell responses. Further in vivo studies using 
transgenic mice (Harlan et al., 1994) demonstrated directly that costimulation 
via CD28 was required to activate T cells, resulting in autoimmunity in this 
mouse model of diabetes. Transgenic mice were produced which expressed 
CD80 on their pancreatic beta cells. Contact with these cells did not result in 
the non-specific activation of T cells. Similarly transgenic mice produced 
which expressed both the lymphocytic choriomeningitis virus glycoprotein 
(GP) via H-2D^ and the TCR specific for H-2D^ presented GP. This resulted 
in the production of CD8 self - reactive T cells but these cells were not 
activated as shown by the lack of spontaneous lymphocyte infiltration or 
diabetes. However cross breeding of the mice to produce triple transgenic 
mice i.e. expressing the self antigen, a TCR specific to that antigen and the 
costimulatory ligand CD80 resulted in the mice developing diabetes due to 
immune-mediated beta cell destruction. These results clearly show that both 
TCR specific responses and costimulation via CD28 are required for T cell 
activation.
Research into how CD28 costimulatory signalling can induce T cell activation 
has demonstrated a number of different effects. CD28/CD80 interactions have 
been shown to provide co-stimulatory signalling in an antigen specific manner 
resulting in IL-2 production (Linsley et al., 1991a; Jenkins et al., 1991). IL-2 is 
the major T cell growth factor required for T cell proliferation. It exerts its 
effect on T cells by binding to a specific receptor - the IL-2 receptor (EL-2R) 
which induces intracellular signalling eventually resulting in T cell 
proliferation (Minami et al., 1993). When T cells were stimulated with PMA
27
in conjunction with mAbs to CD28 there was an increase in IL-2 gene 
transcription & mRNA stability (Lindsten et al., 1989; Fraser et al., 1991). As 
IL-2 production is a key feature of T cell activation and T cells proliferate in 
response to IL-2, the CD28 costimulatory signal would appear to enhance IL-2 
production in two ways - increasing gene transcription and increasing stability 
of the transcripts allowing more translation of the IL-2 mRNA resulting in 
increased IL-2 production.
Another result o f CD28 costimulatory signals is an increase in IL-2R 
expression. The IL-2R consists of three distinct subunits - the a  chain, the P 
chain and the y chain. Only the y chain is expressed constitutively in all T 
cells, with the p chain being found constitutively expressed on CD8 T cells 
but not CD4 T cells. Expression of different combinations of the three subunits 
(a, P and y chains) gives rise to various forms of IL-2R each with different 
binding affinities for IL-2 with the highest affinity receptor comprising all 
three subunits (reviewed by Minami et al.,1993). Binding of IL-2 to its 
receptor induces intracellular signalling eventually resulting in T cell 
proliferation. However for signal transduction to occur both the p and y chain 
must be present. CD28 costimulation has been shown to up-regulate long-term 
EL-2Rp chain expression (Cerdan et al., 1995). This upregulation of IL-2R is 
similar to the increased IL-2 production induced by CD28 costimulation as it 
is achieved by increasing IL-2Rp gene transcription and increasing IL-2R 
mRNA stability. As the y chain of the IL-2R is constitutively expressed on T 
cells and both the y and P chains are required for IL-2R signalling, induction 
of the p chain of the IL-2R would ensure that the T cells expressed an IL-2R 
capable of both binding EL-2 and generating the necessary intracellular signals 
resulting in T cell proliferation. As CD28 also increases IL-2 production 
CD28 costimulation ensures that both the cytokine and its receptor are present 
during T cell activation so enabling T cell proliferation in response to IL-2 
binding to the EL-2R to occur.
This evidence seems to suggest that the role of CD28 costimulation is to 
induce IL-2 and IL-2R expression and so promote T cell proliferation in 
response to the EL-2. In vivo studies with CD28 knockout mice demonstrated 
that although T cell development and negative selection occurred normally, 
the animal's ability to produce IL-2 in response to mitogenic stimulation was 
dim inished (Shahinian et al., 1993). This seems to confirm  the CD28 
costimulatory role as being enhancement of IL-2 production. However this 
may not be the only function of CD28 costimulation. Evidence from CD28
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deficient mice that naive T cells can respond to mitogen stimulation but this 
response cannot be sustained (Lucas et al., 1995) suggests that CD28 
signalling plays a role in T cell survival. The evidence from peripheral 
tolerance suggests that insufficient T cell signalling due to lack of 
costimulatory signals can result in T cell anergy or activation induced cell 
death. CD28 costimulation can prevent both of these outcomes. By providing 
the essential costimulatory signals for T cell activation CD28 prevents anergy 
induction which may occur in response to TCR only signalling. Another 
consequence of CD28 signalling is the increased transcription of the bcl -X1 
gene (Boise et al., 1995) which is known to protect cells from apoptosis. 
CD28 signalling is therefore essential to prevent TCR only signalling inducing 
anergy or apoptosis in T cells and so ensuring survival of the T cells.
CTLA-4 and T cell costimulation.
The discovery of CTLA-4 (Brunet et al., 1987) with its structural homology to 
CD28 suggested that there were perhaps two T cell receptors capable of 
activating T cells. Initial studies have demonstrated that CTLA-4 could not 
provide the necessary costimulatory signals for T cell activation but in 
conjunction with CD28 signalling could synergistically augment TCR-induced 
proliferation of pre-activated T cells (Linsley et al., 1992a). The inability of 
CTLA-4 to provide costimulatory signals to T cells was also suggested by 
generating CD8/CD28 and CD8/CTLA-4 chimeric molecules (the cytoplasmic 
domain of CD28 or CTLA-4 is fused to CD8) and transfecting them into T 
cells. Crosslinking of the CD8/CD28 construct generated costimulatory 
signals whereas crosslinking of the CD8/CTLA-4 construct did not (Stein et 
al., 1994). The results of this experiment demonstrated that the signals 
generated through the CTLA-4 cytoplasmic domain were not costimulatory. 
Since the homology between the cytoplasmic domains of CD28 and CTLA-4 
is only 30% it is unlikely that the signals generated through these cytoplasmic 
domains would be identical. However the original experiments showing 
augmentation of CD28 costimulation of T cells suggested that the function of 
CTLA-4 ligation may be to enhance proliferation and prolong IL-2 production 
and T cell proliferation (Linsley et al., 1992a).
Further insights into CTLA-4 function were generated by research on murine 
T cells which demonstrated that anti-CTLA-4 mAbs and its Fab fragments 
were able to augment T cell responses (Walunas et al., 1994). This would
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appear to confirm the idea that CTLA-4 can augment T cell proliferation. 
However if the mAbs were cross-linked the anti-CTLA-4 mAbs appeared to 
inhibit T cell responses. It would appear from the results of the crosslinking 
experiments that the apparent augmentation of T cell proliferation by CTLA-4 
was possibly due to the anti-CTLA-4 mAbs and Fab fragments blocking 
CTLA-4 inhibitory signals. This has to some extent been confirmed by 
blocking CTLA-4 signals using anti-CTLA-4 mAbs which has resulted in 
increased IL-2 production and T cell proliferation in T cells stimulated by anti- 
CD3 and anti-CD28 mAbs (Krummel and Allison, 1995; Krummel and 
Allison, 1996). Compelling evidence of an inhibitory role for CTLA-4 has 
been shown in vivo in CTLA-4 knockout mice. These animals suffer from a 
lymphoproliferative disorder due to the presence of activated T cells which 
infiltrate a number of major organs resulting in early death of the animals 
(Waterhouse et al., 1995).
Recent in vitro research (Krummel and Allison 1996, Walunas et al., 1996) 
has demonstrated that CTLA-4 inhibits T cell proliferation by blocking IL-2 
production and IL-2R upregulation. This suggests that CTLA-4 signalling 
opposes the costimulatory effects of CD28 which result in IL-2 production, 
IL-2R upregulation and T cell proliferation. As CD28 signalling has also been 
shown to enhance T cell survival by inducing transcription of the protective 
gene bcl-xl, it is possible that CTLA-4 signalling may affect T cell survival. 
However research into the inhibitory role of CTLA-4 on T cell activation has 
shown that CTLA-4 inhibited IL-2 production and T cell proliferation in 
murine T cells stimulated with anti-CD3 and anti-CD28 mAbs in the absence 
of cell death (Krummel and Allison, 1996). Further research has shown that 
the inhibition of T cell proliferation by CTLA-4 is due to blocking cell cycle 
progression by arresting the cell cycle in the G i/S  phase (Krummel and 
Allison, 1996; Walunas et al., 1996). The ability of CTLA-4 to inhibit T cell 
proliferation was more pronounced at later time points (72 hours) following 
the initial activation of the T cells. This is in line with the data that CTLA-4 
surface expression relies on CD28-dependent costimulation and peak surface 
expression o f CTLA-4 occurs 48-72 hours following T cell activation 
(Walunas et al., 1994).
Ligation of CD28 by either CD80 or CD86  has been shown to be essential for 
T cell activation resulting in IL-2 production and T cell proliferation. In 
contrast CTLA- 4 ligation produces the opposite signals i.e. inhibition of IL-2 
production and T cell proliferation. For the effects of ligation of CD28 and
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CTLA-4 to be achieved intracellular signals must be generated within T cells 
following ligation of these surface receptors. Intracellular signalling in T cells 
is a highly complex mechanism which is still being elucidated. However some 
information about the signalling pathways used following TCR and CD28 
stimulation is available.
Intracellular signalling mechanisms.
The recognition of foreign antigen by the TCR/CD3 complex and the 
provision of costimulation through CD28 results in the activation of the T cell. 
This generates a cascade of events including the production of cytokines, T 
cell proliferation, the activation of B cells and phagocytic cells, antibody 
production and the eventual destruction of the foreign antigen. However for 
this outcome to occur the recognition of antigen and the ligation of 
costim ulatory molecules on the surface of the T cell must generate 
intracellular signals which will eventually result in the transcription of the 
appropriate genes to generate the cellular response.
Intracellular signalling can be stimulated by a variety of extracellular stimuli 
e.g. ligand binding to surface receptors, mitogens, hormones and cytokines. 
The signalling pathways generated will produce a variety of responses 
depending on the initial stimulus and the cell involved. However studies have 
shown that there are groups o f similar proteins which are involved in 
intracellular signalling. One of these groups is that of protein tyrosine kinases 
(PTKs). These enzymes are able to phosphorylate the tyrosine amino acids of 
other proteins which then changes the conformational shape of the molecule 
and if the protein is an enzyme may cause a change in its activity (Ullrich and 
Schlessinger 1990). The protein targets of PTKs often contain a conserved 
protein module of approximately 100 amino acids known as the Src homology 
2 (SH2) domain (Pawson and Gish 1992). Proteins with SH2 domains often 
possess a distinct region of approximately 50 amino acids, the Src homology 3 
(SH3) domain which is thought to regulate protein - protein interactions (Clark 
et al., 1992). For binding of a protein target to a PTK to occur a specific 
residue in the PTK must be phosphorylated. However it is the amino acid 
sequence surrounding the phosphorylated amino acid which determines which 
protein target will bind (Cantley et al., 1991). The protein target may itself be 
a PTK as many SH2/SH3 containing proteins have intrinsic PTK activity. As 
some receptors do not contain intrinsic kinase activity it may be possible for 
them to recruit intracellular PTKs by phosphorylation of a tyrosine residue in
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their cytoplasmic tail which will then interact with the SH2 domain of a PTK 
so beginning the biochemical signalling pathway. The eventual effect of many 
signalling pathways is the induction of transcription factors which travel to the 
nucleus and bind to the promoter region of a specific gene so inducing gene 
transcription which will eventually result in the required cellular outcome e.g. 
cytokine production.
TCR/CD3 complex signalling.
The interaction of the TCR/CD3 complex with the MHC/antigen complex on 
the APC results in the generation of a variety of intracellular signals in the T 
cell. The a  and P chains of the TCR have short cytoplasmic domains of 
approximately 5 amino acids and are not involved in signal transduction. 
However the cytoplasmic domains of CD3 are longer (40-113 amino acids) 
and contain copies of a tyrosine based activation motif (TAM), a conserved 
domain of precisely spaced amino acids found in other signal transduction 
chains such as the B cell receptor (Reith, 1989). Within the TAM are two 
tyrosine residues separated by ten amino acids which are potential sites for 
phosphorylation (Sancho et al., 1993). Multiple copies of the TAM are found 
in the £ chain and a single copy is found in y  and 8 chains with a partial copy 
in the e chain of CD3. This may allow the TCR to couple to divergent 
signalling pathways.
As the TCR/CD3 complex has no intrinsic protein tyrosine kinase activity and 
a number of cellular proteins are tyrosine phosphorylated as a result of TCR 
stimulation, cytoplasmic PTKs must be associated with proxim al TCR 
signalling. Two PTKs have been shown to associate with the £ chain of the 
CD3 complex. P59 fyn has been co-immunoprecipitated with the £ chain of 
CD3 (Samelson et al., 1990) and another PTK Zap-70 has also been shown to 
associate with the £ chain of CD3 (Chan et al., 1992). The association of Zap- 
70 with the TCR/CD3 complex results in Zap-70 itself being tyrosine 
phosphorylated. It is thought that phosphorylation of the £ chain of CD3 
possibly by P59 fyn results in recruitment of Zap-70 via one or both of the 
two SH 2-like dom ains of Zap-70 through an SH-2/phosphotyrosine 
association (Koch et al., 1991). More recent studies have shown that the 
tandem SH2 domains of ZAP-70 bind distinct tyrosine phosphorylated TAMs 
of the TCR/CD3 complex (Isakov et al., 1995). The substrates of these PTKs 
are unknown but p59 being a src-like kinase, contains an SH2 domain
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which may bind other phosphotyrosine containing proteins (possibly other 
PTKs). Research into the role of p59 fyn in mouse T cells suggests that the 
PTK may be involved in TCR induced calcium mobilisation, although the 
exact mechanism is unknown (Stein et al., 1992). More recent research using 
human Jurkat T cells suggests that p59 fyn can regulate calcium influx but the 
mechanism is distinct from phosphatidylinositol 4,5-bisphosphate (PIP2 )
hydrolysis.
A third PTK is thought to be indirectly associated with the TCR via the co­
receptors CD4 or CD8 . Although TCR/CD3 interactions with MHC-antigen 
complexes are considered to provide the first signal required for T cell 
activation, the surface receptors CD4 or CD8 expressed on T cells are known 
to help stabilise TCR/CD3 interactions with MHC-antigen complexes 
(Norment et al., 1988). The cytoplasmic domains of CD4 and CD8 associate 
non-covalently with the PTK p56^c^ through cysteine-dependant interactions 
(Shaw et al., 1989) and the association of p56lc^ with CD4 and CD8 suggests 
a potential role in signal transduction for these TCR co-receptors. Evidence for 
the requirement of p56^c^ activity in T cells comes from a number of studies 
of mutant cell lines. A CD4-dependent antigen-specific murine T cell lacking 
endogenous CD4 could only demonstrate TCR function after the introduction 
of CD4 molecules which could associate with p56^c^- Mutant CD4 molecules 
that were unable to associate with p56^c^ were unable to restore TCR function 
(Glaichenhaus et al., 1991). When two p 5 6 ^  deficient T cell lines (a Jurkat 
human T cell leukaemia line and a murine cytotoxic T cell clone) were 
examined both were found to be defective in TCR-mediated signalling. 
Responsiveness to TCR cross-linking could be restored by transfection with 
lck expression plasmids (Kamitz et al., 1992, Straus et al., 1992).
CD45 which is expressed on all T cells may also play a role in TCR signalling. 
From the cDNA of CD45, 8 possible isoforms can be generated by differential 
usage of the 3 exons which encode the extracellular domain of CD45 (Streuli 
et al., 1987). However 2 isoforms predominate on T cells - CD45RA which is 
found on naive T cells and CD45 RO which is present on memory T cells 
(Akbar et al., 1988). The cytoplasmic tail of CD45 has been shown to contain 
phosphotyrosine phosphatase (PTP) activity (Tonks et al., 1988) and evidence 
for CD45 involvement in T cell signalling has been demonstrated using 
mutant CD45“ mouse T cell clones and a CD45" T -leukaemia cell lines both 
of which were unresponsive to signalling via the TCR (Pingel and Thomas, 
1989; Koretzky et al., 1990). CD45 can dephosphorylate the regulatory
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carboxy-terminal tyrosine residue in the kinase domain of the protein tyrosine 
kinases (PTKs) p56^c^ and p59fyn resulting in increased kinase activity 
(Mustelin et al., 1989; Mustelin et al., 1992) and as already seen both these 
PTKs are associated with the TCR.
Stimulation of the TCR results in phosphorylation of a variety of cellular 
proteins including the £ subunit of CD3 and phospholipase C yl (PLC yl). 
The phosphorylation of PLC-yl increases its catalytic activity resulting in 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2 ) to form inositol 
1,4,5-trisphosphate (IP3 ) and diacylglycerol (DAG). These secondary 
messengers raise intracellular calcium levels and stimulate protein kinase C 
(PKC) in a calcium dependent manner, respectively. The increased calcium 
levels result in the activation of calcineurin, a calcium/calmodulin dependent 
protein serine/threonine phosphatase whose target is unknown but may be the 
cytosolic component of a transcription factor (NF-AT) involved in IL-2 gene 
regulation. Activation of PKC by DAG results in the activation of a number of 
other kinases including MAP kinase whose phosphorylation targets are a 
number of transcription factors which may be involved in lymphokine gene 
expression. PKC activation also results in transcription of a number of other 
genes such as c-fos and c-jun which form part of the transcription factors 
(AP-1 and NF-AT) involved in EL-2 gene regulation as well as c-myc which is 
involved in cell division (reviewed by Fraser et al., 1993; Perlmutter et al.,
1993).
Although TCR ligation initiated this complex network of interacting signal 
transduction pathways, the signals generated are insufficient for T cell 
proliferation. As has already been discussed, TCR signalling in the absence of 
other important signals may result in functional inactivation or clonal anergy 
(Jenkins and Schwartz, 1987) or to activation-induced T cell death or 
apoptosis (Groux et al., 1993; Damle et al., 1993) by upregulation of the 
ligand for the death receptor CD95 (Fas) on T cells (Dhein et al., 1995). The 
requirement for costimulatory signals through CD28 has already been shown. 
As with TCR-mediated intracellular signalling pathways, the intracellular 
signals generated following CD28 ligation are still being elucidated.
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CD28 Intracellular signalling.
Like the TCR/CD3 complex, CD28 is unable to initiate intracellular signals 
directly as the cytoplasmic domain of CD28 has no intrinsic enzymatic 
activity. However like the TCR/CD3 complex the cytoplasmic domain of 
CD28 contains a number of consensus sequences. One of these sequences, 
YMNM, is similar to the core phosphotyrosine sequence which has specificity 
for the SH2 domain of signalling proteins. There are also two proline rich 
motifs which conform to SH3 binding consensus sequences. This suggests that 
CD28 should be able to recruit PTKs through binding via these consensus 
sequences. Evidence for PTK activity associated with CD28 stimulation has 
been demonstrated by both the tyrosine phosphorylation o f a number of 
substrates as well as tyrosine phosphorylation of the cytoplasmic domain of 
CD28 itself following ligation of CD28 (Lu et al., 1992; Vandenberghe et al., 
1992; August and Dupont, 1994; Pages et al., 1994). However data from 
studies using herbimycin A, a src-family PTK inhibitor, have suggested that 
CD28 may associate with more than one PTK. When CD28 was ligated using 
cross-linked anti-CD28 mAbs herbimycin A was able to inhibit tyrosine 
phosphorylation of a number of substrates and IL-2 production as well as 
inhibit intracellular calcium levels (Vandenberghe et al., 1992; Ueda et al.,
1994). However if CD80 was used to stimulate CD28 signalling, herbimycin 
A had no effect on intracellular calcium levels (reviewed by Sansom et al., 
1997). This suggests that CD28 can associate with both herbimycin sensitive 
and insensitive PTKs.
As the PTKs p59fyn or p56^c^ are known to associate with the cytoplasmic 
domains of the TCR/CD3 complex and its co-receptors CD4 or CD8 , it is 
possible that the same PTKs may be coupled to CD28 during CD28 signalling. 
It has been demonstrated that CD28 crosslinking results in increased tyrosine 
phosphorylation of PLC yl and increased activity by p56lc ^ and p59fyn 
(Ledbetter and Linsley, 1992) and studies using mAb ligation of CD28 have 
implied an association of CD28 with both p56^c^ and p59fyn (Hutchcroft and 
Bierer, 1994). This suggests that TCR and CD28 signalling may be linked 
possibly by sharing of PTKs.
CD80 co-stimulation of T cells has been shown to be more efficient if the 
CD80 and the TCR ligand are on the same cell (Liu and Janeway Jr, 1992). 
However another study (Sansom et al., 1993) has shown that CD80 transfected 
CHO cells can act as third party co-stimulators of T cells. The difference in the
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results obtained in these two studies suggests that as third party costimulation 
can occur there is no necessity for coassociation of CD28 with the TCR. 
However if TCR and CD28 ligands are present on the same cell the increased 
efficiency may be due to increased adhesion between the T cell and APC 
rather than linkage of intracellular signalling pathways.
As has already been discussed CD28 ligation by CD80 (as determined by 
intracellular calcium  levels) is insensitive to herbimycin A treatm ent 
suggesting that herbimycin-insensitive PTKs can associate with CD28. As 
Zap-70 is a Syk- family PTK known to associate with the TCR, it could be a 
potential candidate for herbimycin A insensitive PTK association with CD28. 
However data from studies where CD28 and interactive components of the 
CD28 signalling pathway were expressed in insect cells suggest that the Syk - 
family PTK Zap-70 does not associate with CD28 (Raab et al., 1995). It is 
possible that the herbimycin-A resistant PTKs are not PTKs associated with 
the TCR and that CD28 association with this PTK generates a completely 
separate signalling pathway from the TCR. There is further evidence of a 
separate signalling pathway by CD28.
The cytoplasmic tail of CD28 contains the consensus motif YMNM which is 
similar to the phosphotyrosine containing consensus motif YXXM which has 
specificity for the p85 subunit of phosphatidylinositol 3- kinase (PI3-kinase). 
This suggests direct interaction between CD28 and PI3-kinase. PI-3 kinase is 
a heterodimer consisting of a 85kDa regulatory subunit containing two SH2 
domains and an SH3 domain tightly associated with a llO kD a catalytic 
subunit. PI3-kinase has dual specificity as it is a lipid and protein serine 
kinase.Evidence for association of CD28 with PI3-kinase has been 
demonstrated using the leukaemic T cell line Jurkat. Ligation of CD28 by 
CD80 induced accumulation of D-3 phosphatidylinositol lipids, the products 
of PI3-kinase activity (Ward et al., 1993). The functional significance of PI3- 
kinase association with CD28 has been demonstrated in murine T cell 
hybridom as expressing mutations in the YMNM m otif of the CD28 
cytoplasmic tail which are no longer able to produce IL-2 following CD28 
ligation (Pages et al., 1994). As a feature of CD28 signalling is increasing both 
the transcription and stability of IL-2 mRNA, the association of CD28 and 
PI3-kinase appears to be an important part of the CD28 signalling pathway 
required to achieve this.
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There is evidence to suggest that like the TCR, CD28 can activate 
phospholipase C. However there are differences in the results obtained 
depending on the activation state of the T cells used and the method of ligating 
CD28. Monoclonal antibodies to CD28 can induce phosphorylation of PLCy-1 
in Jurkat cells in the absence of crosslinking (Nunes et al., 1993). However 
the mAbs must be crosslinked to achieve the same effect in resting T cells and 
activated T cells (Couez et al., 1994). There is evidence to suggest that CD80 
does not induce PLC activation suggesting that the mAb activation of PLC 
may be functionally redundant (Ward et al., 1993). This is to some extent 
confirmed by the finding that, in contract to TCR signalling, signalling 
through CD28 does not require calcium mobilisation. Production of IL-2 by T 
cells stimulated with PMA and soluble anti-CD28 mAbs is unaffected by 
blocking a calcium dependent signal transduction pathway using cyclosporin 
A (CsA) (Crabtree, 1989; June et al., 1987). However it has been suggested 
that the CsA-insensitive and CsA-sensitive pathways may reflect different 
CD28 signalling responses depending on the activation state of the T cell. It is 
possible that the CsA-sensitive pathway is dominant in activated T cells 
whereas the CsA-insensitive pathway predominates in resting T cells (June et 
al., 1994).
There is also evidence for CD28 induction of p21ras which is associated with 
TCR/CD3 signalling. Once again the evidence appears to depend on how 
CD28 is stimulated, with mAbs to CD28 but not CD80 activating p21ras 
(reviewed by Sansom et al., 1997). As can be seen by the conflicting evidence 
from studies on PLC and P21ras activation by CD28, the signalling pathways 
for CD28 are still being determined and it appears from a number of studies 
that the signals generated depend on the activation state of the T cell and the 
method of ligating CD28 i.e. mAbs or natural ligands. However the 
importance of CD28 costimulatory signals on T cell activation cannot be 
underestimated. The effect of CD28 signalling in conjunction with TCR 
signals on cytokine production will now be examined.
Transcription factor targets
The ability of CD28 to provide an intracellular signal which augments that 
provided by the TCR/CD3 complex and is sufficient to induce T cell 
proliferation and IL-2 production has been clearly demonstrated. CD28 
costimulation is known to upregulate production of a number of other
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cytokines including IL-4, IL-8 , IL-13 and ylFN (Thompson et al., 1989; 
Minty et al., 1993; Weschler et al., 1994; Seder et al., 1994). The effect of 
CD28 signalling on the induction of cytokine production is mediated by 
transcriptional effects - upregulation of transcription as well as stabilisation of 
cytokine mRNA (Lindsten et al., 1989; Fraser et al., 1991). However CD28 
signalling alone cannot induce cytokine production, TCR signalling is also 
required (Figure 1.5).
Transcriptional regulation of the IL-2 gene has been investigated and requires 
the binding of a number of transcription factors (AP-1, NF-kB, NF-AT and 
OCT) to the IL-2 promoter (Fraser et al., 1993). CD28 has been shown to 
activate IL-2 gene transcription by regulating the gene enhancer activity by the 
induction of a transcription factor known as the CD28 response element or 
response complex (CD28RE or CD28RC), (Verweij et al., 1991; Fraser et al., 
1991 respectively). CD28 signalling has also been shown to be necessary in 
conjunction with TCR mediated signals for the generation of AP-1 (Rincon 
and Flavell, 1994). However another study has shown that CD28 stimulation 
can cause down-regulation of AP-1 (Los et al., 1994). Furthermore a more 
recent study has suggested that CD28 signalling in T cell blasts can result in 
the generation of NF-kB and AP-1 but not NF-AT. However all three 
transcription factors could be induced through TCR mediated signals (Edmead 
et al., 1996). It is possible that the CD28 signalling pathways generated varied 
depending on both the activation state of the T cell used and the method of 
ligation of CD28 (reviewed by Sansom et al., 1997). Possibly, the CD28 
pathway generated may affect which transcription factors are induced. The 
evidence from the research into induction of transcription factors in T cell 
blasts (Edmead et al., 1996) suggests that NF-AT, NF-kB and AP-1 must all 
be present for IL-2 production. It is possible that in unstimulated T cells TCR- 
mediated signals are not sufficient to generate the required transcription 
factors and that CD28 costimulatory signals are needed not only to generate 






1.5 Schematic of T cell intracellular signalling.
Aims of the project
T cell activation is thought to require two signals - one through the TCR and a 
second costimulatory signal. It has been suggested that ligation of CD28 may 
provide the necessary costimulation. In the absence of CD28 costimulation T 
cells may become unresponsive to subsequent antigenic challenge. There are 
two known ligands for CD28 - CD80 and CD86 which are known to bind to 
CD28 with similar affinities. However it has yet to be established whether 
these two ligands have differential function. Whilst the importance of CD28 in 
activating T cells has been suggested, the role of CD28 in sustaining T cell 
proliferation has not been investigated. Furthermore, the mechanisms by 
which CD28 transmits its signalling information is poorly understood. As 
CD28 has no intrinsic signalling mechanism, it must recruit other intracellular 
molecules for signal transduction to occur.
The aims of this project were therefore to:
1. Establish assays of T cell activation which were dependant on CD28 
costimulation via its natural ligands and study the kinetics with which CD28 is 
used in these assays,
2. Investigate the effects of CD28 engagement on previously activated T cells 
to compare its role in resting and pre-stimulated T cells,
3. Compare the relative abilities of CD80 and CD86  in costimulating 
activation in resting T cells and sustaining proliferation of activated T cells,
4. Investigate the mechanisms of CD28 signalling in normal T cells with 






The majority of standard reagents used were purchased from Sigma Chemical Co 
Ltd, the others are as indicated in the relevant method. A full list of suppliers 
including their addresses can be found in Appendix 1.
Cell culture
A variety of different cells were cultured often requiring both different culture 
media and different cell culture techniques. The cell culture techniques used 
for each cell type are detailed below and the individual cell culture media 
requirements are shown in Table 2.1.
Cell culture reagents and media
All the media and supplements used (except the nucleosides) were purchased 
from Life Technologies Ltd, the nucleosides were obtained from Sigma. 
Phosphate-buffered saline (PBS) tablets were purchased from Unipath Ltd. All the 
tissue culture plastics were obtained from Falcon Ltd.
The individual media requirements of the different cell types cultured are 
listed in Table 2.1 ( Recipes for the culture media and additives are listed in 
Appendix 2).
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CTLLS T cell Blasts 
Hybridomas 
(Complete Medium)
Media Dulbecco's minimal 
e ssen tia l m edium  
without 1-glutamine 
(DMEM)
R P M I1640 RPMI 1640




L-Glutamine - 2mM 2mM
Sodium pyruvate ImM - -
Penicillin 100 units /  ml 100 units /  ml 100 units / ml
Streptomycin 100 jug /ml 100 jug/ ml 100 |ig / ml
Nucleosides 26pM adenosine 





Additional Reagents 500ng/m l G418 - 
sulphate (for CD58 
transfectants)
10-15 international 





All cell culture manipulations were carried out in a Class II Biological Safety 





Chinese Hamster Ovary (CHO) K1 cells transfected with human cDNAs 
encoding CD58 (LFA-3), CD80 (B7) and CD86 (B70) were generated in our 
lab (Sansom et al 1993). The transfectants and the parental cell line were 
maintained in CHO Medium (see Table 2.1).
CHO cells are an adherent cell line and were regularly subcultured (normally 
every 2 - 3  days depending on the rate of growth of the individual 
transfectants). The cell culture medium was removed from the tissue culture 
flask. This also removed any dead cells which were no longer adherent. The 
adherent cells were washed with 5ml of phosphate buffered saline (PBS) 
which was then removed. This washing process was to ensure that all the 
culture medium had been removed and would have no effect on the Trypsin 
-EDTA used to remove the adherent cells from the tissue culture flask. 3ml 
Trypsin-EDTA (1 :250) (Life Technologies Ltd) was added to the culture 
flask which was incubated for 5 minutes at 37°C. The flask was then gently 
tapped to aid removal of the adherent cells. The action of the Trypsin - EDTA 
was neutralised by the addition of 10 ml of CHO medium. The resulting cell 
suspension was passaged 1:10 and the cells cultured for future use. The 
remaining cells were either used in proliferation experiments or after 
examination of the surface expression of their individual human surface ligand 
by flow cytometry were frozen down for storage in liquid nitrogen .
b) CTLLs
(Gillis and Smith 1977).
The murine cytotoxic T cell line 2 (CTLL2) cells were obtained from the 
National Institute for Biological Standards and Controls (NIBSC, South 
Mimms, Hertfordshire) and maintained in complete medium with the addition 
o f 10-15 international units (IU/ml) of recombinant human interleukin -2 
(rhIL-2) (a kind gift from Glaxo Ltd). The CTLLs required rhIL-2 for their 
survival and had to be fed every 3 days. The CTLLs were maintained by 
subculturing 1:10 (2 x 104 cells /ml) in complete medium with the addition of 
1 0 -1 5  IU/ml of rhIL-2. The cells were cultured in tissue culture flasks 
standing upright in the incubator. The excess cells were either used in the IL-2 
bioassay or were frozen down for storage in liquid nitrogen.
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c) Hybridomas
Hybridomas secreting a variety of monoclonal antibodies (mAbs) were 
obtained (see Table 2.2 for a list of mAbs and their sources). The hybridomas 
were subcultured every 3-4 days depending on their individual growth rates. 
The non-adherent hybridoma cells and their culture medium (complete 
medium) were removed from the tissue culture flasks into a 50 ml tube. The 
cell suspension was centrifuged at 420g for 10 minutes and the supernatant 
was removed and stored as this contained the secreted mAbs. The cells were 
then subdivided with 10% of the cells being cultured further by resuspension 
1:10 in complete medium. The excess cells were frozen down for storage in 
liquid nitrogen.
Preparation of cells for cryogenic storage.
To ensure an adequate supply of the many different cells types used in this 
research it was important to establish a good store of healthy cells which could 
be removed from long term storage in liquid nitrogen and cultured as 
required. When cells had been growing well in culture and were due for 
subculturing the excess cells if not required for experiments were removed and 
prepared for storage in liquid nitrogen. The method used was the same for all 
cells except the CTLLs (which is detailed separately).
After passaging the cells were washed in medium, centrifuged at 350g for 10 
minutes and the medium removed. The cells were resuspended in 2ml 40% 
FCS in RPM I 1640. The cells were then put on ice and an equal volume of 
20% DMSO in complete media added slowly. The cells were then subdivided 
between cryogenic storage vials at a density of 1 x 106 cells/vial. The vials 
were then cooled in a freezing box at -80°C overnight before being placed in 
long term liquid nitrogen storage.
CTLLs were prepared in a similar fashion except that the excess cells were 
stored in freshly made freezing mixture (20% FCS, 10% DMSO 70% RPMI 
1640 and 1% rhIL-2) and were cooled more slowly. The vials of cells were 
cooled in a freezing box at -20°C for 8 hours then overnight at - 80°C before 
being transferred to liquid nitrogen storage.
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To recover cells from cryogenic storage the cells were brought to 37°C  
quickly. The vial was swabbed with 70% ethanol to prevent contamination and 
the contents put into a tube containing 10ml of pre-warmed media (37°C). the 
cells were centrifuged at 350g for 5 minutes and the supernatant discarded. 
The cells were then resuspended in their appropriate medium (prewarmed to 
37°C) and placed in culture at 37°C and 5% C02.
Monoclonal antibodies.
(Schlossman et al,. 1995)
The experiments in this research required the use of a number of different 
monoclonal antibodies (mAbs). Some of these antibodies were obtained by 
culturing the relevant hybridoma and collecting the secreted mAb found in the 
culture media. The presence of the secreted mAb was tested by using the 
supernatant as the primary mAb in the preparation of cells for FACS analysis 
and testing its ability to bind to its antigen on cells which expressed the 
antigen and also those which did not. If the mAb was present and the 
concentration of the mAb used in experiments had to be precisely defined the 
mAb was purified and quantified. Other mAbs were kind gifts from a number 
of different researchers. Details of all the mAbs used are shown in Table 2.2.
Table 2.2: Monoclonal antibodies (mAbs). their ligands, source and form of 
supply.
mAb Ligand source form
OKT3 CD3 e chain A.T.C.C. Hybridoma
OKT11 CD2 A.T.C.C. Hybridoma
UCHM1 CD 14 kind gift from 
P. Beverley
Hybridoma
L243 HLA-DR A.T.C.C. Hybridoma
BB1 CD80 (B7) Kind gift from 
P.Linsley, Seattle
Ascites
IT2.2 CD86 (B70) Kind gift from 
M. Azuma
Ascites




TS2/9 CD58 (LFA-3) A.T.C.C. Hybridoma
BU12 CD19 Kind gift from 
R. MacLennan
Ascites
8784 CD25 a  chain A.T.C.C. Hybridoma
(A.T.C.C. - American Type Culture Collection, Maryland, USA)
Monoclonal antibody purification.
(Harlow and Lane, 1988).
The hybridom a culture supernatant containing the secreted mAbs was 
collected and the mAbs were precipitated by a two stage method using 
saturated ammonium sulphate (4.1M at 25°C) . The volume of culture 
supernatant obtained was determined and 0.5 of this volume of saturated 
ammonium sulphate (SAS) was added slowly with stirring and left at 4°C 
overnight. The mixture was centrifuged at 3000g for 30 minutes and the large 
proteins which had precipitated were discarded. A further 0.5 of the original 
supernatant volume of SAS was added and left overnight at 4°C. The mixture 
was centrifuged as before but the precipitate containing the mAbs was retained 
and redissolved in 0.1 volumes (of the original starting volume) of PBS. This 
solution was transferred to dialysis tubing and dialysed against 3 changes of 
PBS at 4°C. The mAbs were further purified using a protein G column where 
the unbound proteins present were washed through the column using 0.02M 
sodium phosphate pH 7.0. The bound mAb was eluted from the column using 
0.1M glycine pH 3.7 into eppendorf tubes containing a small volume (20p.l/ml 
eluant) of neutralising buffer (1.0M Tris-HCL pH 9.0). The concentration of 
p ro te in  in the  a liquo ts o f mAb ob ta ined  was determ ined  
spectrophotom etrically by measuring optical density at 280nm. The 
monoclonal antibodies were tested using flow cytometry.
Purification of T cells from peripheral blood
(Boyum, 1964).
All blood samples were taken from healthy volunteers aged between 19 and 45. 
Blood (50ml) was collected into 2 tubes each containing 60p,l of 5000 units/ml 
Heparin (Monoparin obtained from CP Pharmaceuticals Ltd). The blood was 
diluted 1:1 with PBS and separated on a Ficoll (1.077) density gradient 
(Lymphoprep from Nycomed (UK) Ltd) by centrifugation at 420g for 30 minutes.
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The layer of mononuclear cells (PBMCs) (1 - 2 x 106 cells/ml blood) recovered 
from the gradient was resuspended in 50ml of complete media and centrifuged at 
420g for 10 minutes. The supernatant was removed and the cells wash twice more 
by resuspending in 20ml of complete media and centrifuging at 420g for 5 
minutes. The washed cells were then resuspended in 10ml of complete media.
The adherent sub-population of the mononuclear cells was removed by culturing 
the PBMCs in a small volume (usually 5ml) of medium in tissue culture plastic 
petri-dishes for 1 hour at 37°C. Non-adherent cells which include T cells were 
placed into a fresh tube and these cells were labelled using monoclonal antibodies 
to monocytes (UCHM1, anti-CD 14, 500pl of 10|ig/ml hybridoma supernatant), B 
cells (B U I2 anti-CD 19, 1:10 dilution of ascites) and activated T cells, monocytes 
and macrophages (L243 anti-HLA-DR, 500|il of lOjig/ml hybridoma supernatant) 
for 1 hour at 4°C on a rotator. Having been washed with complete media, the cells 
were incubated with 50 j l l 1 sheep anti-mouse IgG coated magnetic beads diluted 
1:10 in complete media for 1 hour at 4°C and the labelled cells were attracted to a 
magnet (Dynal) applied to the outside of the tube and the non-attracted T cells 
removed. The resulting T cell population was greater than 95% CD2 positive as 
shown by flow cytometry
Analysis of cells by Flow Cytometry (FACS)
(Ormerod 1990)
FACS analysis was used for two distinct purposes. One was to examine the 
surface molecules expressed on a number of different cell types e.g. the human 
surface markers whose cDNA had been transfected into CHO cells as well as 
surface markers on T cells such as CD3 , CD2 and CD28. FACS analysis was 
also used to test whether the hybridomas cultured were secreting their mAbs into 
the culture supernatant. This was achieved by using this supernatant as the source 
of primary mAb and testing a number of cells known to express the antigen for 
the mAb as well as non- expressing cells as a negative control.
P repara tion  of cells for FACS analysis
The cells (1-2 x 105 / tube) were washed in medium and incubated at 4°C for 
20 minutes with 20 |il of heat inactivated human AB serum to block any 
surface Fc receptors. 50pl of the appropriate mAb at a concentration of
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10|Xg/ml (or media as a negative control) was added and the cells incubated at 
4°C for 60 minutes. The excess mAb was removed by washing the cells in 
complete media and the second layer antibody added - 50pl of sheep anti­
m ouse IgG conjugated with fluorescein isothiocyanate (FITC) at a 
concentration of 50pg/ml for all mAbs except B B 1 which is an IgM antibody 
when sheep anti-mouse IgM conjugated with FITC was used. The cells were 
again incubated at 4°C for 60 minutes. The excess second layer antibody was 
removed by washing the cells in complete medium and the cells were 
resuspended in 200pJ PBS for immediate analysis. FACS analysis done at a 
later date was performed on cells resuspended in lOOul 2% FCS/PBS, fixed 
with lOOpl of 2% (w/v) paraformaldehyde in PBS and stored at 4°C. The 
labelled cells were diluted with FACS sheath fluid (Becton Dickinson) and 
analysed using a Facstar Plus (Becton Dickinson) with a lOOmW 488nm argon 
laser. Information about their forward scatter (FSC), side scatter (SSC) and the 
fluorescence intensity of the labelling (FLI) was obtained using the LYSIS II 
program.
T cell proliferation assays
(Waldmann et al., 1987).
Preparation of costimulatory cells
Transfectants were trypsinised and washed twice with PBS to remove traces of 
FCS. Cells were fixed for 2 minutes with 0.025% (v/v) gluteraldehyde (Sigma) in 
PBS. The fixation was stopped by the addition of 200mM glycine and the cells 
washed twice in FCS containing medium to remove excess gluteraldehyde. The 
cells were then counted and resuspended in complete medium at the concentration 
required for each experiment. On all occasions, the transfectants used were 
cultured alone in the proliferation experiments with tritiated thymidine to measure 
background proliferation.
Proliferation of Purified T cells
T cells purified from PBMCs were washed in media, counted and plated out in 
96- well flat bottomed plates (normally at 5x l0 4 cells/50pl/well). Where the T 
cells were stimulated using the mAb OKT3, the 96-well plate was pre-incubated 
with mAb at the appropriate concentration (usually 1 pg/ml) in PBS overnight at
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room temperature before the unbound mAb was washed off. The fixed 
transfectants used to provide costimulation were added at the appropriate 
concentration (normally l-2x 104 cells/50|il/well). The final volume in each well 
of the assay was routinely 200jil. Each culture was plated out in triplicate. The 
assay was incubated at 37°C and 5% CO2. At the time point required by the 
particular assay, 50|il of culture supernatant from each well was removed and 
stored for IL-2 determination. The wells were pulsed with ljiC i 3H thymidine 
(specific activity 6.7 Ci/mmol) (Amersham International pic) (50|il volume) and 
incubated for 18 hours. The pulsed wells would either be removed to another plate 
and frozen for subsequent measurement of 3H thymidine incorporation or if the 
whole plate was being assayed at one time point, the plate would be harvested and 
thymidine incorporation counted. The cells were lysed, the radiolabelled DNA 
trapped onto glass-fibre filter mats using a semi-automatic cell harvester (Skatron 
Ltd). Each disc of filter mat corresponding to each well in the 96-well plate was 
put in a scintillation vial and 0.5ml of scintillant added (Optiscint HiSafe obtained 
from W allac). The amount of radioactivity incorporated in each well was 
measured using a scintillation counter (LKB beta counter from Wallac Ltd).
IL-2 Bioassay
(Gillis et al., 1978).
The CTLLs were used after 3 days in culture when their supply of added 
human rhIL-2 was depleted. The cells were washed twice in culture media and 
a viability count made using the Trypan Blue exclusion method. Providing 
viability was greater than 80% the cells were used. 50fil of the culture 
supernatant from each sample (diluted 1 in 2 and 1 in 10 with complete 
medium) was plated out in triplicate in a 96-well round bottomed plate and 
50jnl of a CTLL suspension in media at 1 x 10 5 cells/ml added to each well. A 
standard curve was always used in the assay using rhIL-2 (NIBSC) at 0.019 
-10 IU/ml. The cells were left in culture overnight at 37°C and 5% CO2 before 
0.5p,Ci of 3H thymidine (specific activity 6.7 Ci/mmol) was added to each 
well. The cells were incubated at 37°C for a further 4 hours. The level of 3H 
thymidine incorporation was determined by harvesting the DNA from the cells 
onto filter mats and counting using a liquid scintillation beta counter. The 
amount of IL-2 present in the supernatant from the proliferation assay was 
calculated using the calibration curve. An example of the standard curve 
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Figure 2.1 : A standard curve for CTLL2 proliferation.
Using known concentrations of human rhIL-2 to provide a calibration curve 
the concentration of IL-2 present in the supernatant of T cell proliferation 
assays could be determined if the values obtained were on the linear portion of 
the standard curve.
T cell blasts 
Production of T cell blasts
The addition of specific mitogens to PBMCs in culture stimulates the T cells 
present to proliferate. Within a few days most of the other mononuclear cells 
have died and the culture consists predominantly of T cell blasts. The 
mitogens used to stimulate the PBMCs were either
a) SEB at a final concentration of lpg/ml 
or
b) PHA at a final concentration of 10|ig/ml 
or
c) PMA at a final concentration of 50ng/ml and Ionomycin at a final 
concentration of ljiM.
51
Following stimulation the cells were cultured in complete medium without the 
addition of exogenous IL-2.
Culturing of T cell blasts
T cell blasts were cultured in complete medium and were given fresh medium 
as required (normally every 2-3 days) with the maximum duration in culture 
being 10 days post-mitogenic stimulation.
Proliferation of T cell blasts
(Waldmann et al., 1987).
T cell blasts were washed in medium to remove any cytokines present in the 
culture media, counted and plated out in 96-well round bottom plates (except 
when stimulated with OKT3 when mAb-coated flat bottom plates were used) 
at the appropriate concentration (normally 5xl04 cells/50|il/well). The fixed 
transfectants used to provide stimulation were prepared and added as for pure 
T cell proliferation assays. Each culture was plated out in triplicte.The total 
volume in each well of the assay was made up to 200jil with medium. The 
plates were incubated at 37°C and 5% CO2 for two days before 50JLL1 of 
supernatant was removed for IL-2 determination and ljxCi of 3H thymidine 
(specific activity 6.7 Ci/mmol) added. After overnight incubation with the 
radiolabelled nucleotide the cells were harvested and 3H thym idine 
incorporation was measured as for purified T cell proliferation assays.
Inhibitors 
Handling and storage
The fungal metabolite wortmannin was used to inhibit intracellular signalling 
in T cell proliferation assays. As this chemical is thought to be carcinogenic, 
mutagenic and possibly teratogenic it was handled wearing appropriate safety 
clothing and in a laminar flow cabinet. Wortmannin was dissolved in ethyl 
acetate at a concentration of 20mM, aliquoted into Eppendorf tubes and stored 
at -20°C.
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Using wortmannin in proliferation assays
As wortmannin is unstable in aqueous solutions, when being used in 
proliferation assays, it was diluted to the required concentrations in cultured 
media immediately prior to use.
Cytokine mRNA determination.
The recipes for the various solutions used for cytokine mRNA determination 
are given in Appendix 3.
RNA extraction.
RNA was extracted from cells using the Chomczynski and Sacchi method 
(Chomczynski and Sacchi, 1987). As RNA is easily degraded due to the 
presence of the enzyme RNase on hands and in solutions all manipulations 
were carried out wearing gloves and all reagents used were dedicated to RNA 
work only.
Cells (approximately 10^ cells/lOOpl RNA extraction solution) were lysed in 
RNA extraction solution (4M guanidinium thiocyanate, 25mM sodium citrate 
pH7, 0.5% sarcosyl, made up in diethylpyrocarbonate (DEPC) - treated 
distilled water with 0.1 M 2 - mercaptoethanol being added immediately prior 
to use) in a microfuge tube to a final volume of 500pl. The following reagents 
were added sequentially with mixing by inversion between each addition - 
50pl 2M sodium acetate pH4, 500pl water saturated phenol (Appligene) and 
IOOjliI chloroform - isoamyl alcohol (49:1). The mixture was vortexed for 10 
seconds and incubated on ice for 15 minutes prior to centrifugation at 12,000g 
for 10 minutes at room temperature. The top aqueous layer was removed to a 
fresh microfuge tube and an equal volume of chloroform - isoamyl alcohol 
added. The mixture was then vortexed and centrifuged at 12,000g for 5 
minutes at room temperature. This chloroform - isoamyl alcohol extraction 
was repeated and the final aqueous layer precipitated overnight at -20°C by 
the addition of an equal volume of isopropanol. The precipitate was 
centrifuged at 12,000g for 10 minutes at room temperature and the RNA 
redissolved in 150}il of RNA extraction solution. The RNA was reprecipitated 
at -20°C overnight by the addition of 150jil of isopropanol. The RNA was 
centrifuged at 12,000g for 10 minutes at room temperature and the pellet
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washed twice with 70% ethanol and once with 100% ethanol before drying 
under vacuum for approximately 15 minutes. The RNA was redissolved in 
50jnl DEPC - treated water.
RNA quantitation
The concentration of RNA was determined spectrophotometrically. The RNA 
was diluted 1:24 in water and the optical density measured at 260nm and 
280nm. The concentration of RNA was calculated using the following 
formula:-
A 26O x 40 x dilution = pg/ml RNA.
The purity of the sample was determined from the ratio A260/A28O, whh pure 
samples having a ratio of 2.0. Lower ratios indicated proteins present or 
contamination by phenol.
Agarose gel electrophoresis
Horizontal submarine gel electrophoresis was used to analyse the RNA 
extracted to determine its integrity and also to identify DNA fragments 
produced by Reverse Transcription - Polymerase Chain Reaction (RT-PCR). 
A l%(w/v) gel (for RNA analysis) or 2%(w/v) gel (for RT-PCR analysis) was 
produced by dissolving agarose in Tris - acetate ethylenediaminetetraacetic 
acid (EDTA) buffer (TAE) ( 0.04M Tris base, 5mM sodium acetate and ImM 
disodium EDTA ). The agarose / buffer mixture was heated in a microwave to 
allow the agarose to dissolve and then cooled to approximately 60°C before 
the addition of ethidium bromide (final concentration 0.5|ig/ml). The cooled 
agarose gel was poured into a gel mould and allowed to set. The gel was 
covered with TAE buffer and the samples to be analysed were loaded onto the 
gel in the appropriate loading buffer (20% w/v Ficoll (Type 400) and 0.2% 
w/v bromophenol blue for RNA and 25% w/v Ficoll (Type 400), 0.25% w/v 
bromophenol blue and 0.25% w/v xylene cyanol for DNA). The samples were 
electrophoresed at 100mA until the leading edge of the loading dye was 
approximately half/three quarters of the way down the gel. The RNA or DNA 
was visualised using a UV transilluminator.
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When the DNA fragments from the RT-PCR were being analysed a (j)X 174 
DNA digested with Hae 111 (Northumbria Biologies Ltd or Promega Ltd) was 
run at the same time to allow sizing of the fragments. The size of the markers 
in base pairs (bp) are as follows -l,358bp, 1078bp, 872bp, 603bp, 310bp, 
281 bp, 271 bp, 234bp, 194bp, 118bp and 74bp.
Reverse transcription of RNA
RNA was reversed transcribed to produce cDNA prior to amplification by 
PCR. The reaction was carried out in silanised microtubes to prevent the 
cDNA from sticking to the tube. Approximately 500ng of total RNA was 
mixed with lOmM dithiothreitol, 0.5mM each of dATP, dCTP, dGTP and 
dTTP, 1.5|iM pd(T) 12 - 18, 30 units RNAguard (RNase inhibitor , all from 
Pharmacia Biotech Ltd), 400 units M-MLV reverse transcriptase (Life 
Technologies Ltd) and 1 x RT buffer (supplied with the enzyme). The total 
volume was made up to 30|il with DEPC - treated water. The mixture was 
incubated at 37°C  for 60 minutes then heated at 95°C for 10 minutes. The 
cDNA was then put on ice if being used immediately for PCR or stored at 
-20°C.
Polymerase chain reaction (PCR)
(McPherson et al., 1992)
Although all the cDNA produced by the reverse transcription of the total cell 
RNA was used in the PCR process only the fragments o f interest were 
amplified. This was achieved by using primer pairs specific to the DNA 
sequences under investigation. The primer pairs used were able to amplify 
cDNA produced from RNA for IL-2 and Glyceraldehyde - 3 - phosphate 
dehydrogenase (GAPDH) respectively. Their sequences are shown below -
IL-2 5' G A ATGG ATTT A AT AATT AC A AG A AT CCC 3’
3' TGTTTCAGATCCCCTTTTAGTTCGAC 5’
GAPDH 5’ GGTGAAGGTCGGAGTCAACGG 3’
3’ GGTCATGAGTCCTTCCACGAT 5’
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The products produced by the PCR amplification process had molecular 
weights of 229bp and 520bp for IL-2 and GAPDH respectively. The primer 
pairs span introns in the gene sequence so ensuring that any contaminating 
genomic DNA would not be amplified or would have a much higher molecular 
weight.
PCR reactions were carried out in a final volume of lOOpl, made up as follows
IOjllI of Taq buffer (supplied with enzyme)
200jnM each of dATP, dGTP, dCTP and dTTP. 
lOOnM each of 5' and 3' primers 
1.25mM MgCl2
2.5 units Taq polymerase (Northumbria Biologies Ltd or Promega Ltd) 
2|il cDNA reaction mix
The reaction mixture was overlaid with 40 |il of mineral oil to minimise 
evaporation and amplification carried out for 30 cycles on an Astec PC-700 
machine using the following programme - 
1 minute at 94°C
1.5 minutes at 55°C
1.5 minutes at 72°C
This was followed by 10 minutes at 72°C and the samples were stored at 4°C  
until examined using gel electrophoresis.
Data Analysis
All experiments were carried out a minimum of three times using different 
blood donors on each occasion. The data presented in the results section are 
representative of each set of experiments and the number of experiments 
carried out is shown in the figure legend.
The data from proliferation assays represent the mean values from triplicate 
cultures and the error bars represent standard errors. Where error bars are not 
visible this is due to the scale of the graph being too large relative to the 
magnitude of the error.
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Chapter 3 
CD28 costimulation in purified T cells
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Generation of CD86 transfectants.
In order to investigate the role of CD28 in T cell activation and to be able to 
use the natural ligands for CD28 to provide costimulatory signals to T cells, 
transfected cells expressing the CD28 ligands CD80 and CD86 were generated 
in the laboratory. However the newly transfected cells have to be grown and 
selected to produce a stable expressing cell line which can be used repeatedly 
in different experiments so allowing comparisons between experiments to be 
made. CHO cells were chosen as the vehicle for transfection as they have been 
used successfully by many groups to express human surface molecules and 
are unreactive to human T cells.
Although the method used to transfect the CHO cells (electroporation) is 
considered to be a highly effective technique not all the CHO cells were 
transfected with the cDNA or expressed the required protein. Surface 
expression of the human CD86 molecule on the CHO cells was determined by 
FACS analysis. The level of expression of CD86  on newly transfected CHO 
cells ( 24 hours after transfection) is shown in Figure 3.1b (the background 
fluorescence level is shown in Figure 3.1a). This shows that 39% of the cells 
expressed CD86  (B70) on their surface which was quite a high level of 
transfection - sometimes less than 10% of transfected cells are shown to 
express the required protein. The FACS analysis also shows a highly variable 
level of expression of CD86 on the transfected CHO cells with the majority 
having low levels o f expression. The fluorescence intensity (FL1) shown on 
the x - axis is a measure of the number of CD86 molecules expressed on the 
surface of each CHO cell - the greater the number of CD86 molecules on the 
cell surface the higher the fluorescence intensity detected (i.e. FL1 value). The 
wide range of FL1 values shown in figure 3.1b indicates that the cells 
transfected expressed CD86 at different levels and the general level of the 
expression was low.
Cells transfected with foreign cDNA are highly unstable with the vast majority 
of the cells either not expressing the required protein or the foreign cDNA 
being destroyed or expelled during cell division. In order to produce a high 
expressing stable transfectant, the transiently expressing CHO cells had to be 
sorted and the required cells selected. This was achieved in three ways. 
Initially, the cells expressing CD86  were selected using a magnetic bead 
system to separate those cells expressing CD86 from the non-expressors. This 
is a quick and easy method to separate out large numbers of cells, which
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express the required surface marker, for further selection. The cells expressing 
CD86 were cultured and their surface expression analysed by FACS. The cells 
were then reselected using the magnetic bead method twice more and the 
resulting improvement in the percentage of cells expressing of CD86  can be 
seen in Figure 3.1c - nearly 6 8 % compared to the initial 39% before 
immunomagnetic selection. However this method was of limited use as all 
cells expressing CD86  were selected using a magnetic bead system regardless 
o f their level of expression. To be able to distinguish and separate out 
transfectants expressing high levels of CD86  (as shown by FACS analysis) a 
second method w'as employed - FACS sorting.
This is a more complex method of sorting cells where specific parameters such 
as the level of expression of the CD86 were used to separate out the required 
cells from the rest of the transfectants . As a result only small numbers of cells 
could be processed using this method (compared to the more crude magnetic 
bead selection method).The sorted transfectants were cultured and examined 
for their surface expression of CD86 . This basic method of FACS sorting had 
resulted in an increase in the number of cells expressing CD86 (95.6% 
compared to 68.48% following magnetic bead selection - Figure 3. Id ) and the 
selected cells showed a high level of expression of CD86  with a mean 
fluorescence to 146.5 (as compared to a mean fluorescence of 58.61 in 
transfectants sorted using magnetic beads).
However there was still variation in the level of expression of CD86  on 
individual cells as the cell population was still polyclonal. To overcome this 
variation in surface expression of the transfectants cultured, a third method of 
selection was used which involved not only sorting the cells expressing CD86 
but also directly cloning them using an Automatic Cell Deposition Unit 
attached to the FACS machine. The cells were again selected using criteria 
such as the level of expression of CD86  on their surface but the individual 
cells selected were collected separately and cultured as individual clones. This 
was carried out in as sterile conditions as possible. The cloned transfectants 
were initially cultured in 96 well tissue culture plates, the cultures expanded 
and the cells screened for surface expression on the FACS. Not all the clones 
successfully grew or expressed CD86 but a number of high expressing clones 
were cultured for use in the T cell activation experiments.
FACS analysis of the surface expression of two of CD86 clones is shown in 
Figures 3.1e and 3 .If. This demonstrates that although both clones were
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expressing CD86 the clone G8 had a much more uniform level of expression 
when compared to that of clone F9. It is likely that F9 was not a single clone 
but possibly biclonal - i.e. two cells were sorted into one of the wells on the 96 
-well plate and both were cultured and expanded together. This would explain 
the variation in the level of surface expression of CD86 . Transfectants from 
clones such as Clone G8 were selected for use in future experiments. All the 
transfectants used (CD80, CD86 and CD58 ) have been screened and cloned to 
ensure similar levels of expression of their particular human surface molecule.
The transfectants used in any experiment were routinely screened to determine 
not only the level of expression of their own surface ligand but to ensure that 
they did not express any other surface molecules which could have an effect 
on the results of the experiment. An example of this is shown in Figure 3.2. 
The CD80 transfectant has been screened using mAbs to CD80 (BB1), CD86 
(IT2.2), CD58 (TS2/9), and HLA-DR (L243) and only CD80 shows a 
fluorescence intensity (FL1) greater than the background level. This clearly 
demonstrates that the transfectant expressed only the desired surface 
molecule.
Having established transfected cell lines which could be used to provide 
costimulatory signals to T cells, it was necessary to establish a method of 
providing the initial stimulus via the T cell receptor.
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Figure 3.1 The effect of cell selection processes on the surface expression of 
CD86 on CHO cells transfected with CD86 cDNA.
Transfectants were stained with IT2.2 (anti-CD86 mAb) and analysed by 
FACS. The surface expression of CD86 on transfectants 24 hours after 
insertion of CD86 cDNA is shown in figure b), the effect on surface 
expression following selection using magnetic beads is shown in c) and cell 
sorting selection is shown in d). The background fluorescence level is shown 
in a). Figures e) and f) show the differences in surface expression that can 


















Figure 3.2 FACS analysis of surface expression of CD80 on transfected CHO 
cells.
CD80 transfectants were stained with mAbs to HLA-DR (L243), CD58 
(TS2/9), CD86 (IT2.2) and CD80 (BB1). The cells were then examined by 
FACS to determine which of these surface molecules was being expressed on 
the transfectants. The background level of fluorescence is also shown. The 
data are representative of a single experiment (n>10).
T cell stimulation by anti-CD3 mAb.
The normal primary stimulus in T cell activation is the interaction of the TCR- 
CD3 complex of the T cell with the MHC - antigen complex on the antigen 
presenting cell (APC). However this interaction only occurs in those T cells 
which express the appropriate T cell receptor and activation of such a small 
number of T cells would be difficult to detect. A more general signal was 
required to stimulate the heterogeneous TCR specificity found in peripheral T 
cells and this was provided by a mAb (OKT3) to the £ chain of the CD3 
complex which associates with the TCR. To ensure that this signal was 
consistent between experiments the mAb produced by the hybridoma cells was 
purified using Protein G affinity chromatography and a known amount used 
to provide the primary stimulus .
The primary signal was supplied by coating the mAb diluted in PBS onto 96- 
well flat bottomed plates. The efficiency of coating the plates was detected 
using an anti-mouse IgG alkaline phosphatase conjugate in an enzyme-linked 
immunosorbant assay (ELISA) (see Appendix 4 for the method). The results 
are shown in Figure 3.3. The results demonstrated that the optimal time of 
those examined for coating plates with OKT3 was 24 hours at room 
temperature and this was used in all subsequent experiments.
The final component of the T cell activation experiments was the purified T 
cells. It was important to ensure that the method used to generate these T cells 
was efficient and reliable. In this way the purity of the T cells obtained would 











®  OKT3 (lflg/ml)
Figure 3.3 : Time dependency coating of 96 -well plates with the mAb OKT3. 
A 96-well flat bottomed plate was coated with the mAb OKT3 at 1 pg/ml 
(diluted in PBS) for various times at room temperature. The amount of mAb 
which adhered to the plate was detected using an anti-mouse IgG alkaline 
phosphatase conjugate and disclosed with p-nitrophenyl phosphate (pNPP) 
w hich produces a coloured product that can be m easured 
spectrophotometrically at 410nm. The data are from triplicate samples from a 
single representative experiment (n = 3).
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Analysis of purified T cells
The purity of the T cells used in the costimulation assays was determined by 
FACS analysis using mAbs to detect the presence of contaminating monocytes 
(UCHM1 for CD 14), B cells (B U I2 for CD 19) and activated T cells, 
monocytes and macrophages (L243 for HLA-DR which is upregulated on 
activation). A typical FACS result is shown in Figure 3.4a. The level of 
expression of these surface molecules was compared to a negative control 
(when no primary mAb is used to give the background level of fluorescence). 
The level of expression of CD 19 , CD 14 and HLA-DR was similar to the 
background level of fluorescence demonstrating the lack of contaminating 
cells in the T cell sample.
The purified T cells were then analysed by FACS to examine the expression of 
a number of surface molecules as shown in Figure 3.4b. This was to ensure 
that the cells obtained were T cells and that the sample did not contain T cells 
which were already activated. The levels of expression of CD3, CD2, CD28 
and CD25 on the surface of the T cells ( using the mAbs OKT3, OKT11, 9.3 
and 8784 respectively) were determined. The purified T cells were found to 
express CD3, CD2 and CD28 but not CD25 which is a marker of activation 
(Figure 3.4b). As not all T cells express CD3, the percentage of cells 
expressing CD2 was taken as an indication of the purity of the T cells 
obtained. On all occasions this was at least 95% (Figure 3.5b). The 
background fluorescence level is shown in Figure 3.5a. FACS analysis of 
purified T cells was carried out before each experiment to ensure that the 
purification process had been successful and that any variation in the 
experimental results was not due to the presence of contaminating cells.
Having established appropriate reagents initial experiments were undertaken 
to determine whether CD80 transfectants would stimulate T cells via their 
CD28 receptor in conjunction with a signal via the TCR- CD3 complex and 
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Figure 3.4. FACS analysis of Purified T cells.
a) Purified T cells were analysed by FACS to determine whether there was 
contamination by monocytes , B Cells or activated T cells.
b) Purified T cells were analysed by FACS to determine their surface 
phenotype using mAbs to CD3, CD2, CD28 and CD25. The data are 
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Figure 3.5 Analysis of purity of T cells obtained from human blood.
Purified T cells from human blood were stained with OKT11 (anti- CD2 mAb) 
and analysed by FACS. The percentage of positive cells was determined by 
setting a gate on the negative control corresponding to approximately 95% of 
all cells (a). Using the same gate parameters the percentage of positive cells 





CD28 costimulation of purified T cells
To determine whether CD28 ligation by CD80 transfectants could generate the 
necessary costimulatory signals for T cell activation, purified unactivated T 
cells were stimulated using a monoclonal antibody (mAb) to the 8  chain of 
the CD3 complex (OKT3) and signals provided by Chinese Hamster Ovary 
(CHO) cells transfected with CD80 (B7), and/or CD58 (LFA-3) with the 
untransfected parental cell as a control. Three different concentrations of 
OKT3 were used and the resulting T cell activation was measured in terms of 
T cell proliferation (via 3H thymidine incorporation) and IL-2 production 
(using a CTLL bioassay).
The proliferation results are shown in Figure 3.6a. The T cells were stimulated 
to proliferate at all three concentrations of OKT3 only when CD80 was 
present on the costimulatory cell. The parental CHO cell line did not provide 
co-stimulatory signals and the OKT3 mAb was insufficient to activate the T 
cells. The CD58 transfectants were also unable to provide co-stimulation to 
the T cells and it is possible that this may have been due to lack of interaction 
between the CD58 transfectant and its ligand CD2 on the T cell. However 
when the double transfectant CD58/CD80 was used to provided costimulation 
a higher level of proliferation was generated than when the single transfectant 
was used. This suggests that CD58 expressed on the double transfectant was 
able to interact with its ligand CD2 on the T cells so increasing adhesion 
between the T cells and the transfectants resulting in a higher level of 
proliferation. This increased level of proliferation in T cells costimulated with 
the double transfectant may also have been due to increased signalling via the 
CD3 complex following CD2 ligation by CD58 as this is the known pathway 
of CD2 signalling (Howard et al., 1992). There was little difference in the 
level of proliferation obtained using increasing concentrations of OKT3 to 
coat the 96-well plates suggesting that the level of binding to the T cells was 
saturated at 1 jig/ml. As a result lpg/ml was used routinely in all experiments.
The proliferation results were paralleled by the IL-2 production figures (Figure 
3.6b) with IL-2 only being produced when CD80 was present on the 
costimulatory cell either as a single or double transfectant. However although 
the double transfectants produced a higher level of proliferation than the single 
transfectant there was little difference in the level of IL-2 detected. It is likely 
that the IL-2 produced when costimulation was provided by the double 
transfectant was used more rapidly by the T cells resulting in higher levels of
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proliferation. As the bioassay used to detect IL-2 production measures only 
unbound IL-2 any increase in IL-2 production when the double transfectant 
was used would not be detected if it was being taken up by the rapidly 
proliferating T cells.
To ensure that the proliferation observed using CD80 transfectants as 
costimulators was not due to any mitogenic effects of the transfected CHO 
cells, purified T cells were cultured with transfectants in the presence or 
absence of OKT3. The results in Figure 3.7 show that CD80 provides co­
stimulation in the presence of OKT3 but does not induce T cell proliferation 
on its own. The background levels of proliferation for T cells and fixed 
transfectants were also determined. Proliferation of T cells and fixed 
transfectants was generally less than lOOOcpm and EL-2 production could not 
be detected. This demonstrated both the necessity of appropriate stimuli to 
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Figure 3.6 : OKT3 and CD80 stimulation of purified T cells.
Purified T cells (2 x 104) were stimulated at three concentrations of OKT3 in 
the presence of transfected CHO cells (2 x 104). This resulted in (a) T cell 
proliferation, measured after 48 hours using ^H Thymidine incorporation and 
(b) IL-2 production measured after 48 hours using a CTLL bioassay.The data 















Figure 3.7 : Costimulation of purified T cells by OKT3 and CD80.
Purified T cells (2 x 10^) were cultured with transfectants (2 x 10^) in the 
presence or absence of OKT3 (ljig/m l) for 72 hours. Proliferation was 
measured by thymidine incorporation. The data are from triplicate 
samples from a single representative experiment (n = 5).
These initial experiments established that ligation of CD28 by CD80 
expressed on transfected CHO cells in the presence of OKT3 was essential for 
T cell activation to occur as demonstrated by T cell proliferation and IL-2 
production. T cell activation could not occur unless both these signals were 
present and ligation of CD2 by CD58 in the absence of CD28 - CD80 
interactions could not provide the necessary costimulatory signals. Thus
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these data were consistent with other reports that CD28 was necessary for T 
cell activation (e.g. Linsley et al., 1991a).
Kinetics of T cell activation following CD28 costimulation
Having established that CD28 could provide costimulatory signals to T cells 
(following ligation by CD80 transfectants) to induce T cell activation, it was 
then possible to examine CD28 costimulation in greater detail. The effect of 
CD28 costimulation on the kinetics of T cell activation was studied by 
examining the proliferative response and IL-2 production of purified T cells 
over a number of days following culturing with transfectants (CD80, CD58 or 
the CHO parental cells) in the presence of OKT3.
The results (Figure 3.8a) demonstrated that CD80 transfectants provided the 
necessary costim ulatory signals to T cells with maximum proliferation 
occurring by 120 hours in culture. Neither the untransfected parental cell nor 
the CD58 transfectants were able to provide costimulatory signals to induce T 
cell proliferation.
When production of IL-2 by the T cells was examined, only the CD80 
transfectants were able to provide the necessary costimulatory signals for IL-2 
production. W hen CD58 transfectants or untransfected CHO cells were used 
to provide costimulation, they were unable to induce the T cells to produce EL- 
2. Under these conditions, the maximum level of IL-2 detected occurred much 
earlier than maximum proliferation - after 48 hours in culture (Figure 3.8 b).
The fact that CD80 ligation of CD28 resulted in IL-2 production was not 
unexpected as it had already been shown that CD28 signalling results in a two 
fold increase in the rate o f DL-2 transcription as well as increasing the stability 
of IL-2 mRNA (Lindsten et al., 1989; Fraser et al., 1991). More recent 
research has demonstrated that CD28 signalling can induce a number of IL-2 
gene transcription factors - CD28RC, NF-kB and AP -1 (Fraser et al., 1993; 
Edmead et al., 1996).
The data from figure 3.8 demonstrated that IL-2 production preceded T cell 
proliferation. This is not unexpected as T cells proliferate in response to IL-2. 
To be able to do this T cells must express the IL-2 receptor (which is not 
constitutively expressed on T cells) and signals generated by CD28 are known 
to upregulate IL-2R P chain (Cerdan et al., 1995). As a result of CD28 
signalling, EL-2R bearing T cells were generated and were able to respond to
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the IL-2 already produced, therefore increased proliferation was detected after 
IL-2 production had reached its maximum. The loss of IL-2 detected as 
proliferation was increasing was probably due to the cytokine being used by 
the IL-2R bearing T cells.
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Figure 3.8 : Stimulation of purified T cells over time.
2 x 10^ purified T cells were cultured with 2 x 10^ transfectants (CHO or
CD80 or CD58) in the presence of OKT3 (lpg/m l). Proliferation (a) and IL-2 
production (b) were measured every 24 hours. Proliferation was measured 
using ^H thym idine incorporation and IL-2 production using a CTLL 
bioassay. The data are from triplicate samples from a single representative 
experiment (n = 3).
73
Although the CD80 transfectants were able to stimulate purified T cells in the 
presence of OKT3 it was important to demonstrate that the costimulatory 
signal supplied to CD28 was due to ligation by the CD80 transfectant. This 
was investigated by the addition of CTLA-4-Ig to the assay. CTLA-4-Ig is a 
chimeric molecule, composed of the extracellular domain of CTLA-4 (which 
includes the CD80 binding site) fused to the constant region of an IgG 
antibody, which can bind CD80 with high affinity. The results in Figure 3.9 
clearly show that the costimulatory function of the CD80 transfectant was 
disrupted by the addition of CTLA-4-Ig at concentrations as low as 500ng/ml. 
This demonstrated that CD80 binding of CD28 could be inhibited by the 
higher affinity ligand CTLA-4 and that proliferation was dependent on CD80 
costimulation. It was not possible to examine the specificity of the CD80- 
CD28 interaction as a blocking agent for CD28 was unavailable. This could be 
investigated by using either Fab fragments of anti-CD28 mAbs or a chimeric 
CD28-Ig molecule and including either of these in the costimulation assay.
Effect of delaying the costimulatory signal.
In all the experiments described so far, costimulatory signals were provided by 
the transfectants at the same time as the initial first signal through the 
TCR/CD3 complex (using OKT3). To determine how long after an initial 
signal (via the TCR/CD3 complex) T cells were responsive to costimulation 
the effect of delaying this costimulatory signal was examined.
The results shown in Figure 3.10 demonstrated that if  the second signal 
provided by CD80 transfectants was delivered more than 6 hours after the 
primary signal the T cells were unable to respond to the costimulation. This 
lack of responsiveness by the T cells was not due to loss of function by the 
fixed CD80 transfectants as these transfectants could stimulate freshly purified 
T cells to proliferate in the presence of OKT3 (Figure 3.11). This would 
suggest that the T cells were unable to respond to the costimulatory signals 
generated following ligation of CD28 by CD80.
The necessity of costimulation provided by CD28 has been demonstrated in a 
number of in vitro and in vivo systems where lack of costimulation results in 
T cell anergy or programmed cell death (Kawabe and Ochi, 1991; Tanaka et 
al., 1995; Nicolle et al., 1994; Shahinian et al., 1993; Mittrucker et al., 1996). 
As CD28 signalling has been shown to result in upregulation of IL-2 gene
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transcription and stabilisation of IL-2 mRNA this suggests that lack of 
costimulation results in insufficient intracellular signals being induced, 
resulting in lack of IL-2 production - a necessary requirement for T cell 
proliferation. This has been demonstrated in previous research (Sansom et al., 
1993) where the mitogen PHA was used to stimulate purified T cells. The T 
cells did not proliferate but were able to induce IL-2R surface expression. The 
T cells could be rescued by the addition of IL-2. It is possible that the T cells 
that were unresponsive to delayed signalling through CD28 (Figure 3.10 ) 
could also be rescued by addition of exogenous IL-2. However the 
unresponsive cells may not have been rendered anergic by TCR-only 
signalling but had been induced to undergo programmed cell death 
(apoptosis). As another role of CD28 signalling is to protect the T cells from 
apoptosis, (by upregulation of the bcl-xl gene which is known to protect cells 
from apoptosis) (Boise et al., 1995), lack of this protective signal may have 
induced apoptosis in the T cells.
There are a number of different methods to test which of these two hypotheses 
are correct. If the T cells are being induced to undergo apoptosis, viability of 
the T cells over time could be measured (by cell counting using the Trypan 
Blue exclusion method or by FACS analysis either by examining DNA 
content of the cells or by using propidium iodide which is taken up by dead 
cells). If the cells are viable and have possibly been anergised this could be 
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Figure 3.9 : Blocking the CD28 - CD80 interaction using CTLA4 -Ig.
5 x 10^ purified T cells were cultured in the presence of OKT3 (1 pg/ml) and 
2 x 10^ CD80 transfectants The chimeric molecule CTLA4-Ig ( which binds 
CD80 with a higher affinity than CD28) was added at various concentrations 
(with a positive control being proliferation in the absence of CTLA4-Ig). 
Proliferation was measured using thymidine incorporation after 48 hours. 
The data are from triplicate samples from a single representative experiment 
(n = 3).
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Figure 3.10 : Delay in providing costimulatory signal to purified T cells.
2 x 10^ purified T cells were stimulated using OKT3 (ljug/ml) and 2 x 10^ 
transfectants (CHO or CD80 or CD58) which were added at different times 
after the initial OKT3 stimulus. Proliferation was measured by 3H thymidine 
incorporation 48 hours after the transfectants were added. The data are from 











Figure 3.11 : The effect of fixation on CD80 transfectant function.
2 x 10^ purified T cells were stimulated in the presence of OKT3 (lp.g/ml) by 
2 x lO^ transfectants (either CHO or CD80) which had been fixed 7 days 
previously. Proliferation was measured after 72 hours by thymidine 
incorporation. The data are from triplicate samples from a single 
representative experiment (n = 3).
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Effect of costimulation on CD28 surface expression.
The data generated so far have demonstrated the requirement for CD28 
costimulation to activate T cells resulting in proliferation and IL-2 production. 
This costimulatory signal has also been shown to be time dependent i.e. CD28 
signalling must occur within a few hours of TCR signalling to be effective in 
generating T cell proliferation. Since CD28 plays such an essential role in T 
cell activation it was important to examine whether ligation of CD28 by CD80 
had any effect on the expression of CD28 itself.
Studies using polyclonal activators of T cells had already shown that CD28 
expression was enhanced following T cell activation (Turka et al., 1990). To 
determine whether CD28 expression was similarly enhanced following T cell 
activation using OKT3 and CD80 transfectants, T cells cultured with OKT3 
and transfectants were stained with mAbs to CD28 and surface expression of 
CD28 determined by FACS analysis.
Interestingly, the FACS analysis in Figure 3.12a shows that the surface 
expression of CD28 on T cells decreased within 24 hours of ligation by CD80 
in the presence of OKT3. However CD28 surface expression slowly returned 
over a number of days towards its original unligated level. If no ligation of 
CD28 occurred, as when CHO cells were used in place of CD80 transfectants, 
there was no loss of CD28 from the T cell surface (Figure 3.12b). It would 
appear that ligation of CD28 by its ligand CD80 results in a decline in surface 
expression which is eventually reversed. However when T cells were 
stimulated by CD80 transfectants only (Figure 3.12c) the surface expression of 
CD28 also declined but on this occasion re-expression did not occur. This 
suggests that ligation of CD28 by CD80 is sufficient for downregulation of 
CD28 surface expression but that additional factors are required for re- 
expression o f CD28. To ensure that these changes in the level of surface 
expression of CD28 were not due to variations in the machine set-up, the 
FACS was calibrated using standard fluorescent beads to the same level of 
intensity on each occasion as shown in Figure 3.13.
The data from figure 3.12c suggest that downregulation of CD28 surface 
expression occurred in response to CD80 ligation but re-expression of CD28 
required additional factors. It has already been demonstrated that T cells 
stimulated by CD80 transfectants only (Figure 3.7) were unable to 
proliferate whereas T cells stimulated by OKT3 and CD80 transfectants could
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proliferate (Figure 3.6). As the T cells stimulated with OKT3 and CD80 
transfectants were able to re-express CD28 whereas the CD80 only stimulated 
T cells did not re-express CD28, this suggests that re-expression of CD28 may 
be linked to T cell activation.
Downregulation of CD28 surface expression following CD80 ligation has 
been previously reported (Linsley et al., 1993). In contrast to the results seen 
in figure 3.12b, the T cells in this study showed a much faster rate of 
downregulation and re-expression of CD28 - i.e. CD28 expression was 
downregulated within 12- 24 hours of ligation by CD80 and was re-expressed 
at its initial level or higher by 48 hours. However the T cells used by Linsley 
et al. had been stimulated using either PMA or PHA prior to ligation of CD28 
by CD80 transfectants. It is possible that the T cells would be rapidly dividing 
in response to PMA or PHA whereas the T cells used in Figure 3.12 were 
unstimulated T cells and as has already been shown (Figure 3.8) T cell 
proliferation does not reach a maximum until 5 days after initial stimulation. It 
is possible that the difference in the kinetics of CD28 re-expression is due to 
differences in the level of cell cycling of the T cells used in these studies. As 
T cells stimulated by CD80 transfectants only are unable to proliferate and re- 
expression of CD28 on T cell stimulated by CD80 transfectants only did not 
occur (Figure 3.12c) this suggests the idea that CD28 surface expression is in 
some way responsive to proliferative signals.
Interestingly, Linsley et al. (1993) also found that the T cells following re­
expression of CD28 had impaired CD28 signalling. This would suggest that 
although CD28 may be re-expressed at higher levels in activated T cells, 
signalling through CD28 would be ineffective. However, it is important to 
note that the T cells used to examine CD28 signalling by Linsley et al. had 
been stimulated twice - initially by PMA or PHA and then through CD28 
following ligation by CD80 transfectants. It is possible that the 
hyporesponsiveness o f the T cells is a method of preventing repeated 
restimulation of already activated T cells. Although T cells which have been 
activated can be restimulated further by ligation of CD28 (see Chapter 4) to 
enhance and prolong the immune response, restimulation of already activated 
T cells could not be allowed to occur repeatedly. The immune response would 
have to be controlled to allow it to subside when no longer required. This may 
occur by preventing further restimulation of the T cells due to CD28 
hyporesponsiveness ( as seen by Linsley et al.,1993 ) or by the generation of 
negative signals to switch off T cells.
80
Negative signalling may be a function of CTLA-4 which is upregulated on T 
cell activation and has been shown to generate intracellular signals following 
ligation which results in blocking IL-2 production (Krummel and Allison, 
1996). Studies have suggested that CTLA-4 upregulation may be CD28- 
dependant - anti-CD28 mAbs were able to accelerate the kinetics of CTLA-4 
mRNA in human peripheral blood lymphocytes and the level of CTLA-4 
upregulation was significantly reduced on T cells from CD28-deficient mice 
(Lindsten et al., 1993; Walunas et al., 1994). More recent studies have shown 
that blockading CD28 ligation inhibits CTLA-4 upregulation (Walunas et al., 
1996). These results suggest that a consequence of CD28 ligation is the 
surface expression of CTLA-4. As CTLA-4 has a higher affinity for CD80 
than CD28, CTLA-4 would be expected to bind CD80 preferentially when T 
cells were restimulated. It may be the negative signals generated following 
CTLA-4 ligation predominate and override any positive signals due to CD28 
ligation. In this way the immune response could be allowed to subside.
So far all these experiments have examined the role of CD28 in activating 
previously unstimulated T cells. However the surface expression of CD28 has 
been shown to be enhanced in activated T cells, stimulated by polyclonal 
activators ( Turka et al., 1990, Linsley et al., 1993) and this increased surface 
expression of CD28 can also be seen on activated T cells even in the absence 
of CD80 ligation (Figure 4.3). Similarly, FACS analysis of T cell blasts 
generated using SEB has shown that the activated cells are larger and express 
higher levels of CD28 (McLeod et al., submitted). This increased level of 
expression of CD28 in activated T cells suggests that stimulation of CD28 
may play an important role in augmentation of the immune response. As the 
CD80 transfectants had been able to ligate to CD28 on unstimulated T cells 
resulting in T cell activation (in conjunction with OKT3), these transfectants 
could be used to examine whether CD28 signalling following ligation of 
CD80 had any effect on already activated T cells.
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Figure 3.12 Surface expression of CD28 on purified T cells following 
stimulation by OKT3 and CD80
6 x 105 T cells were stimulated with OKT3 and 3 x 10 5 transfectants (CHO or 
CD80 transfectants) or CD80 transfectants only. The cells were removed at 24 
hourly intervals and stained with 9.3 ( anti-CD28 mAb). The surface 
expression of CD28 on the T cells was determined by FACS analysis.
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Figure 3.13. Calibration of Becton Dickinson FACStar Plus.
Standard fluorescent beads were analysed on the FACS and the laser 
calibrated to ensure that the same intensity of fluorescence (FL1) was 
obtained on all occasions.The data are representative of a single experiment 
(n>10).
Chapter 4.
CD28 stimulation in T cell blasts
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Effect of stimulating CD28 on T cell blast proliferation.
Previous studies have shown that both PHA activated T cell blasts and SEB 
activated T cell blasts were responsive to stimulation through CD28 (Ledbetter 
and Linsley, 1992; Linsley et al., 1993; Sansom et al., 1993). In order to 
investigate the role of CD28 in stimulating activated T cells, T cell blasts 
were produced by stimulating PBMCs with a number of mitogens - SEB 
(l|lg /m l) or PHA (10|ig/ml) or PMA (50ng/ml) plus Ionomycin (lpM ).
The resulting T cell blasts were washed and cultured in the presence of 
transfectants 4 days after their initial mitogenic stimulation. All three types of 
blasts showed an increase over background proliferation levels (using 
untransfected CHO cells as a control) when CD80 transfectants were present 
but not when CD58 transfectants were used (Figure 4.1). Under these 
conditions CD28 was able to respond to ligation by CD80 and the 
proliferative response of the T cell blasts was augmented. This was in contrast 
to unstimulated T cells which were unable to respond to CD80 transfectants 
alone.
Although all the T cell blasts generated could respond to CD80 stimulatory 
signals PMA/Ionomycin blasts were chosen for further experiments as the 
mitogenic stimuli could be removed by washing and it was possible to culture 
them in the absence o f exogenous IL-2 for longer than either the SEB or PHA 
blasts.
The time dependency of stimulation of T cell blasts was examined by 
stimulating T cell blasts 4, 6 , 8 and 10 days after initial mitogenic stimulation 
with CD80 transfectants. This revealed that proliferation of T cell blasts 
proliferation appeared to be time dependent as CD80 could only stimulate the 
blasts between days 4 - 8  post initial mitogenic signalling (Figure 4.2) - after 
that time the effect of CD80 was limited. This low response by the T cell 
blasts was not due to changes in the level of expression of CD28 as FACS 
analysis showed (Figure 4.3) that CD28 was always expressed on the surface 
of the T cells and was indeed upregulated with time. The method of producing 
T cell blasts did not result in downregulation of CD28 expression even at the 
initial stages of stimulation unlike stimulation of resting T cells using OKT3 
and CD80 transfectants. This was due to PMA and Ionomycin stimulating the 
T cells via components of the T cell signalling pathway (stimulation of PKC 
and extracellular Ca++ influx respectively) and not involving CD28 ligation. It
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may be that the lack of responsiveness by T cell blasts to further costimulation 
after 8 days represents a form of control by the T cells to ensure that an 
immune response can be enhanced in the early stages but not indefinitely so 
that the immune response may subside when no longer required.
The activated T cell blasts stimulated by the CHO cells show high levels of 
proliferation at day 4 but this level of proliferation declines rapidly over time 
(Figure 4.2). As the T cell blasts are able to proliferate without any further 
stimulation being supplied, this would suggest that some active signalling 
pathways are present in the T cells. However the decline in T cell proliferation 
with time in the absence of other stimuli suggests that these activation 
pathways may decay and proliferation as a result declines. The ability of 
CD80 to augment proliferation in activated T cells suggests that signalling 
through CD28 may synergise with the active signals present in activated T 
cells resulting in increased proliferation levels. The lack of augmented 
proliferation in older T cell blasts despite CD80 stimulation may be due to the 
signalling pathways in the T cells decaying to a point where the T cells are 
unable to respond to the CD28 signals generated.
Although CD28 signalling has been shown to augment proliferation of 
activated T cells, it is important to realise that this stimulation of already 
activated T cells is also a method of sustaining the immune response. The 
importance of CD28 in sustaining T cell responses has been demonstrated in 
vivo in CD28 knockout mice where murine T cells were able to respond to 
mitogen stimulation but this response could not be sustained (Lucas et al., 
1995). CD28 may play a major part in ensuring that T cells activated in 
response to foreign antigen can survive to ensure that the immune response 
generated does not quiesce too soon. However the activated T cells cannot be 
allowed to be continually sustained and lack of response of older T cell blasts 
to CD28 signalling may be a controlling mechanism.
However it should also be remembered that activation of T cells results in 
upregulation of CTLA-4 on the T cells which is known to provide negative 
signals to the T cells following ligation by CD80 (Krummel and Allison 1996, 
Walunas et al., 1996). The lack of responsiveness of older T cell blasts may be 
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Figure 4.1 Stimulation of T cell blasts by CD80.
T cell blasts (5 x 10^) 4 days after initial stimulation (with either PMA and 
Ionomycin or PHA or SEB) were cultured with transfectants (2 x 10^) as 
shown. Proliferation was measured after 48 hours using ^H thymidine 
incorporation. The data are from triplicate samples from a single 
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Figure 4.2 CD80 augmentation of T cell blast proliferation over time.
2 x 10^ PMA/Ionomycin T cell blasts at 4, 6, 8 and 10 days after their initial 
stimulation were cultured with 5 x 10^ transfectants as shown. Proliferation 
was measured after 48 hours using thymidine incorporation.The data are 
from triplicate samples from a single representative experiment (n = 3). 











Figure 4.3 Surface expression of CD28 on T cell blasts over time.
PMA and Ionomycin T cell blasts were stained on a daily basis using 9.3 
(anti-CD28 mAb) and the surface expression of CD28 on the T cell blasts 
determined by FACS analysis. The data are representative of a single 
experiment (n=5).
IL-2 production by T cell blasts stimulated through CD28.
As the CD80 transfectants were able to augment the proliferation of T cell 
blasts and a major feature of CD28 costimulation of purified T cells is 
increased IL-2 production, it was important to determine whether IL-2 
production in T cell blasts was affected by CD28 stimulation. T cell blasts 
were cultured with either CD80 transfectants, CD58 transfectants or the CHO 
parental cell line at 4, 6 , 8 and 10 days after the initial PMA/Ionomycin 
stimulation. The proliferation (Figure 4.2) demonstrated that only CD80 was 
able to augment the proliferation of the already activated T cell blasts.
In striking contrast to the proliferation data, IL-2 was only produced at 
significant levels when using T cell blasts 4 days after their initial stimulation 
Figure 4.4). However if older T cell blasts were used in the experiment (i.e. 6 , 
8 or 10 days after initial stimulation) although proliferation was enhanced by 
culturing in the presence of CD80 transfectants there was negligible 
production of IL-2 either by stimulated or unstimulated T cell blasts.
These results were surprising since it may suggest that IL-2 is not essential for 
some forms of T cell proliferation. However as has already been stated in 
chapter 3, the lack of detection of IL-2 may be due to the poor sensitivity of 
the bioassay used as only unbound IL-2 is measured. If the rate of IL-2 
production increases but at the same time the turnover rate of IL-2 also 
increases, the increase in IL-2 production levels would not be detected by the 
bioassay as there would be no increase in the levels of unbound EL-2. To try 
and address this issue, cytokine production was measured by examining the 
transcription levels of mRNA for EL-2. If EL-2 was being produced at higher 
levels but the turnover rate of the protein was such that its presence could not 
be detected using a bioassay there should have been an increase in the level of 
mRNA produced. Since the increase in proliferation of T cell blasts in 
response to CD28 stimulation using CD80 transfectants was striking, if IL -2 
production had increased and was responsible for generating this enhancement 
of T cell proliferation, the change in cytokine mRNA levels should be 
obvious. It was necessary to use RT-PCR (a method of amplifying mRNA) to 
detect levels of the mRNA of interest for two reasons - 1) the number of T 
cells available for use in each experiment was restricted by the amount of 
blood that could be donated and 2) the amount of RNA found in each cell is 
also limited (lOpg/cell) of which only 1-5% is mRNA.
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Figure 4.4 IL-2 production by T cell blasts.
2 x 104 T cell blasts 4, 6, 8 and 10 days post initial stimulation were cultured 
with 5 x 103 transfectants (as shown). IL-2 production was measured after 48 
hours using a CTLL bioassay respectively. The data are from triplicate 
samples from a single representative experiment (n = 3). Additional data is 
tabulated in appendix 5.
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Before determining whether the IL-2 mRNA levels of T cell blasts were 
increased by CD80 costimulation it was necessary to establish a reliable RT- 
PCR method. The RNA collected from the cells in each experiment was run 
out on a 1% agarose gel to ensure it had not degraded during its extraction. 
Figure 4.5 shows a typical RNA gel with the bands of ribosomal RNA (28s, 
18s and 6s) being visible. The next parameter to be determined was how soon 
after stimulation IL-2 mRNA was produced. PBMCs were stimulated with 
PMA and Ionomycin as before and RNA extracted either before stimulation or 
1, 3 or 5 hours after stimulation. The results of RT-PCR using primers for IL-2 
gene are shown in figure 4.6a. The IL-2 mRNA was not detected in 
unstimulated PBMCs (lane 4) but was present as soon as 1 hour after 
stimulation of the PBMCs with PMA and Ionomycin. The lack of EL-2 mRNA 
in unstimulated PBMCs was not due to degradation of the RNA as not only 
was the RNA checked prior to the RT-PCR being performed but primers for 
the GAPDH housekeeping gene were able to amplify cDNA from the 
unstimulated PBMCs (Figure 4.6b Lane 4). As there appeared to be little 
difference in the amount of IL-2 mRNA detected after 1, 3 or 5 hours it was 
decided to use 3 hours as a standard stimulation time before collecting RNA 
samples.
As T cell blasts were being cultured with fixed transfectants it was important 
to determine whether RNA could be extracted from the transfectants. Figure 
4.5 lane 1 clearly shows RNA from CD80 transfectants. However, when RNA 
from fixed transfectants was used in RT-PCR using primers for IL-2 and 
GAPDH only the GAPDH mRNA was detected (Figure 4.7 lane 3), IL-2 RNA 
transcripts were not present (lane 2). This suggested that although the mRNA 
from the fixed transfectants would be extracted along with that from the T cell 
blasts, the lack of mRNA for IL-2 in the transfectants would ensure that any 
IL-2 mRNA amplified using RT-PCR would have originated in the T cell 
blasts.
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Figure 4.5. Evaluation of RNA extraction from T cell blasts and transfectants. 
Approximately lpg of RNA extracted from T cell blasts and transfectants was 
evaluated on a 1% agarose gel by electrophoresis. The gel contained ethidium 
bromide which intercalates between the bases of the RNA and is fluorescent in 
UV light making the RNA visible. The bands in both lane 1 (RNA from CD80 
transfectants ) and lane 2 (RNA from T cell blasts) correspond to ribosomal 
RNA (28s, 18s and 6s).There is no large accumulation of RNA at the bottom 
of the gel indicating that the RNA had not degraded during the extraction 
process.
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Figure 4.6 IL-2 transcription in stimulated PBMCs.
5 x 10^ PBMCs were stimulated with PMA (50ng/ml) and Ionomycin (lpM ) 
and the RNA extracted 1, 3 and 5 hours post stimulation. RNA was also 
extracted from unstimulated PBMCs. The RNA was reverse transcribed and 
the cDNA produced was amplified using primers to the IL-2 and the GAPDH 
genes. The amplified DNA was separated on a 2%  agarose gel by
electrophoresis. The marker <j)X 174 DNA digested with Hae 111 was also run 
to indicate to size of the individual bands. Figure 4.6a shows IL-2 transcripts 
Figure 4.6b -GAPDH transcripts. Lane 1 contains the marker. Lane 4 
unstimulated PBMCs. The RNA extracted, reverse transcribed and cDNA 
amplified from stimulated PBMCs is shown in lane 5 (1 hour post 
stimulation) lane 6 (3 hours post stimulation) and Lane 7 (5 hours post 
stimulation).
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Figure 4.7 RNA from transfectants did not include IL-2 mRNA.
RNA from CD80 transfectants was extracted and reverse transcribed, the 
cDNA obtained was amplified by PCR using primers for the IL-2 and GAPDH 
genes. The resulting DNA was evaluated on a 2% agarose gel. The marker 0X 
174 DNA digested with Hae 111 was also run to indicate to size of the 
individual bands. The marker is in lane 1. The DNA produced by 
amplification using the IL-2 primers is shown in lane 2 whereas the DNA 
produced using the GAPDH primers is in lane 3.
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Having established that RT-PCR could be used to detect mRNA for IL-2 in 
PBMCs and that although fixed transfectants did contain mRNA this did not 
include IL-2 mRNA, this technique was used to examine IL-2 mRNA in T cell 
blasts. T cell blasts were cultured with either CD80 transfectants or CHO 
parental cells for 3 hours and their RNA extracted. RT-PCR showed (Figure 
4.8a) there were no substantial differences in the level of EL-2 mRNA present 
in the T cell blasts comparable to that seen in Figure 4.6. If the level of the 
mRNA from GAPDH is examined (Figure 4.8b) similar levels were found in 
all T cell blasts regardless of age and stimulation confirming that the lack of 
substantial variation in IL-2 levels was not due to discrepancies in the RT- 
PCR method.
The lack of tangible variation in IL-2 mRNA levels in T cell blasts was 
unexpected since proliferation in response to CD28 signalling in T cell blasts 
increased and a major feature of CD28 signalling in resting T cells is to 
increase IL-2 mRNA transcription and increase its stability. However, the 
ability of CD28 to generate signals resulting in increased proliferation o f T 
cell blast in the absence of IL-2 production suggests that a different signalling 




Figure 4.8: EL-2 transcription from T cell blasts stimulated by transfectants.
T cell blasts were produced (as detailed in figure 4.6) and 5 x 10^ blasts (4, 6 
or 8 days post stimulation) were cultured with 1 x 10^ transfectants (CHO or 
CD80) and the RNA extracted after 3 hours. The RNA was reverse transcribed 
and amplified by PCR using IL-2 or GAPDH primers. The resulting DNA was 
evaluated on a 2% agarose gel by electrophoresis. The marker <J)X 174 DNA 
digested with Hae 111 was also run to indicate to size of the individual bands. 
Figure 4.8a shows IL-2 transcription 
Figure 4.8b shows GAPDH transcription
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The increase in T cell proliferation by activated T cell blasts following 
stimulation of CD28 in the absence of IL-2 production highlights the multiple 
roles CD28 signalling has in T cell activation. Although the most obvious 
feature of CD28 signalling is the effect these signals have on IL-2 gene 
transcription (increasing transcription, stabilising IL-2 mRNA and induction 
of IL-2 transcription factors (Tonks et al., 1988; Fraser et al., 1991; Fraser et 
al., 1993; Edmead et al., 1996) other signals must be involved to sustain T 
cell proliferation in already activated T cells in the absence of IL-2. Previous 
research has demonstrated that CD28 costimulatory signalling is required to 
prevent induction of anergy or apoptosis in unstimulated T cells. The ability of 
CD28 to sustain the survival of T cells may be as a result of CD28 signalling 
upregulating the transcription of the bcl-xl gene which is known to protect 
cells from apoptosis (Boise et al., 1993). The evidence from CD28 knockout 
mice also suggest a protective role for CD28 as the T cells in these mice 
although able to respond to stimuli are not able to sustain an immune response 
(Lucas et al., 1995). Perhaps the lack of a protective signal by CD28 to the 
activated T cells in the knockout mice resulted in the induction of apoptosis.
The signals generated by CD28 following ligation by CD80 are complex and 
can result in the induction of IL-2 production which will activate unstimulated 
T cell and generate proliferation, as well as prolong an already established 
immune response in the absence of IL-2. In both these situations CD28 
signalling results in the survival of the T cell - lack of CD28 signalling can 
result in apoptosis in previously unstimulated cells and prevent sustaining an 
immune response in activated T cells (Tanaka et al., 1995; Kawabe and Ochi, 
1991; Nicolle et al., 1994; Lucas et al., 1995). One of the consequences of T 
cell activation is the upregulation of CTLA-4 and CD80 and the possible 
interactions between T cells bearing all three surface ligands (i.e. CD80, CD28 
and CTLA-4) has still be fully investigated and understood.
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Chapter 5 
CD86 - a second ligand for CD28
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Effect of CD86 on costimulation of purified T cells.
With the discovery of a second ligand for CD28 - CD86 (also known as B70 
or B7-2) (Hathcock et al., 1993; Freeman et al., 1993; Azuma et al., 1993a), it 
was important to determine whether CD86 had a role to play in T cell 
activation. As described in Chapter 3, a CD86 transfectant was generated and 
cloned to produce a stable expressing cell line which could be used in the 
established test system to determine if there were any functional differences 
between the two CD28 ligands - CD80 and CD86 .
To determine whether the CD86  transfectant could provide the necessary 
costimulatory signals to activate T cells, purified unstimulated T cells were 
cultured in the presence of OKT3 with CD80, CD86  transfectants and the 
untransfected parental cell line. CD86 transfectants were capable of providing 
costimulatory signals to purified T cells in conjunction with OKT3 resulting in 
IL-2 production and T cell proliferation (Figure 5.1). This demonstrated that 
CD86 ligation of CD28 could generate the necessary costimulatory signals to 
induce T cell proliferation and IL-2 production and CD86 could function as an 
alternative ligand for CD28 costimulation. However, although both CD80 and 
CD86  costimulation resulted in T cell proliferation the level of proliferation 
produced by CD86  transfectants was always greater than that produced by 
CD80 transfectants. The margin of this difference varied between individuals 
(Figure 5.2) but on all occasions proliferation in response to CD 86 
costimulation was higher. This variation in proliferation levels generated was 
not due to differences in surface expression of CD80 and CD86  on the CHO 
transfectants as FACS analysis of the cloned transfectants show similar levels 
of expression (Figure 5.3). The increased levels of proliferation generated 
when CD86  transfectants were providing costimulation was not due to greater 
affinity of the ligand for its receptor as CD86 has a similar receptor binding 
properties to CD80 (Linsley et al., 1994). The only major difference between 
CD80 and CD86  is in their distribution with CD86  being more widely 
expressed than CD80 which tends to be expressed later following activation. It 
would therefore seem likely that CD86 would be the ligand available to bind 
CD28 in unstimulated T cells and provide the necessary costimulatory signals 
i.e. CD 86  may be the primary natural ligand for CD28. This difference 
between the efficiency of CD86  and CD80 transfectants to costimulate 
purified T cells has also been seen in research on antigen - specific mouse T 
cells (Hathcock et al., 1994). Using blocking mAbs to CD80 and CD86 , 
proliferation of the antigen specific T cells in response to antigen presented by
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mitomycin -treated APCs could only be inhibited by the addition of anti- 
CD86  mAbs and that addition of anti-CD80 mAbs did not result in increased 
inhibition. This suggested that CD86 was primarily involved in providing the 
necessary costimulation to the T cells. In vivo studies also suggest a dominant 
role for CD86 in the primary immune response as CD86 knockout mice were 
found to be severely immunocompromised whereas CD80 knockout mice 
were able to mount an effective humoral and cell mediated immune response 
(Borriello et al., 1997).
The research using antigen- specific mouse cells (Hathcock et al., 1994) also 
showed that blocking CD86  costimulation inhibited IL-2 production but not 
the induction of activation antigens - CD69 and IL-2R a  chain. Blocking 
CD86  - CD28 interactions would result in inhibiting the CD28 signals which 
are involved in induction of the IL-2 gene - increasing IL-2 mRNA 
transcription, increasing the stability of the IL-2 mRNA and the induction of 
transcription factors for the IL-2 gene. The lack of IL-2 production suggests 
that the antigen specific signals generated by the TCR were insufficient to 
induce IL-2 production. This requirement for CD28 signalling has already 
been demonstrated (Chapter 3) where costimulatory signals provided by either 
CD58 transfectants or untransfected CHO cells were unable to induce IL-2 
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Figure 5.1 CD86 costimulation of purified T cells.
3 x 10^ T cells were stimulated in the presence of OKT3 (lpg/m l) with 2 x 
10^ transfectants as shown. Proliferation and IL-2 production were measured 
after 48 hrs by thymidine incorporation and CTLL bioassay respectively. 
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Figure 5.2 Comparison of CD86 and CD80 costimulation of purified T cells 
from different donors.
3 x 10^ T cells were stimulated in the presence of OKT3 (lpg/m l) with 2 x 



















Figure 5.3 Comparison of surface expression levels of CD80 and CD86 on 
transfectants.
CD80 and CD86 transfectants were stained with their respective mAbs (BB1 
for CD80 and IT2.2 for CD86). The surface expressions of CD80 and CD86 
on the transfectants was determined by FACS analysis. The background level 
of fluorescence for each transfectant is also shown. The data are representative 
of a single experiment (n>10).
Effect of CD86 stimulation on activated T cells.
Having demonstrated that CD86 ligation could provide the necessary 
costimulatory signals to induce IL-2 production and T cell proliferation, it was 
important to assess if CD86 could stimulate previously activated T cells. The 
results shown in Figure 5.4 demonstrated that CD86  was indeed able to 
enhance T cell blast proliferation as had CD80. Similarly, this enhancement of 
proliferation was time dependent with the greatest effect being seen in day 6 
and day 8 blasts. By day 10 there was limited stimulation by CD86 . However, 
although CD86  was able to enhance proliferation of previously activated T 
cell blasts it did not appear as effective a stimulator as CD80. This was seen 
on every occasion but as with comparison of costimulation of unactivated T 
cells, the margin of the difference in proliferation generated varied depending 
on the individual T cell donor (Figure 5.5). This difference in enhanced 
proliferation between CD80 and CD86 was not due to variation in the surface 
expression of these molecules (see Figure 5.3). In fact the effect of stimulating 
T cell blasts with CD80 and CD86 transfectants was the reverse of that 
obtained when resting T cells were used where CD86  provided the greater 
costimulatory signals. It may be that as CD80 expression is upregulated on 
activation, CD80 rather than CD86 is the more natural ligand for CD28 on 
activated T cells. This suggests that CD86 is involved in induction of T cell 
proliferation, whereas CD80 may be responsible for sustaining T cell 
activation.
CD86 has been shown to stimulate T cell blasts although not as effectively as 
CD80. As a major feature of CD28 costimulation in unactivated T cells is 
increasing IL-2 production it was important to assess if CD86 stimulation of T 
cell blasts had any effect on IL-2 production. The results of stimulation of T 
cell blasts by CD86 on IL-2 production were consistent with those produced 
by CD80 stimulation of T cell blasts - i.e. high levels of IL-2 production were 
only detectable in Day 4 T cell blasts (figure 5.6). Older blasts although 
stimulated by both CD80 and CD86 (as seen by their increased proliferation 
levels) did not produce detectable levels of IL-2. As with CD80 stimulation of 
T cell blasts this lack of detection of IL -2 production by older blasts may be 
due to the limitations of the bioassay used which only measures unbound IL-2. 
To determine whether there was increased IL-2 production by older T cell 
blasts, mRNA from T cell blasts stimulated by CD86 was extracted and 
amplified using RT-PCR (Figure 5.7). As already seen for CD80 in chapter 4 
although T cell proliferation was augmented by ligation of CD86  transfectants
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there was no substantial increase in the level of IL-2 mRNA transcription 
detected in the T cell blasts. This lack of substantial variation in IL-2 
transcription levels was not due to inconsistencies in the RT-PCR method used 
as the level of transcription of the housekeeping gene GAPDH was the same 
for all the T cell blasts regardless of their age or the cells they had been 
cultured with.
Thus, as with CD80 stimulation of T cell blasts, although CD86  was able to 
enhance proliferation of T cell blasts this did not appear to be due to increased 
IL-2 production as demonstrated by both the bioassay and the RT-PCR. This 
suggests that although CD86 ligation of CD28 was having an effect on T cell 
blast proliferation the signals generated by the interaction of CD28 and CD86 
were not the same as those generated when purified unstimulated T cells were 
stimulated. A major function of CD28 signalling is to increase IL-2 mRNA 
transcription and increase its stability (Lindsten et al., 1989; Fraser et al., 
1991). The IL-2 data from the bioassay and the RT-PCR suggests that IL-2 
was not involved in increasing T cell blast proliferation in response to 
signalling through CD28 and that an alternative signalling pathway had been 
used resulting in increasing T cell blast proliferation. CD28 signalling will be 
discussed in Chapter 6 .
These experiments have shown that CD86 can act as a ligand for CD28 and 
induce T cell proliferation in both unstimulated T cells (in conjunction with 
OKT3) and in T cell blasts. The signals generated by CD28 in unstimulated T 
cells following ligation with CD86 induced IL-2 production whereas in T cell 
blasts there was no apparent induction of IL-2 production 6 or more days after 
the initial stimulation by PMA and Ionomycin. Although CD86  appeared to 
function in a similar way to CD80 there were differences in their efficiency. 
CD86  was more efficient in stimulating previously unactivated T cells (in 
conjunction with OKT3) to proliferate but was less efficient at increasing the 
proliferation of activated T cell blasts. It may be that each ligand has a specific 
role to play in the T cell immune response with CD86  being involved in the 
initial response and CD80 in augmenting the already activated T cells. The 
distribution of CD80 and CD86 to some extent confirms this suggestion as 
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Figure 5.4 CD86 stimulation of T cell blasts over time.
2 x 10^ PMA/Ionomycin T cell blasts at 4, 6, 8 and 10 days after their initial 
stimulation were cultured with 5 x 10^ transfectants as shown. Proliferation 
was measured after 48 hours using thymidine incorporation . The data are 
from triplicate samples from a single representative experiment (n = 3). 
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Figure 5.5 CD86 stimulation of T cell blasts.
5 x 104 T cell blasts (6 days post initial stimulation) from two different blood 
donors were cultured with 5 x 10^ transfectants as shown. Proliferation was 
measured after 48 hours using thymidine incorporation.
108
600 V
□  CHO 






Figure 5.6 IL-2 production by T cell blasts in response to CD86 stimulation.
2 x 10^ PMA/Ionomycin T cell Blasts at 4, 6, 8 and 10 days after their initial 
stimulation were cultured with 5 x 10^ transfectants as shown. EL-2 production 
was measured after 48 hours using a CTLL bioassay. The data are from 
triplicate samples from a single representative experiment (n = 3).
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Figure 5.7 IL-2 transcription from T cell blasts stimulated by CD86 
transfectants.
IL-2 transcription from T cell blasts stimulated by transfectants.
T cell blasts were produced (as detailed in figure 4.6) and 5 x 10^ blasts (4, 6 
or 8 days post stimulation) were cultured with 1 x 10^ transfectants (CHO, 
CD80 or CD86) and the RNA extracted after 3 hours. The RNA was reverse 
transcribed and amplified by PCR using IL-2 primers. The resulting DNA was 
evaluated on a 2% agarose gel by electrophoresis. The marker (J)X 174 DNA 
digested with Hae 111 was also run to indicate to size of the individual bands. 
Figure 5.7a shows IL-2 transcription 
Figure 5.7b shows GAPDH transcription
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The research on mouse T cells discussed earlier suggests that CD86 may be 
the main provider of costimulation of T cells in conjunction with TCR 
signalling (Hathcock et al., 1994). This has also been seen in human T cells 
where anti-CD86  blocking antibodies were more effective at inhibiting a 
mixed leukocyte reaction (MLR) than anti-CD80 mAbs (Azuma et al., 1993b). 
Examination of the role of CD80 and CD86 in generating cytokine production 
has shown that CD 86 costimulation preferentially induces EL-4 production 
particularly in naive T cells (Freeman et al., 1995). In repeatedly costimulated 
T cells both CD80 and CD86 induce both IL-2 and EL-4 but CD80 is the more 
potent stimulator of EL-2 (Freeman et al., 1995). The induction of IL-2 by 
repeatedly activating T cells seems to contradict the lack of EL-2 production by 
T cells blasts stimulated by CD80 and CD86 transfectants as demonstrated 
above and in Chapter 4. However it should be noted that the restimulation of 
the T cells by Freeman et al. was by MLR which would involve stimulation 
via both the TCR and CD28. This double signal is required for IL-2 
production. More recent in vivo studies using double knock-out mice (i.e. 
lacking both CD80 and CD86  genes) has found that both CD80 and CD86 
play a critical role in humoral immune responses particularly in 
immunoglobulin class switching (Borriello et al., 1997). Although this 
research is investigating the role CD28 plays in T cell responses following 
ligation by either CD80 and CD8 6 , the knockout mice data clearly 
demonstrates that CD28 and its ligands also play a major role in B- cell 
generated immune responses.
The data generated so far have shown that CD28 is as essential molecule 
whose stimulation by CD80 and CD86 results in the generation and sustaining 
of T cell responses. The fact that there are two counter-receptors for CD28 
which appear to generate similar signals resulting in T cell proliferation in 
resting T cells as well as augmenting T cell blast proliferation may suggest 
that one of these receptors is functionally redundant. However there are a 
number of differences between CD80 and CD86  which suggest they may 
perform different functions.
Distribution of CD80 and CD86  is markedly different, with CD80 expression 
being restricted to activated cells whereas CD86  is found on resting 
monocytes. Studies examining CD80 and CD86 expression on activated B 
cells shows marked differences in both the kinetics of expression and the 
induction of CD80 and CD86 expression which appears to depend on the 
stimulus applied (Hathcock et al., 1994). This difference in expression of
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CD80 and CD86 suggested that perhaps CD86 was required for the initiation 
of an immune response and CD80 was required for amplification of the 
immune response. This is to some extent seen in this research where CD86  is 
more effective at providing costimulation to resting T cells than CD80 i.e. 
more effective in the initiation of T cell activation. However when already 
activated T cells are examined CD80 is more effective at augmenting T cell 
proliferation.
The functional outcome of CD80 and CD86  ligation in terms of cytokine 
production has also shown marked differences. Although both ligands are able 
to stimulate T cells to produce IL-2 and IFN-y, CD86 preferentially stimulates 
IL-4 production (Freeman et al., 1995). As IL-4 is associated with the Th2 
subpopulation of T helper cells, it may be that stimulation of T cells by CD86 
results in the generation of Th2 T cells whereas CD80 stimulation results in 
Thl cells being generated. This has been to some extent supported by research 
into the mouse model of experimental allergic encephalomyelitis (EAE). If 
CD80 interactions were blocked using mAbs the mice generated Th2 cells 
whereas if CD86  interactions were blocked T h l cells were generated 
(Kuchroo et al., 1995).
It is well established that CD80 and CD86 can act as counter-receptors for 
CD28 resulting in the generation of signals which can induce IL-2 production 
and proliferation in resting T cells as well as sustaining proliferation of already 
activated T cells. However there is a CD28 homologue, CTLA-4 , which is not 
considered to be a redundant molecule. Evidence for CTLA-4 involvement in 
T cell activation has been predominantly from mouse studies where CTLA-4 
signalling has been shown to act as a negative regulator of T cell activation. 
This negative regulation has been shown to be due to inhibition of IL-2 
production and inhibiting proliferation by disruption of the cell cycle rather 
than induction of apoptosis (Krummel and Allison, 1996; Walunas et al., 
1996). It is possible that a feature of CD80 and CD86  interactions with T cells 
could be that CD86 is predominantly involved with CD28 whereas CD80 is 
the main counter-receptor for CTLA-4. This is seen to some extent by the 
binding kinetics of CD80 and CD86 to CTLA-4. Both CD80 and CD86 bind 
CTLA-4 with similar affinity but the rate o f dissociation of CD80 from 
CTLA-4 is much slower than CD86  (Linsley et al., 1994). The surface 
expression of CTLA-4 and CD80 is also similar - both are expressed following 
T cell activation i.e. both receptor and counter-receptor are only present 
following activation. The involvement of CTLA-4 in T cell activation is still
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being investigated and the interactions between of CD80, CD86 and their 
receptors CD28 and CTLA-4 may prove to be highly complex. It is likely that 
CD28 and CTLA-4 as well as CD80 and CD86 have distinct roles to play in 





The ability of CD28 to provide the correct signals to the T cell requires a 
sophisticated signalling system. Although the signalling mechanism of CD28 
was not examined directly, it was possible using a selective inhibitor to 
determine the effect on T cell function of disrupting CD28 signalling. A major 
insight into CD28 signalling was the observation that ligation of CD28 by 
CD80 led to an increase in phosphatidylinositol-(3,4,5)-trisphosphate 
production (Ward et al., 1993). This suggested that the CD28 signalling 
pathway utilised phosphoinositide 3 kinase (PI3-kinase). Further research 
demonstrated that ligation of CD28 by CD80 resulted in the p85 subunit of 
PI3-kinase associating with CD28 possibly via the YXXM m otif in the 
cytoplasmic tail of CD28 (Ward et al., 1995). The association of PI3-kinase 
with CD28 signalling meant it was possible to utilise inhibitors of PI3-kinase 
such as wortmannin to examine the effect of disruption of this CD28 
signalling pathway on T cell activity.
Effect of wortmannin on CD28 costimulation of purified T cells.
W ortmannin (a fungal metabolite) is known to bind irreversibly to the p i 10 
catalytic subunit of PI3-kinase and inhibit the catalytic activity of the enzyme 
(Arcaro and Wymann 1993). To test whether disruption of PI3-kinase activity 
had any effect on T cell activation, wortmannin was added to T cells cultured 
in the presence of OKT3 10 minutes prior to the addition of costimulatory 
transfectants. This allowed the wortmannin time to bind to the p i 10 subunit 
of PI3-kinase prior to costimulation of the T cells. As T cell costimulation has 
been shown to be CD28 dependent, this is a reasonable test of whether PI3- 
kinase might be involved in CD28 signalling.
The experiment revealed that wortmannin, at concentrations as low as InM, 
could inhibit T cell activation, in response to OKT3 and CD80 costimulation, 
resulting in reduced proliferation (Figure 6.1). The reduction in proliferation 
was irreversible as measuring proliferation on a daily basis following 
incubation of T cells with wortmannin (ljuM) in the presence of OKT3 and 
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Figure 6.1: Wortmannin inhibition of T cell proliferation 
Purified T cells (5 x 10^ ) were cultured with CD80 transfectants (2 x 10^ ) in 
the presence of OKT3 (lpg/m l) and wortmannin at various concentrations 
Proliferation was measured after 72 hours using thymidine incorporation. 
The data are from triplicate samples from a single representative experiment 
(n = 4).
116




















Figure 6.2: Kinetics of wortmannin inhibition of T cell proliferation .
Purified T  cells (2 x 104  ) were cultured with transfectants (2 x 10^ ), either 
CHO or CD80 in the presence of OKT3 (lpg/m l) and the presence / absence 
of wortmannin (lpM ). Proliferation was measured every 24 hours using 
thymidine incorporation .The data are from triplicate samples from a single 
representative experiment (n = 3).
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To test whether the efficiency of blocking PI3-kinase activity was affected by 
preparing wortmannin in advance, the drug solution was prepared and 
incubated overnight at 37°C before being added to a T cell stimulation 
experiment as before. The wortmannin which had been pre-incubated for 24 
hours was unable to prevent T cell activation in the presence of OKT3 and 
CD80 transfectants (Figure 6.3b). However freshly prepared wortmannin was 
able to inhibit T cell proliferation (Figure 6.3a). This clearly demonstrated that 
the ability of wortmannin to block T cell activation could be impaired if the 
PI3-kinase inhibitor was prepared in advance. In all experiments wortmannin 
was freshly prepared and used immediately to overcome the problem of its 
instability in aqueous solutions.
Although wortmannin was shown to inhibit T cell proliferation it was possible 
that wortmannin was not blocking CD28 signalling but was preventing 
proliferation by disrupting the IL-2 receptor signalling pathway as T cells 
proliferate in response to DL-2 ligation of the IL-2R. To determine whether 
wortm annin was blocking CD28 signalling or IL-2R signalling two 
experiments were carried out. Firstly the effect of wortmannin on IL-2 
production by T cells stimulated with OKT3 and CD80 was examined. As a 
major function of CD28 signalling is to increase IL-2 mRNA transcription and 
increase IL-2 mRNA stability, loss of IL-2 production would indicate that the 
CD28 signalling pathway was being blocked by wortmannin. To determine if 
wortmannin was blocking IL-2R signalling rather than CD28 signalling, 
addition of the PI3-kinase inhibitor should prevent the IL-2 stimulated 
proliferation of T cell blasts.
The results of the experiments clearly showed that wortmannin blocked EL-2 
production in T cells stimulated with OKT3 and CD80 (Figure 6.4b) but had 
no effect on the stimulation of T cell blasts using exogenous IL-2 (Figure 
6.4a). This suggests that wortmannin was blocking the signalling pathway 
which led to activation of the IL-2 gene and not the downstream event of EL-2 
receptor signalling. The lack of inhibition of IL-2 specific proliferation of T 
cell blasts by wortmannin also demonstrated that its effect on purified T cells 
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Figure 6.3: Stability of wortmannin in aqueous solution.
Purified T cells (5 x 10^ ) were cultured in the presence of OKT3 (lpg/m l) 
with either CHO or CD80 transfectants (2 x 10^ ) with either freshly prepared 
wortmannin or wortmannin which had been pre-incubated at 37°C for 24 
hours prior to its use. Proliferation was measured using thymidine 
incorporation after 48 hours. The data are from triplicate samples from a 
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Figure 6.4 : Wortmannin inhibition of T cell signalling.
a) T cell blasts (5 x 10^ )  were induced to proliferate in response to increasing 
amounts of IL-2 in the presence/absence of wortmannin (10|iM). Proliferation 
was measured using thymidine incorporation after 48 hours in culture.
b) Purified T cells (5 x 10^ )  were cultured with CD80 transfectants ( 2  x 10^)
and OKT3 ( l|ig /m l)  in the presence of increasing concentrations of
wortmannin. Proliferation and IL-2 production were measured using 
thymidine incorporation and a CTLL bioassay respectively after 48 hours The 
data are from triplicate samples from a single representative experiment (n =
3).
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Although the signalling pathways utilised by CD28 were not examined 
directly, it was possible to show that wortmannin could functionally effect the 
stimulation of previously unactivated T cells and that this involved inhibition 
of IL-2 production. This inhibition indicated that the blockade occurred during 
the initial signals required for IL-2 production and not a later signal generated 
when IL-2 bound to its receptor.
Subsequent research by Ueda et al., (1995) has also shown that wortmannin 
was able to block IL-2 production in primary T cells when stimulated by anti- 
CD3 mAbs and either anti-CD28 mAbs or CD80 transfectants confirming the 
results shown in Figure 6.4b. However, the T cells used by Ueda et al., were 
rested T cell blasts (which had been generated using anti-CD3 and anti-CD28 
mAbs) and subsequently restimulated. The sensitivity to wortmannin of these 
rested T cell blasts contradicts the results found when wortmannin was used to 
block IL-2 stimulation of T cell blasts (Figure 6.4a). The difference in the 
sensitivity of T cell blasts to wortmannin may depend on whether they are 
activated or resting i.e. may be due to the differences in the cell cycling of 
rested and activated T cell blasts. The T cell blasts which were being IL- 2 
stimulated were already dividing in the absence of EL-2 whereas the rested T 
cell blasts were not actively cell cycling and on stimulation via CD3 and 
CD28 the T cell blasts would then enter the cell cycle. This induction to cell 
cycling may involve signalling via PI3-kinase which could then be blocked by 
the addition of wortmannin. In the case of the activated T cell blasts which 
were already cell cycling, it is possible that the signalling pathways used in 
these cells do not require PI3-kinase and therefore T cell blasts are insensitive 
to wortmannin.
This difference in response to wortmannin depending on the activation state of 
the T cell is also seen when wortmannin is used to block CD28 signalling in 
Jurkat cells. Wortmannin has been shown to have no effect on EL-2 secretion 
in Jurkat cells following ligation of CD28 in the presence of PMA and 
Ionomycin (Lu et al., 1995). As Jurkat cells are an activated cell line and 
therefore actively dividing their insensitivity to wortmannin could also be due 
to the signalling pathways used in the cell cycle not requiring PI3-kinase.
The functional studies undertaken to examine the effect of wortmannin on T 
cell activation have shown that not only was T cell proliferation inhibited but 
this was achieved by blocking IL-2 production. As wortmannin is known to 
bind irreversibly to the p i 10 subunit of PI3- kinase and inhibit its activity this
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would suggest that PI3 - kinase is involved in T cell signalling. Additionally, 
as CD28 signalling is involved in the induction of IL-2 gene transcription (by 
increasing transcription and the stability of the mRNA as well as induction of 
gene transcription factors such as the CD28RC) this would suggest that PI3- 
kinase may be associated with the CD28 signalling pathway.
There have been a number of biochemical studies showing the relationship 
between CD28 and PI3-kinase. Ligation of CD28 by CD80 resulted in the 
formation of D - 3 phosphoinositides (which are the products of PI3-kinase 
activity) in the absence of TCR/CD3 activation (W ard et al., 1993). 
Subsequently, it was demonstrated that CD28 was directly associated with the 
p85 subunit of PI3-kinase and that this association was ligand dependant. 
(Ward et al., 1995). The lipid kinase activity associated with CD28 following 
ligation by CD80 was shown directly using HPLC analysis to be due to PI3- 
kinase as well as indirectly by increased formation of D-3 phosphoinositides. 
The PI3-kinase activity was abrogated by the addition of lOOnM wortmannin 
but the physical association of CD28 and the regulatory p85 subunit was 
unaffected (Ward et al., 1995). There is further evidence of PI-3 kinase 
association with CD28 in two studies examining CD28 signalling in Jurkat 
cells. An examination of the protein tyrosine kinases (PTKs) involved in 
phosphorylating the YMNM m otif in the cytoplasm ic tail o f CD28 
demonstrated that p56lc^ and p59fyn were capable of phosphorylating the 
YMNM m otif which led to recruitment of the p85 subunit of PI3-kinase 
(Raab et al., 1995). It has also been shown that the association between CD28 
and PI3-kinase in Jurkat cells can be inhibited by the phorbol ester PMA. This 
inhibition was found to persist and blocked PI3-kinase activity following 
stimulation of the cells with anti-CD28 mAbs (Hutchcroft et al., 1995). The 
same study also demonstrated the lack of inhibition of wortmannin on IL-2 
induction following stimulation of Jurkat cells with PMA and anti-CD28 
mAbs. As PMA activates protein kinase C and wortmannin was unable to 
block IL-2 production by Jurkat cells this suggests that PI3-kinase is not 
involved in CD28 dependent IL-2 production in Jurkat cells. The conclusion 
that CD28 signalling in Jurkat cells may not involve PI3-kinase suggests that 
there may be more than one signalling pathway following CD28 ligation 
depending on the state of activation of the T cells. This has also been shown 
by the lack of effect of wortmannin on IL-2 stimulation of T cell blasts (Figure 
6.4a). It was therefore important to examine the effect of wortmannin on 
CD28 only stimulation of T cell blasts. This would give an insight into 
whether PI3-kinase was involved in CD28 signalling in T cell blasts in the
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same way as it is involved in CD28 signalling in previously unstimulated T 
cells.
Effect of wortmannin on stimulation of T cell blasts.
Having previously demonstrated that T cell blasts could be stimulated by 
CD80 transfectants resulting in increased proliferation, it was now possible to 
investigate CD28 signalling and determine whether PI3-kinase was involved 
in the CD28 signalling pathway in activated T cell blasts.
T cell blasts were cultured in the presence or absence of wortmannin in 
conjunction with transfectants. The results in Figure 6.5 show that even at a 
concentration as high as 10|iM, wortmannin had no effect on the 
augmentation of T cell blast proliferation by CD80 costimulation. This 
inability o f wortmannin to block CD28 signalling was irrespective of the time 
after initial mitogenic stimulation that costimulation was administered (Figure 
6 .6 ). Similarly wortmannin had no obvious effect on IL-2 production by the 
T cell blasts with high levels of IL-2 being produced by T cell blasts 4 days 
post initial stimulation and negligible IL-2 by older T cell blasts. (Figure 6.7). 
These data suggest that PI-3 kinase was not involved in the CD28 signalling 






Figure 6.5 Wortmannin inhibition of T cell blasts.
5 x 10^ PMA/Ionomycin T cell blasts 7 days post initial stimulation were 
cultured with 2 x 10^ transfectants in the presence of increasing concentrations 
of wortmannin. Proliferation was measured using thymidine incorporation 
after 48 hours. The data are from triplicate samples from a single 
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Figure 6.6  Wortmannin inhibition of T cell blasts over time.
5 xlO^ T cell blasts (4, 6 and 8 days post initial stimulation) were cultured 
with 1 x 10^  transfectants in the presence of increasing concentrations of 
wortmannin. Proliferation was measured using thymidine incorporation 
after 48 hours. The data are from triplicate samples from a single 
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Figure 6.7 Wortmannin inhibition of IL -2 production by T cell Blasts.
IL-2 production by T cell blasts (5 x 10^), cultured with transfectants (1 x 
10^) and in the presence of increasing concentrations of wortmannin, was 
measured after 48 hours using a CTLL bioassay (see Figure 6.6 for 
proliferation data). The data are from triplicate samples from a single 
representative experiment (n = 3).
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The lack of inhibition of wortmannin on CD28 stimulation of T cell blasts is in 
line with research on Jurkat and other activated T cells. The slight induction of 
IL-2 production shown in Day 6 T cell blasts at high concentrations of 
wortmannin (Figure 6.7) coincides with results obtained when Jurkat cells 
were cultured with wortmannin where a small induction of IL-2 secretion was 
seen (Ueda et al., 1995). The lack o f inhibition of wortm annin on 
enhancement of T cell proliferation as a result of CD28 ligation suggests that 
PI3-kinase was not involved in the CD28 signalling pathway in activated T 
cells. In chapter 5, wortmannin has already been shown to inhibit IL-2 
production in previously unstimulated T cells (cultured with OKT3 and CD80 
transfectants) which suggests that the IL-2 induction pathway in those T cells 
involves PI3-kinase. Lack of IL-2 production by T cell blasts (Day 6 or older 
- Figure 4.4) would suggest that the IL-2 production signalling pathway was 
not involved in the CD28 signals generated in the activated T cell blasts and 
therefore no PI3-kinase activity was occurring. However the ability of 
activated T cell blasts to respond to CD28 signalling in the absence of IL-2 
suggests that an alternative signalling pathway is involved and lack of 
inhibition by wortmannin suggests that this alternative signalling pathway 
generated by CD28 does not involve PI3-kinase.
Recent research has shown that CD28 can utilise a sphingomyelinase 
signalling pathway (Edmead et al., 1996). The research examined the 
induction of transcription factors and the sensitivity of this induction to 
enzym e inhibitors. CD28 ligation was shown to generate the AP-1 
transcription factor and since this AP-1 induction was wortmannin sensitive, 
PI3-kinase was probably involved in the signalling pathway. However 
induction of the transcription factor, NF-kB, by CD28 was insensitive to 
wortmannin but could be inhibited by chloroquine (which modifies lysosomal 
pH and can inhibit acidic sphingomyelinase) suggesting that PI-3 kinase is not 
involved in this signalling pathway - acidic sphingomyelinase was used 
instead. IL-2 production requires the presence of a number of transcription 
factors including AP-1, NF-kB and NF -AT. Using T cell blasts and 
stimulating them with CD80 transfectants resulted in the production of AP-1 
and NF-kB only and no IL-2 production. This suggests that TCR engagement 
and signalling is required for NF-AT production and all three transcription 
factors required for IL-2 production. Using TCR only or TCR and CD28 
stimulation in T cell blasts 6 days or more post initial stimulation all three 
transcription factors were induced and IL-2 production could be detected 
which confirmed the necessity of NF-AT for IL-2 production.
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The ability of CD28 to use a different signalling pathway - acidic 
sphingomyelinase could perhaps explain the lack of effect of wortmannin on T 
cell blasts stimulated by CD80 transfectants (Figure 6.5). It may be that 
mitogen stimulation of PBMCs using PMA and Ionomycin results in the 
generation of the transcription factors AP-1, NF-kB and NF-AT and therefore 
IL-2 production (as detected by the bioassay for Day 4 blasts). The T cells 
then proliferate in response to EL -2. With time the level of proliferation of the 
T cell blasts declines due to a decrease in the level of IL-2 production (as seen 
by lack of detection of IL-2 by the bioassay in older T cell blasts). This decline 
in IL-2 production in the T cell blasts is similar to the profile of IL-2 
production by purified T cells stimulated with OKT3 and CD80 transfectants 
(Figure 3.8b). As already discussed in Chapter 3 this may be due to the IL-2 
gene being switched off as the original stimulation signals become quiescent. 
Alternatively, the upregulation of CTLA-4 on T cell activation (as well as 
CD80 and CD86) may result in T cell - T cell interactions and the generation 
of negative signals by CTLA-4 which inhibit production of EL-2.
Elowever, when the T cell blasts were stimulated through CD28 using CD80 
transfectants, proliferation of older T cell blasts (Day 6 and Day 8 ) was 
augmented in the absence of increased IL-2 production. It is possible that 
CD28 signalling utilised the sphingomyelinase pathway resulting in 
production o f the AP-1 and NF- kB transcription factors. Lack of the 
transcription factor NF-AT due to lack of TCR stimulation would result in no 
induction of IL-2 gene transcription as all three transcription factors are 
required. The T cell blasts may be proliferating in response to another 
cytokine. It has been demonstrated elsewhere (Freeman et al., 1995) that 
CD86  and to a lesser extent CD80 were able to induce production of IL-4 in 
repeatedly stimulation T cells. In that research the T cell blasts were able to 
generate IL-2 due to restimulation involving TCR signalling and therefore the 
generation of NF-AT. However as one of the transcription factors associated 
with the IL-4 gene promoter is NF-AT it is unlikely that IL-4 is involved in 
augmenting older T cell proliferation by stimulation through CD28 alone. A 
method o f determining whether cytokines were involved in augmenting 
proliferation of T cell blasts in response to ligation of CD28 would be 
supernatant transfer experiments. If the augmented T cell blasts proliferation, 
in response to CD28 stimulation, was cytokine driven then the supernatant 
from these T cells should contain unbound cytokine which if added to T cell 
blasts (but not stimulated by C80 or CD86 transfectants) should result in 
augmented proliferation.
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The requirement for TCR signalling to generate the transcription factor NF- 
AT (which is essential for IL-2 production) may also help explain the 
inhibitory effect o f wortmannin on restimulated rested T cell blasts as 
demonstrated by Ueda et al., (1995). As the rested T cell blasts were 
restimulated via the TCR and CD28 it is likely that all three transcription 
factors were generated. The inhibition of PI3-kinase by the addition of 
wortmannin may have inhibited induction of NF-AT and so prevented EL-2 
production. As NF-AT induction requires TCR engagement and signalling , it 
is possible that the inhibitory effect of wortmannin was due to inhibition of 
PI3-kinase activity known to be associated with the TCR (Ward et al., 1992). 
This could also be true for wortmannin inhibition of proliferation of 
unstimulated T cells stimulated by OKT3 and CD80 (Figure 6.4b). The lack 
of IL-2 production may be due to inhibiting NF-AT transcription caused by 
blocking the PI3-kinase activity associated with TCR signalling and not with 
CD28 signalling. However as PI3-kinase has been shown to be associated with 
CD28 and the enzymatic activity of PI3-kinase generated following CD80 
ligation of CD28 could be inhibited by nanomolar quantities of wortmannin 
(Ward et al., 1995) it is possible that wortmannin inhibition of proliferation of 
T cells (in response to OKT3 and CD80) is due to blocking PI3-kinase signals 
generated by both the TCR and CD28.
Effect of wortmannin on CD86 stimulation of T cells
It has already been demonstrated (Chapter 5) that either CD28 ligand is able to 
costimulate purified T cells to proliferate in conjunction with OKT3. Both 
ligands have also been shown to augment proliferation in T cell blasts 
following ligation with CD28. Comparison of the two ligands demonstrated 
that CD86  was more effective at costimulating purified T cells whereas CD80 
was more effective at augmenting proliferation in T cell blasts. It was 
important to determine whether the effects of wortmannin on CD28 signalling 
in response to CD86  ligation were the same as that seen when CD80 was used 
to provide the stimulus to CD28. If there were any differences, this would 
give an indication that the signals generated by CD28 in response to CD86 
were different to those generated in response to CD80 ligation.
When purified T cells were cultured with OKT3 and either CD80 or CD86 
transfectants in the presence of wortmannin, inhibition of proliferation 
occurred (Figure 6 .8 ). Although proliferation was inhibited regardless of
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which ligand was present, the concentration of wortmannin required to inhibit 
proliferation due to CD86 costimulation was greater than for CD80. It has 
already been demonstrated that CD86 costimulation generated higher levels of 
proliferation than CD80. This would suggest that the signals generated by 
CD28 in response to CD86 were more potent than those following CD80 
ligation. As a result a higher concentration of wortmannin would be required 
to inhibit the stronger signals generated in response to CD80 ligation. As has 
already been stated in the comparison of CD80 and CD86 stimulation of T cell 
blasts (Chapter 5), the stronger signals generated by CD28 in response to 
CD86  ligation were probably not due to increased affinity of CD28 for CD86 
rather than CD80. The levels of receptor binding by the ligands is similar with 
CD86  binding levels 2 -3 fold less than CD80 (Linsley et al., 1994). However 
the binding kinetics data was determined using the chimeric molecules CD28- 
Ig and CTLA-4-Ig to bind to CD80 and CD86 CHO transfectants. It has been 
demonstrated that binding of C28 and also CTLA-4 with their ligands is in 
fact oligomeric (i.e. a disulphide homodimer of CD28 or CTLA-4 binds two 
CD80 or CD86  monomers) (Linsley, 1995), the affinity data obtained using 
these chimeric molecules may not represent the true affinities of CD80 and 
CD86  for CD28 and CTLA-4. Unfortunately, the differences in the strength of 
signal generated by CD28 following CD80 and CD86  ligation are not 
consistent (i.e. CD86 is better at providing costimulation to naive T cells 
whereas CD80 is better at stimulation of already activated T cells). It is likely 
that factors other than the affinity of CD80 and CD86 for their ligands may 
be involved.
As with CD80 stimulation of T cell blasts, wortmannin had no effect on CD86 
stimulation of T cell blasts even at concentrations as high as 10|iM (Figure 
6.9). This would suggest that like CD80, CD86  ligation of CD28 does not 
involve signalling through PI-3 kinase. As has already been discussed above 
the signals generated by CD28 may involve a sphingomyelinase pathway and 
not PI3-kinase. The data obtained using CD86  ligation of CD28 on T cell 
blasts were no different to that obtained using CD80 transfectants - i.e. T cell 
blast proliferation was augmented in response to CD28 ligation and this 
proliferation was not inhibited by wortmannin. Although this does not confirm 
that CD80 and CD86  ligation of CD28 generates the same signals it does 
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Figure 6.8  Inhibition of T cell proliferation by wortmannin.
5 x 10^ T cells were cultured with OKT3 (l|lg/m l) and 2 x 10^ transfectants 
in the presence of increasing dosages of wortmannin as shown. Proliferation 
was measured after 48 hours by thymidine incorporation. The data are 
from triplicate samples from a single representative experiment (n = 3). 











Figure 6.9 Effect of wortmannin on CD86 stimulation of T cell blasts.
5 x 10^ T cell blasts (6 days post initial stimulation) were cultured with 1 x 
10^ transfectants as shown in increasing concentrations of wortmannin. 
Proliferation was measured after 48 hours using -^H thym idine 
incorporation.The data are from triplicate samples from a single 
representative experiment (n = 5).
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All the data generated in this research suggest multiple functions for CD28. 
Signals through CD28 appear to be essential for induction of EL-2 production 
and proliferation in resting T cells. By providing this costimulatory stimulus, 
CD28 is able to ensure the survival of the resting T cells which may undergo 
apoptosis as a result of TCR only signals or be rendered anergic. CD28 has 
also been shown to be important in sustaining an immune response by 
augmenting proliferation of activated T cell blasts. This sustaining of the 
immune response does not appear to require IL-2 production suggesting that 
the signals generated by CD28 vary depending on the activation state of the T 
cell. This variation in signalling by CD28 is also seen when the PI3-kinase 
inhibitor wortmannin is used. PI3-kinase activity can be inhibited in resting T 
cells activated via the TCR and CD28 resulting in blocking EL-2 production 
and T cell proliferation. However if T cells are already activated wortmannin 
has no effect on their ability to proliferate in the presence or absence of CD28 
stimulation. This suggests that the signalling pathways used in activated T cell 
proliferation does not require PI3-kinase activity and that the signals generated 





During the course of this research CD28 has been shown to play an important 
role in both the induction of T cell proliferation and amplifying the 
proliferation of activated T cells. The initial results demonstrated clearly that 
costimulation through CD28 was essential for T cell activation whereas 
signalling through CD2 was unable to induce IL-2 production and T cell 
proliferation. Interestingly there did not appear to be any effect on T cell 
proliferation by CTLA-4. This CD28 homologue is known to be upregulated 
following T cell activation (Linsley et al., 1992a) and has a higher affinity for 
the CD28 counter-receptors CD80 and CD86 (Linsley et al., 1994). Research 
also suggests that ligation of CTLA-4 results in the generation of negative 
signals - i.e. inhibition of IL-2 production and T cell proliferation by arresting 
cell cycling rather than inducing apoptosis (Krummel and Allison 1996, 
Walunas et al., 1996). This would suggest that CTLA-4 should perhaps be 
involved in inhibiting the activation of resting T cells. This was not seen from 
the data as although CTLA-4 upregulation can occur within 24 hours of T 
cells being activated (Linsley et al., 1992a) T cell proliferation reached a 
maximum after 5 days (Figure 3.8) suggesting that there was no inhibition by 
CTLA-4. However the data on CTLA-4 signalling are from mouse studies 
and although there is 100% homology in the cytoplasmic domains of mouse 
and human CTLA-4 it has still to be demonstrated whether the signals 
generated by human CTLA-4 are inhibitory. More recent studies on CTLA-4 
surface expression has shown that CTLA-4 is retained intracellularly and 
cycled to the cell surface and that surface expression of CTLA-4 is raised by 
increasing intracellular calcium levels (Linsley et al., 1996). TCR signalling is 
known to activate PLCy-1 which results in the release on calcium from 
intracellular stores. However when CD28 signalling in mouse splenic T cells 
was examined calcium levels were not increased following CD28 ligation 
(Abe et al., 1995). Similarly, CD28 signalling in human resting T cells is 
thought to be CsA insensitive suggesting that calcium mobilisation is not 
involved(June et al., 1994). It may be that the levels of calcium generated in 
activating resting T cells is insufficient to induce adequate levels CTLA-4 
surface expression and so negative regulation by CTLA-4 does not occur. This 
would make sense as it would be inefficient of the immune system to activate 
T cells in response to foreign antigen and as a consequence of this activation 
switch o ff the T cells possibly before a complete immune response is 
mounted.
However it may be that CTLA-4 plays a more important role in regulating an 
active immune response. This research has demonstrated that CD28 can
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augment proliferation in activated T cells. Activated murine splenic T cells 
have been shown to induce increased intracellular calcium levels (Abe et al., 
1995) and similarly signals generated by CD28 in activated human T cells are 
considered to be CsA sensitive suggesting calcium mobilisation is occurring 
(June et al., 1994). It is possible that CTLA-4 expression is upregulated 
rapidly on activated T cells in response to increased levels of calcium and 
therefore due to CTLA-4 having higher affinity for CD80 and CD86 , CTLA-4 
may play an important role in regulating the immune response by inhibiting 
continued T cell proliferation so allowing the immune response to quiesce.
Additionally, research has suggested that CD28 expression is downregulated 
in activated T cells in response to ligation and that the re-expressed CD28 is 
hyporesponsive to further stim ulation (Linsley et al., 1993). This 
hyporesponsiveness may be a method of ensuring that signals generated 
through CTLA-4 in activated T cells predominate so arresting T cell 
proliferation. In contrast, the results from stimulating T cell blasts (Chapter 4) 
suggest that CD28 expressed on activated T cells is capable of responding to 
ligation by CD80 and CD8 6 . However, the T cell blasts used in CD28 
stimulation experiments were generated using mitogens and this may not 
involve CD28 ligation. Similarly, although downregulation of CD28 was 
examined in resting T cells activated through the TCR and CD28, the 
responsiveness of the re-expressed CD28 was not determined. It is important 
to assess whether the CD28 downregulation following activation of resting T 
cells results in re-expression of a hyporesponsive CD28 and this could be 
achieved by examining whether the activated T cells were responsive to 
further stimulation by CD80 or CD8 6 . In this way it would be possible to 
demonstrate both the responsiveness of the re-expressed CD28 to further 
stimulation and whether the proliferation of T cells, activated through TCR 
and CD28, can be augmented by stimulation through CD28.
Augmentation of proliferation of T cells blasts appeared to be independent of 
IL-2 production. This cessation of IL-2 production was dramatic - large 
amounts o f IL-2 were produced by Day 4 blasts (approximately 400IU/ml) 
and two days later none was detected (Figure 4.4). Although IL-2 production 
in resting T cells activated via the TCR and CD28 also shows a decline in IL-2 
production by day 5 (Figure 3.8b), the sudden loss of IL-2 in T cell blasts 
suggests that this may be in response to a negative signal. It has been 
demonstrated that CTLA-4 signalling results in inhibition of IL-2 production 
(Krummel and Allison 1996, Walunas et al., 1996) and it may be that CTLA-4
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is responsible for switching off IL-2 production. However, although there is 
no EL-2 production by older T cell blasts (day 6 or older), these T cells are 
still able to proliferate and this proliferation can be augmented by CD28 
signalling. This is at odds with the data from mouse studies which suggested 
that CTLA-4 signalling also inhibited T cell proliferation by arresting the cell 
cycle (Krummel and Allison 1996, Walunas et al., 1996). It may be that the 
signals generated by CTLA-4 in human T cells are different from those seen in 
mouse and that although IL-2 production may be inhibited by CTLA-4 
signalling in human T cells proliferation of activated T cells is not inhibited. 
The continued proliferation of the activated T cells in the absence of IL-2 may 
be in response to other cytokines or may be due to signalling pathways which 
are independent of EL-2. The possible role of other cytokines in the augmented 
proliferation o f T cell blasts could be examined using supernatant transfer 
assays. Nevertheless, proliferation of T cell blasts has been shown to decline 
with time. It is possible that the signals responsible for the continued 
proliferation of the T cell blasts decay or perhaps the inhibitory effects of 
CTLA-4 signalling on proliferation are effective at this time.
The role o f CTLA-4 in the regulation of T cell activation is still being 
investigated and although there is evidence for negative regulatory effects of 
CTLA-4 signalling in mice it remains to be determined whether CTLA-4 
signalling effects are the same in human T cells. Nevertheless, the importance 
of the regulatory role of CTLA-4 has been demonstrated in CTLA-4 knockout 
mice where lack of CTLA-4 has been shown to be lethal (Waterhouse et al.,
1995). The mice exhibited a lymphoproliferative disorder with marked 
infiltration of activated T cell blasts into many major organs which resulted in 
early death. The CTLA-4 knockout mice demonstrate the importance of 
CTLA-4 to act as a negative regulator of T cell activation.
Blocking T cell activation may be a method of inhibiting inappropriate 
immune responses in transplant patients and in treatment of autoimmune 
diseases. There have been a number of studies carried out using the chimeric 
molecule CTLA-4-Ig to block T cell activation in both transplants in mice and 
murine models of autoimmune disease with startling results. When mice were 
treated in vivo with human CTLA-4-Ig rejection of xenogeneic (human) 
pancreatic islet cells was blocked and this inhibition was due to blocking 
CD80 costimulation of T cells and therefore T cell activation (Lenschow et al., 
1992). The use of CTLA-4-Ig to prevent the rejection of transplants also
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resulted in long-term donor specific tolerance of the transplant. The normal 
therapy used to prevent transplant rejection relies on pan-immunosuppressive 
drugs. Although suppression of the immune system will help prevent rejection 
of the transplanted tissue it also makes the transplant recipient susceptible to 
infection from  other sources. The transplant recipient is therefore 
immunocompromised and subsequent infections from other sources, which 
under normal circumstances would be cleared by the immune system, may 
have fatal consequences. It would appear from these results that CTLA-4-Ig 
may be a less hazardous method of prolonging transplant survival providing 
CTLA-4-Ig is itself not detrimental to the transplant recipient.
Research to examine the role of CTLA-4 in regulating autoimmune diseases 
using mAbs to CTLA-4 has shown that in mice with murine relapsing- 
remitting experimental autoimmune encephalomyelitis (R-EAE) the presence 
of CTLA-4 mAbs accelerated and exacerbated the disease. If the mice were 
treated with CTLA-4 mAbs during remission the treatment resulted in 
increased disease severity and a higher incidence of relapses (Karandikar et 
al., 1996). This data suggests that as blocking CTLA-4 responses with mAbs 
resulted in increased disease severity, CTLA-4 may play a major role in the 
regulation of autoimmune disease. As many autoimmune diseases are 
characterised by the presence of autoantibodies, a function of CTLA-4 may be 
to inhibit production of these potentially destructive autoantibodies. The use of 
a soluble form of human CTLA-4-Ig in vivo in mice (Linsley et al., 1992b) 
resulted in suppressed T cell dependant antibody responses to two 
immunogens - sheep erythrocytes and keyhole limpet hemocyanin. Unlike the 
transplant studies, the CTLA-4-Ig did not induce tolerance to the immunogens. 
However the immunosupression by CTLA-4 was prolonged and was shown to 
be associated with the continued presence of CTLA-4-Ig found in the serum. 
The continued presence of CTLA-4-Ig without any obvious deleterious effects 
on the mice suggests that CTLA-4 -Ig may be a potent immunosuppressive 
agent which has low toxicity, high specificity and is highly stable in vivo.
This immunosuppressive use of CTLA-4-Ig has also been demonstrated in the 
suppression of murine lupus - a murine model for the human autoimmune 
disease, systemic lupus erythematosus (SLE) (Finck et al., 1994). The mice 
used in this study spontaneously develop an autoimmune disease that closely 
resembles human SLE. Using a murine CTLA-4-Ig chimeric molecule, 
autoantibody production (a clinical symptom of the disease) was suppressed 
and the life of the mice was prolonged. This protective function of CTLA-4-
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Ig was possible even at the most advanced stages of the disease. This data 
seem to suggest a therapeutic role for CTLA-4-Ig in autoimmune diseases. 
However this was not the case when CTLA-4-Ig was used to treat spontaneous 
autoimmune diabetes in the non-obese diabetes (NOD) mouse model. The 
disease is characterised by early islet inflammation (insulitis at 2 - 4 weeks) 
followed by overt diabetes (at 12 weeks or more) but not all animals become 
diabetic even if they have insulitis. Initial studies showed that CTLA-4-Ig or 
anti-CD86 mAbs blocked the development of full-blown diabetes but had little 
effect on primary insulitis (Lenschow et al., 1995). If early CD28-CD80/CD86 
interactions were inhibited (by breeding CD28 knockout NOD mice) the 
disease was not inhibited. Instead an earlier and more severe insulitis was 
followed by increased incidence and severity of diabetes (Lenschow et al.,
1996). This clearly demonstrated that simply blocking CD28 interactions 
would not necessarily result in inhibition of autoimmune disease. The 
treatment of normal NOD mice with CTLA-4-Ig also demonstrated this point. 
If the CTLA-4-Ig was administered early (at 2-4 weeks ) or very late (at 10 
weeks or later) it had no effect on the disease. This suggests that CD28 has a 
different role to play at different stages of the disease. It would appear from 
both the NOD mice and the CD28 knockout NOD mice that CD28 
interactions are critical for disease progression after the development of 
insulitis and if CTLA-4-Ig is not administered shortly after this stage, full 
blown diabetes will develop. This was demonstrated by the inhibition of 
disease by administration of CTLA-4-Ig in 5 - 7 week old NOD mice.
Early blockade of CD28 interactions in the NOD mice resulted in expansion of 
Th 1 cells and the severity of the disease increased whereas later blockade of 
CD28 interactions blocked T h l expansion and the severity of disease is 
diminished. There is also evidence to suggest that if the balance of T cell 
responses is skewed towards Th2 using anti-IFN-y mAbs or IL-4 the 
development of the disease can be blocked (Debray-Sachs et al., 1991; 
Rapoport et al., 1993). This suggests that disease development may be 
inhibited by influencing the cytokine profile produced by T cells. This 
modulation of Thl/Th2 development and therefore the cytokines produced 
may play a role in therapies for a number of other diseases.
It has been shown that CD86 preferentially induces IL-4 production in 
activated T cells (Freeman et al., 1996) and as IL-4 is associated with the Th2 
subpopulation of T helper cells, it may be that CD86 stimulation results in the 
generation of Th2 T cells whereas CD80 stimulation results in Thl cells being
139
generated. Although this research did not examine the cytokines produced by 
T cells following CD80 and CD86 stimulation, the data generated did suggest 
that CD80 and CD86 may play different roles in T cell activation. CD86 
appeared to be more effective at costimulating resting T cells whereas CD80 
stimulation of activated T cell blasts augmented proliferation more effectively. 
It may be that in the initial phase of T cell activation either CD28 ligand can 
stimulate T cells to produce IL-2 and proliferate. As CD86 is expressed on 
unactivated APCs, it is the ligand more readily available to initiate T cell 
activation. At this stage the T cells are expanding in number in response to IL- 
2 and differentiation into Thl and Th2 cells may require additional signalling 
through CD28. As both CD80 and CD86 expression is upregulated following 
T cell activation (Hathcock et al., 1994) it may be that subsequent stimulation 
of activated T cells (as seen in Chapter 4) results in differentiation in to Thl 
and Th2 T cells. Although it is still to be determined whether CD80 and CD86 
stimulation of activated T cells results in the differential development of Thl 
and Th2 T cells, there is evidence to support this potential role for CD80 and 
CD86.
Using blocking mAbs to CD80 and CD86 it has been demonstrated in vivo 
that treatment with anti-CD80 mAbs during immunisation of mice with 
proteolipid protein (which induces EAE) resulted in the generation of Th2 
cells resulting in reduced incidence of disease. In contrast, treatment with anti- 
CD86 mAbs resulted in generation of T h l T cells resulting in increased 
disease severity. The amelioration of disease in response to anti-CD80 mAbs 
could be inhibited by cotreatment with anti-IL-4 mAbs. This suggests that the 
initial secretion of IL-4 by Th2 cells is an important feature of the protective
effect of the anti-CD80 mAbs. Furthermore, adoptive transfer of the Th2 cells 
prevented the establishment of disease and also abrogated already established 
disease (Kuchroo et al., 1995). Both the NOD mouse research and the EAE 
mouse data suggest that modulation of T cell differentiation and as a 
consequence the cytokine profile produced may be a potential therapy for 
autoim m une disease. However the NOD mouse data has also clearly 
demonstrated that timing the treatment is also of great importance. The 
research data is unclear as to whether the manipulation of the immune 
response in these mouse models of disease has had any effect on the ability of 
the mouse immune system to deal with other pathogens.
Although the role of CD80 and CD86 in modulating T cell differentiation has 
yet to be established, both CD28 ligands have been shown in this research to
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be effective at costimulating resting T cells and stimulating activated T cells. 
However the differences in the effectiveness of CD80 and CD86 stimulation 
requires further investigation particularly as the magnitude of the differences 
between CD80 and CD86 varied depending on the T cell donor (Figures 5.2 
and 5.5). The difference in proliferation levels generated between donors may 
be due to variation in the ratio of CD4 and CD8 T cells present. As only 50% 
of CD8 T cells express CD28 (Turka et al., 1990), T cells from one donor 
which have a higher ratio of CD8 T cell than T cells from another donor may 
have a lower level of proliferation as there is less CD28 available for 
stim ulation. However this does not explain the difference in T cell 
proliferation in T cells from the same donor in response to CD80 and CD86 
stimulation or explain why CD80 is more effective at stimulating T cell blasts 
and CD86 more effective at providing costimulation to resting T cells. 
Although binding assays have suggested that the affinity of CD80 and CD86 
for CD28 is similar, the studies used chimeric CD28-Ig molecules (Linsley et 
al., 1994) and did not take into account that two CD80 and two CD86 
molecules may bind a single CD28 molecule (Linsley 1995). Binding assays 
using surface iodination of T cells may help to clarify whether the differences 
in efficiency of stimulation by CD80 and CD86 is due to differences in 
binding to CD28. Since the efficiency of stimulation by CD80 and CD86 was 
different between resting and activated T cells, binding assays on both resting 
and activated T cells may determine whether affinity of CD28 for its ligands 
depends on the activation state of the T cell.
Although there are still may questions to be answered regarding the role of 
CD80 and CD86 in T cell activation, initial studies have determined a role for 
CD80 in the treatment of cancer. Using murine melanoma cells which express 
the E7 gene product of the human papilloma virus 16, the E7+ tumour cells 
were found to grow progressively when injected into immunocompetant hosts. 
This demonstrated that the murine immune system was failing to respond to 
the presence of the human viral antigen expressed on the tumour cells. This 
may have been due to the lack of costimulatory molecules expressed on the 
surface o f the melanoma cells. If the tumour cells were transfected with 
murine cDNA for CD80 (B7) and the resulting E7+B7+ tumour cells were 
injected into immunocompetant hosts, the tumour cells were rejected. The 
immune response was shown to be CD80 specific as it could be blocked by the 
addition of CTLA-4-Ig. A more startling result was seen when E7+B7+ cells 
were injected into mice with E7+B7" tumours. The immune response 
generated in response to the E7+B7+ tumour cells also resulted in rejection of
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E7+B7" tumours at distant sites as well as resulting in regression of E7+B7" 
metastases (Chen et al., 1992).
Similar results were obtained using another murine melanoma cell line to 
induce tumours in immunocompetant mice (Townsend and Allison, 1993). 
The melanoma cells although expressing MHC Class I and Class II molecules 
did not appear to provide the required costimulatory signals for T cell 
activation. If the melanoma cells were transfected with CD80 the tumour cells 
were rejected. It was possible to demonstrate that this rejection was mediated 
by CD8 cytotoxic T cells and that CD4 T cells were not required. Interestingly 
the rejection of the CD80+ melanoma cells was found to protect a high 
percentage of the mice from subsequent challenge with CD80“ melanoma 
cells. This suggested that the CD80+ melanoma cells could effectively prime 
the immune response. The results of both these studies suggest that CD80 
transfection may play a role in both the regression of existing tumours and 
also in prim ing the immune response to respond to the presence of 
tumourigenic cells in the future. It is interesting to note that in both studies 
tum our rejection was mediated by CD8 T cells in response to CD80 
costimulation. It is possible that the results obtained in the mice models would 
not be as effective in humans due to the difference in expression of CD28 - all 
murine T cells express CD28 whereas only approximately 50% of human 
CD8 T cells express CD28. However if the transfection of CD80 into tumour 
cells can result in rejection of tumours (without any deleterious side effects) 
and reduce the need for chemotherapy and radiotherapy both of which have 
unpleasant side effects, its possible use as a therapy for cancer should be 
considered.
The research so far from animal models of disease has shown that 
immunotherapies based on immunomodulation of CD28 interactions may be 
the way forward to treating a number of incapacitating and sometimes 
potentially fatal diseases. However the same research has also highlighted the 
need for caution as the efficacy of a particular form of treatment will depend 
not only on the disease involved but may vary depending on the timing of the 
immunotherapy. It is therefore very important to increase our knowledge of 
the role o f CD28 in normal immune responses to ensure that in any 
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Appendix 2
Recipes for culture media.
1. Glutamine - free medium for CHO transfectants.






0.70 mg/ml cytidine 
0.70mg/ml uridine
The nucleosides were added to 50ml of distilled deionised water, filter 
sterilised and stored at 4°C.
G418. Geneticin G418 - sulphate (lOOx)
50mg was dissolved in 1ml PBS which had been made up sterilely in 
autoclaved distilled and deionised water.
2. RPMI/10% FCS| (complete medium!
RPMI 1640 400ml
FCS 50ml
Penicillin / streptomycin (10,000 IU/ml/10,000pg/ml) 5ml 
L-glutamine (200mM) 5ml
Dulbeccos MEM (10 x)
Foetal Calf Serum (FCS)
Penicillin/streptomycin (10,000 IU/ml/10,OOOpg/ml) 
Sodium bicarbonate (7.5%)
Sodium pyruvate (lOOmM)








This medium was used for culturing CTLLs and T cell blasts and in all 
proliferation assays.
Where media were required for washing cells and other non culturing 
requirements the following recipe was used
To 400 ml of autoclaved distilled deionised water the following were 
added
RPMI 1640 (lOx) 50ml
FCS 50ml
Penicillin / streptomycin (10,000 IU/ml/10,OOOpg/ml) 5ml 
L-glutamine (200mM) 5ml
Sodium bicarbonate (7.5%) 28ml




Recipes for Solutions /buffers used in mRNA determination.
Guanidinium thiocvanate fStock solution).
Guanidinium thiocyanate 
DEPC treated water 










Add the final three components to the guanidinium thiocyanate in the 
manufacturer's bottle and dissolve at 65°C. Store at 4°C.
To use for in RNA extraction -
add 72pl of 2-mercaptoethanol to 10ml of the stock solution.
Tris acetate EDTA (TAE IPX).
For 500ml of solution
Tris Base 24.22g
Sodium acetate 2.05g
Disodium dihy drate-EDT A 1.8 6g
add to deionised distilled water and pH to 8.1 with approximately 6 ml of 
glacial acetic acid.
Diethvl pvrocarbonate (DEPCVtreated water
Add 500jil of DEPC to 500ml distilled water , mix and leave overnight at 
room temperature in a Class 1 safety cabinet then autoclave.
DNA loading buffer (TOX)
to 10ml of distilled water add Final concentration,
bromophenol blue 25mg 0.25%
xylene cyanol 25mg 0.25%
Ficoll (type 400) 2.5g 25%
Store at room temperature.
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RNA loading buffer (10X).
To 5ml of DEPC-treated water add 
bromophenol blue lOmg
Ficoll (type 400) lg






ELISATest for analysis of mAb binding.
The 96-well flat bottom tissue culture plate was coated with OKT3 at lpg/m l 
for the required time periods (2, 4, 8 , 24 hours). At each time point the 
appropriate wells were aspirated and washed with 250fil PBS, aspirated and 
then left covered with 250pl PBS until the whole plate was ready for testing 
using the ELISA kit (Supplied by Boehringer Mannheim).
The wells were aspirated and lOOjil/well of 2%v/v FCS/PBS added and the 
plate incubated at 37°C  for 1 hour.
The FCS/PBS block was aspirated and lOOpl of the enzyme linked antibody 
added (anti- mouse IgG alkaline phosphatase diluted 1:999 in 2% v/v 
FCS/PBS). The plate was incubated for 1 hour at 37°C.
The wells were aspirated and washed (250fxl/well each wash) with 2% 
FCS/PBS twice for 5 minutes each time and twice for 5 minutes with substrate 
buffer (0.5M sodium carbonate/bicarbonate pH9.6).
lOOjil/well of substrate ( p-nitrophenyl phosphate (pNPP) at 1 mg/ml in 
substrate buffer) was added and the plate incubated at 37°C for 30 minutes. 




Figure 4.2: CD80 augmentation of T cell blast proliferation over time.
Days CHO Std error CD80 Std error CD58 Std Error
4 217182.5 1797.8 272314.6 2818.5 233738.8 4882.8
6 88016.8 2896.6 258403.5 5700.4 86077.6 1747.4
8 89029.4 4629.5 213257.2 13861.7 63312.9 5080.2
10 80261.3 4093.3 156286.5 2031.9 61458.2 3761.2
Days CHO Std error CD80 Std error CD58 Std Error
4 113382.3 4500.1 130178.6 740.7 111914.5 2718.4
6 58815.4 4960.5 93579.5 305.1 66959.2 2014.8
8 55045.9 4802.8 98145.9 1298.0 42714.3 1823.9
10 25641.4 1248.8 38036.1 1579.3 16391.3 1210.5
Proliferation data are shown as the mean of triplicate cultures in cpm.
Figure 4.4 : EL-2 production by T cell blasts
Days CHO Std error CD80 Std error CD58 Std Error
4 48.5 1.1 284.2 5.1 40.6 1.0
6 0 - 2.4 0.1 0 -
8 0 - 0 - 0 -
10 0 - 0 - 0 -
Days CHO Std error CD80 Std error CD58 Std Error
4 197.7 7.5 385.5 15.1 173.8 19.1
6 0 - 7.5 0.6 0 -
8 0 - 0 - 0 -
10 0 - 0 - 0 -
The IL-2 production data are shown as the mean of triplicate cultures in iu/ml.
Figure 5.4 : CD86 stimulation of T cell blasts over time.
Days CHO Std error CD80 Std error CD86 Std Error
4 174150.5 7575.5 258955 8470.4 243146.1 9886.3
6 109963.5 3248.3 293074.5 7186.1 215317.8 4080.3
8 76282.5 2704.2 266510.3 18820.9 191891.2 7831.1
10 65742.5 2370.8 126721.8 5334.9 104376.9 5970.4
Days CHO Std error CD80 Std error CD86 Std Error
4 105694.9 128.4 119814.3 2000.9 116271.9 3267.2
6 48208.8 3254.6 87058.2 168.9 78555.4 3619.8
8 57573.4 2476.8 87222.4 777.2 70104.6 3422.5
10 19952.6 1259.0 36756.3 2157.2 30051.9 1877.3
The proliferation data are shown as the mean of triplicate cultures in cpm.
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Figure 5.6: IL-2 production by T cell blasts in response to CD86  stimulation.
Days CHO Std error CD80 Std error CD86 Std Error
4 63.7 1.2 267.2 4.9 102.7 8.7
6 0 - 10.3 1.0 0 -
8 0 - 0 - 0 -
10 0 - 0 - 0 -
Days CHO Std error CD80 Std error CD86 Std Error
4 203.9 8.1 403.4 9.7 281.9 10.7
6 1.2 0.1 11.8 1.2 3.5 0.3
8 0 - 0 - 0 -
10 0 - 0 - 0 -
The EL-2 production data are shown as the mean of triplicate cultures in iu/ml.
Figure 6.8 : Inhibition of T cell proliferation by wortmannin.
Wortmannin 
concentration (|iM)
OKT3/CD80 Std Error OKT3/CD86 Std Error
0 99170.0 7931.6 197408.7 5987.4
0.0001 98639.2 7594.1 193627.1 5527.6
0.001 96815.2 7443.2 181579.4 5024.3
0.010 69960.3 3562.7 198213.1 19821.3
0.100 28276.4 675.5 199357.1 15106.1
1.0 5209.9 119.4 124820.7 9115.6
10.0 1459.0 79.4 32424.6 3383.5
Wortmannin 
concemtration (fiM)
OKT3/CD80 Std Error OKT3/CD86 Std Error
0 176778.9 12669.7 187280.5 5403.0
0.0001 170648.2 6571.7 192734.5 16712.5
0.001 168701.5 5816.8 208221.6 8678.0
0.010 152978.6 10090.5 129489.5 12796.3
0.100 93011.6 9132.8 96316.4 1504.8
1.0 45790.4 1793.9 63494.0 4648.8
10.0 1009.2 51.4 22471.2 1105.8
The proliferation data are shown as the mean of triplicate cultures in cpm.
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T lymphocyte activation requires at least two signals, one via the antigen-specific 
T cell receptor and a second via the surface molecule CD28 which provides signals 
critical to interleukin-2 (IL-2) production and T cell proliferation. We have 
previously shown (Ward S. G ., Westwick J., Hall N. and Sansom D. M. Eur. J. 
Immunol. 1993. 23: 2572) that CD28 stimulates phosphoinositide (PI) 3-kinase 
activity, indicating that D-3 phosphoinositides may act as mediators of CD28- 
induced T cell costimulation. Here, we report that immunoprecipitation of CD28 
molecules from Jurkat cells stimulated with the CD28-ligand B7, results in a 
ligand-dependent association of CD28 with PI 3-kinase. This association 
correlates with the appearance of PI 3-kinase enzymatic activity in CD28 
immunoprecipitates and the formation of D-3 phosphoinositides. Consistent with 
the hypothesis that D-3 phosphoinositides are important mediators of CD28 
signaling, treatment of T cells with the PI 3-kinase inhibitor wortmannin, 
inhibited bothT cell proliferation and production of IL-2, but not the response of 
T cells to exogenous IL-2. Hence, abrogation of PI 3-kinase activity by 
wortmannin, appears sufficient to disrupt the costimulatory pathway utilized by 
CD28, indicating a central role for this enzyme in the CD28 signaling pathway.
1 Introduction
Activation of resting T lymphocytes requires at least two 
signals: one provided by engagement of theTcR by foreign 
antigen complexed with self-MHC and the second by a 
costimulatory molecule present on antigen presenting cells 
[ 1, 2]. The major costimulatory signal is believed to involve 
the CD28 antigen on T cells (reviewed in [2] and [3]) 
binding to its ligands B7-1 (also termed CD80, herein 
referred to as B7) or B7-2 (also termed B70) [3-6] on the 
antigen presenting cell. This interaction has been shown to 
control proliferation and IL-2 production from TcR-stimu- 
lated CD28+ T cells [7, 8] and it has recently been shown 
that T lymphocytes derived from CD28_/_ knockout mice 
exhibit major defects in responses to mitogens [9].
The nature of the intracellular events responsible for 
CD28-mediated costimulation is currently ill-defined (re­
viewed in [2]). However, we have previously shown that 
ligation of CD28 by B7 induced the formation of D-3
[I 13384]
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phosphoinositides inT lymphocytes [10]. Since these lipids 
are formed as a result of phosphoinositide (PI) 3-kinase 
activity, our findings suggested that CD28 activates the PI 
3-kinase signaling pathway. PI 3-kinase phosphorylates the 
membrane lipid phosphatidylinositol, at the position 3 on 
the inositol ring, resulting in the generation of phosphati- 
dylinositol-(3)-monophosphate [PtdIns(3)P], phosphatidy- 
linositol-(3,4)-bisphosphate [Ptdlns(3,4)1*2] and phospha- 
tidylinositol-(3,4,5)-trisphosphate [PtdIns(3,4,5)P3] [11]. 
These phosphoinositide lipid isoforms represent only a 
minor fraction of cellular phosphoinositides [11] but con­
siderable importance has been attached to this pathway, 
particularly concerning their putative role as regulatory 
molecules (reviewed in [11] and [12]. Recent kinetic 
evidence has suggested that PtdIns(3,4,5)P3 formed by a 
phosphatidylinositol-(4,5)-bisphosphate- [PtdIns(4,5)P2] 
specific-3-kinase, is the probable physiological intracellular 
mediator and this is subsequently degraded by sequential 
dephosphorylation to PtdIns(3,4)P2 and PtdIns(3)P (re­
viewed in [11]).
The PI 3-kinase enzyme is a heterodimer consisting of a 
85-kDa regulatory subunit containing two src-homology 
(SH2) domains and an SH3 domain [13], tightly associated 
with a catalytic 110-kDa subunit [14]. Studies of the binding 
specificity of the p85 SH2 domains reveal a core phospho- 
tyrosine-containing consensus motif, namely YXXM [15]. 
Analysis of the cytoplasmic domain of CD28 reveals such a 
motif (YMNM) around the tyrosine at position 173, 
suggesting a direct interaction between PI 3-kinase and 
CD28 [3]. However, the functional relevance of this 
association remains unclear. In this study, we have used the 
fungal metabolite wortmannin which has recently been 
described as a specific inhibitor of PI 3-kinase [16-18], to 
assess the importance of PI 3-kinase to CD28-mediated 
costimulation.These experiments demonstrate that CD28- 
mediated increases in D-3 phosphoinositides, but not the 
association between CD28 and PI 3-kinase following liga­
tion by B7, can be specifically inhibited by wortmannin.
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Furthermore, wortmannin abrogates B7-dependent T cell 
proliferation, but has no effect on T cell proliferation 
elicited by other stimuli. These data demonstrate that 
recruitment and activation of PI 3-kinase by CD28 is of 
major importance in CD28-mediated T cell functions.
2 Materials and methods
2.1 Reagents and antibodies
CD28 mAb 9.3 was kindly provided by Carl June (Naval 
Medical Research Institute, Bethesda); CTLA4Ig fusion 
protein was obtained from P. Linsley (Bristol-Myers 
Squibb, Seattle); UCHT1 and p85 mAb were from Doreen 
Cantrell (ICRF, London); p85 rabbit polyclonal antisera 
was from Mike Waterfield (Ludwig Institute, London); 
human rIL-2 was a gift from I. Lindley, (Sandoz, Vienna). 
OKT3 was obtained from ATCC (Rockville, MD). Iono- 
mycin and fura-2 acetoxymethyl ester were purchased from 
Calbiochem-Novachem (Nottingham, GB). Wortmannin, 
PMA and phosphoinositide lipids [soybean Ptdlns and 
bovine PtdIns(4)P] were purchased from Sigma. Wortman­
nin was dissolved in ethyl acetate to a concentration of 
20 mM and stored in ahquots at — 20 °C in the dark. 
Immediately prior to use, the stock was diluted in tissue 
culture medium to the concentrations shown in the figure 
legends. The final concentration of ethyl acetate was 
generally less than 0.05% , a concentration that had no 
effect on any of the T cell responses. Ethyl acetate, in an 
equivalent concentration to the maximum wortmannin 
concentration in each experiment, was used as a vehicle 
control.
2.2 Cell culture
The leukaem icT cell line Jurkat, T lymphoblasts and the 
IL-2-dependent cell line CTLL were grown in RPMI-1640 
supplemented with 10% FCS, streptomycin (50 pg/ml) and 
penicillin (50 U/ml) at 37 °C [19, 20]. CTLL cultures were 
also supplemented with 20 IU/ml EL2. Parental CHO cells 
(CHO-B7- ) and CHO cells transfected with B7 cDNA  
(CHO-B7+) were established and maintained as previously 
described [21].
2.3 T cell purification and proliferation
Heparinized blood samples were separated on a histopaque 
(1.077) density gradient. Peripheral blood mononuclear 
cells were removed from the gradient and purified T cells 
were obtained by negative selection as described [21]. 
T cells were stimulated as described in the figure legends 
and proliferation was measured at 72 h by adding 1 pCi of 
[3H] thymidine/well (1 mCi/ml, 2 Ci/mmol, Amersham 
International, GB) for the last 18 h of culture, followed by 
harvesting cells onto Whatman GF/A filters and analysis by 
liquid scintillation counting. Where appropriate, T cell 
supernatants were harvested, and assayed for EL-2 activity 
using the GTLL EL-2-indicator cell line [20]. In exogenous 
IL-2 response assays, 6 -8  day T lymphoblasts [19] were 
washed and cultured in IL-2 at the concentrations shown 
and proliferation determined as already described.
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2.4 Cell lysis and immunoprecipitation
Jurkat cells (6 x  107; except where otherwise stated) were 
gently co-sedimented with 2 x  107 B7-expressing CHO 
cells in a volume of 1 ml at 200 g for 2 min, incubated at 
37 °C in RPMI-1640 for the times indicated and the pellets 
lysed in 1 ml lysis buffer (1 % N P 40,100 mM NaCl, 20 mM 
Tris pH 7.4, 10 mM iodoacetamide, 10 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride, 1 pg/ml leupeptin, 1 pg/ml 
antipain, 1 pg/ml chymostatin, 1 pg/ml pepstatin A , 1 mM 
sodium orthovanadate). Lysates were pre-cleared and 
immunoprecipitates performed for 2 h at 4 °C as described 
[22] using the following antibodies coupled to protein 
A-Sepharose beads (Pharmacia): CD28 mAb 9.3 (1 pg/ml 
lysate), p85.polyclonal rabbit antisera (1 pl/ml lysate).
2.5 In vitro lipid kinase assays
Immunoprecipitates were washed and subjected to in vitro 
lipid kinase assays as described [22] using a lipid mixture of 
100 pi o f 0.1 mg/ml Ptdlns and 0.1 mg/ml phosphatidylser- 
ine dispersed by sonication in 20 mM Hepes, pH 7.0, 1 mM 
EDTA). The reaction was initiated by the addition of 
20 pCi [y-32P] ATP (3000 Ci/mmol, DuPont-NEN, Steven­
age, GB) and 100 pM ATP to the immunoprecipitates 
suspended in 80 pi kinase buffer. The reaction was termi­
nated after 15 min and phospholipids were then separated 
by thin layer chromatography (TLC) [22].
2.6 Electrophoresis and immunoblotting
Immunoprecipitated samples for immunoblotting were 
electrophoresed on 7-17 % SDS-PAGE and transferred by 
electroblotting onto polyvinylidene difluoride (PVDF) 
membranes (Immobilon P, Millipore, Bedford, MA) as 
described previously [22] using 10 mM Caps ([cyclohexy- 
lamino]propane-sulfonic acid) buffer, pH 11 for 20-24 h at 
0.3 mA. Blots were probed with p85 mAb and proteins 
visualized by chemiluminescence detection system (ECL, 
Amersham) with a sheep anti-mouse Ig conjugated with 
horseradish peroxidase as a secondary antibody (Amer­
sham).
2.7 D-3 phosphoinositide labeling, extraction and HPLC 
separation
Jurkat cells (4 x  108) were labeled with 1 mCi [32P] ortho­
phosphate [8500-9120 Ci/mmol, DuPont-NEN] as des­
cribed [10, 23]. 32P-labeled Jurkat cells were stimulated as 
described in the figure legends and phospholipids were 
extracted with 750 pi o f chloroform: methanol: H2O 
(32.6:65.3:2.1 %, v/v/v, respectively) as described [24, 25]. 
The samples were deacylated and analyzed by anion 
exchange high performance liquid chromatography 
(HPLC) analysis using a Partisphere SAX column (What­
man) [10, 26]. The eluate was fed into a Canberra Packard 
A-500 Flo-One on-line radiodetector and the results ana­
lyzed by the Flo-one data program (Radiomatic, USA)
[10]. Similarly, p2P] PtdlnsP which had been produced, 
separated and visualized in the in vitro  lipid kinase assays, 
was recovered and collected into 2 ml Eppendorf tubes, 
deacylated and further separated by this HPLC method.
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Eluted peaks were compared to retention times for stan­
dards prepared from [3H] phosphoinositides (Amersham) 
and 32P-labeled D-3 phosphoinositides as described else­
where [10, 22].
2.8 Determination of cytosolic free calcium 
concentration ([Ca2+]j) in Jurkat cells
Jurkat cells were suspended at 107 cells/ml in RPMI-1640 
medium supplemented with 10% FCS and incubated for 
30 min at 37 ° C  with 2.5 p M  fura-2 acetoxymethyl ester as 
described previously [27]. The fluorescence of a 2 ml 
cellular suspension was monitored with a Photon Techno­
logy International Delta Scan Fluorimeter (dual excitation 
\  340 nm and 380 nm, single emission X 510 nm) at 37 °C. 
[ C a 2 + ]i was determined by fluorescence using Photon 
Technology International software program (South Brun­
swick, NJ, USA).
3 Results
3.1 An in vitro lipid kinase activity associates with CD28 
immunoprecipitates
Experiments were carried out to determine whether liga­
tion by B7 could promote association of CD28 with PI 
3-kinase. Following co-sedimentation of Jurkat cells with 
CHO-B7+ cells, CD28 immunoprecipitates were assayed to 
detect lipid kinase activity co-associated with CD28 follow­
ing stimulation.This approach revealed that a phosphoino­
sitide lipid kinase activity responsible for the formation of 
[32P] PtdlnsP was present in CD28 immunoprecipitates and 
that the appearance of this activity was dependent on 
stimulation by B7 (Fig. la , lanes 1-4). Lipid kinase activity 
was not observed in unstimulated Jurkat cells (Fig. la , 
lane 5), Jurkat cells co-sedimented with CHO-B7- cells 
(Fig. la , lane 6) or in control CD28 immunoprecipitates 
derived from CHO-B7- (Fig. la , lane 7). In addition, the 
lipid kinase activity was not present in immunoprecipitates 
derived from Jurkat cells co-sedimented with CHO-B7+ 
that had been pre-incubated for 10 min with CTLA4Ig 
fusion protein to block the B7/CD28 interaction (data not 
shown).
The lipid kinase activity associated with CD28 immunopre­
cipitates (Fig. lb , lanes 1 and 2) was inhibited by the PI 
3-kinase inhibitor wortmannin at a concentration of 
100 nM.This concentration of wortmannin also inhibited PI 
3-kinase activity immunoprecipitated by p85 polyclonal 
antisera (Fig. lb , lanes 3 and 4) but did not affect lipid 
kinase activity associated with total Jurkat cell lysates 
(Fig. lb , lanes 5 and 6). Immunoblotting of CD28 immu­
noprecipitates with p85 mAb confirmed that the p85 
subunit of PI 3-kinase was coprecipitated with CD28 
following ligation by B7 (Fig. lc , lanes 2 -4 ) but was absent 
from CD28 immunoprecipitates derived from resting Jur­
kat cells (Fig. lc , lane 1) as well as CHO-B7-  and CHO- 
B7+ cells (Fig. lc , lanes 5 -6 ) .To confirm that the phosphoi­
nositide lipid kinase activity was attributable to PI 3-kinase 
activity, the phosphorylated lipids were recovered and 
separated by anion exchange HPLC (Fig. 2a,b and c). This
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Figure 1. CD28 immunoprecipitates co-precipitate an in vitro lipid 
kinase activity, (a) Jurkat cells (6 x 107) were sedimented alone 
(lane 5), with CHO-B7+ cells (2 x 107, lanes 1-4) or with parental 
CHO-B7- cells (2 x 107, lane 6). Parental CHO-B7" cells were 
also sedimented (2 x 107) as a control (lane 7). (b) Jurkat cells 
(6 x  107) were sedimented alone (lanes 3-6), or whith CHO-B7+ 
(2 x 107), lanes 1-2). All lysates (a, lanes 1-6 and b, lanes 1 and 2) 
were subjected to immunoprecipitation with CD28 mAb. In 
addition, (b) resting Jurkat were lysed and immunoprecipitated 
with p85 polyclonal antisera (lane 3 and 4). (b) The washed 
immunoprecipitates, as well as 40 pi of total resting Jurkat cell 
lysate (lanes 5 and 6) were divided into two and analyzed for Ptdlns 
kinase activity in the presence (lanes 2 ,4 ,6 )  and absence 
(lanes 1, 3, 5) of 100 nM wortmannin using Ptdlns as a substrate. 
Extraction and separation of the 32P-labeled phosphoinositide lipid 
products was performed as described in Sect. 2.7. (c) Jurkat cells 
(3 x 107) were sedimented alone (lane 1), or with CHO-B7+ 
(1.5 x  107), lanes 2—4) for the times indicated. CHO-B7- cells 
(lane 5) and parental CHO-B7+ cells (lane 6) were also sedimented 
(1.5 x 107 cells) as a control. Cells were lysed and all lysates were 
subjected to immunoprecipitation with CD28 mAb. The immuno­
precipitates were washed and proteins resolved by SDS-PAGE, 
immunoblotted with p85 mAb and proteins visualized with the 
ECL detection system as described in Sect. 2.6. Migration of the 
molecular mass standards is indicated to the left in kDa.
analysis showed unequivocally, that the lipid kinase activity 
associated with B7-activated CD28 molecules was indeed 
PI 3-kinase, whilst that present in lysates was predominant­
ly Ptdlns 4-kinase.
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Figure 2. HPLC analysis of lipid kinase activity associated with 
CD28. (a) Jurkat cells (1 x  108) were sedimented alone (lane l),or  
with CHO-B7+ (5 x  107, lane 2). Cells were incubated at 37 °C for 
5 min. All lysates (lanes 1 and 2) were subjected to immunopreci­
pitation with CD28 mAb. The washed immunoprecipitates and 
40 pi of total resting Jurkat cell lysate (1 x  108 cells, lane 3) were 
analyzed for Ptdlns kinase activity using Ptdlns as a substrate, (b) 
The HPLC elution profile of the glycerophosphoinositol derivative 
of [32P] PtdIns(3)P formed by CD28 immunoprecipitates derived 
from B7-activated Jurkat cells in panel a (lane 2). (c) HPLCelution 
profile of the glycerophosphoinositol derivative of [32P] PtdlnsP 
(predominantly [32P] PtdIns(4)P) formed by Jurkat lysates in 
panel a, (lane 3). Extraction, TLC and HPLC separation of the 
lipid products was performed as described in Sect. 2.7.
3.2 Effect of wortmannin on CD28-mediated formation 
of D-3 phosphoinositides and [Ca2+]i
Having established that CD28 directly associated with PI 
3-kinase following B7 ligation, we sought to correlate this 
interaction with the modulation of D-3 phosphoinositide 
lipids in intact Jurkat cells. The experiment shown in Fig. 3 
demonstrates that co-sedimentation of CHO-B7+ with 
Jurkat cells resulted in formation of PtdIns(3 ,4 ,5 )P3 and 
PtdIns(3,4)P2. However, 10-min pre-treatment of 32P- 
labeled Jurkat cells with wortmannin resulted in the 
concentration-dependent inhibition of the CD28-mediated 
increase in both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 follow­
ing hgation by B7 (Fig. 3a and 3b).The IC50 for inhibition of 
CD28-mediated formation of PtdIns(3 ,4 ,5 )P3 and 
PtdIns(3,4)P2 was 10 ±  5 nM  and 7 ±  5 nM  (n =  5) respec­
tively. Immunoblotting with p85 mAb revealed that wort­
mannin pre-treatment at concentrations that inhibited D-3 
phosphoinositide formation, had no effect on the physical 
co-association of CD28 with PI 3-kinase following ligation 
by B7 (Fig. 3c, lanes 1-3). In addition, wortmannin had no 
effect on the elevation of [Ca2+]j induced by cross-linked 
CD28 mAb 9.3 (Fig. 4) or by the CD3 mAb UCHT1 (data 
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Figure 3. Wortmannin inhibits CD28-mediated formation of D-3 
phosphoinositide lipids but not the association of CD28 with PI 
3-kinase. 32P-labeled Jurkat cells (3 x  107) were incubated for 
10 min at 37°C with vehicle or wortmannin (1-100 nM).  Jurkat 
cells were then sedimented alone or with CHO-B7+ cells 
(1.5 x  107) for 5 min. PtdIns(3,4,5)P3 (a) and PtdIns(3,4)P2 (b) 
were extracted, deacylated and analyzed by HPLC separation as 
described in Sect. 2.7. Data shown are mean ± SEM of at least four 
experiments, (c) Jurkat cells (3 x  107) were incubated for 10 min 
alone (lane 1), with vehicle (lane 2) or with 100 nM wortmannin 
(lane 3) at 37 °C. The Jurkat cells were then sedimented alone 
(lane 1), or with CHO-B7+ cells (1.5 x  107, lanes 2-3). CHO-B7+ 
cells were also sedimented (1.5 x  107) as a control (lane 4). Cells 
were lysed and all lysates were subjected to immunoprecipitation 
with CD28 mAb (lanes 1-4). The immunoprecipitates were 
washed, proteins resolved by SDS-PAGE under reducing condi­
tions and immunoblotted with p85 mAb as described in Sect. 2.6. 
Migration of the molecular mass standards is indicated to the left in 
kDa.
of PtdIns(4,5)P2 (an indication of phospholipase C activa­
tion) induced by UCHT1 [26] was also unaffected by 
wortmannin (data not shown).

















Figure 4. Effect of wortmannin on elevation of [Ca2+]i induced by 
CD28 mAb 9.3. Fura-2 loaded Jurkat cells were incubated with 
vehicle or 10 pM wortmannin for 10 min prior to the addition of 
10 pg/ml CD28 mAb 9.3 and goat anti-mouse cross-linking Ig 
(10 pg/ml).The trace is a recording of [Ca2+]; as determined by the 
Photon Technology International software program. Data is from a 
single experiment representative of six others.
3.3 Wortmannin inhibits CD28-mediated costimulation 
of T cell proliferation and IL-2 production
Since wortmannin clearly inhibited the activity of PI 
3-kinase in Jurkat cells, we next determined whether this 
compound could affect CD28-dependent costimulation of 
normal T cells. These experiments were performed using 
purified peripheral blood T cells which were stimulated to 
proliferate using a combination of the CD3 mAb OKT3 and 
CHO-B7+ cells [21]. In this system, wortmannin inhibited 
T cell proliferation in a concentration-dependent manner 
(Fig. 5a) with an IC50 of 2.5 ± 15 nM (n =  5). More 
importantly,T cell production of IL-2 induced in this system 
was also abrogated by wortmannin (Fig. 5b).This suggested 
that the lack of T cell proliferation in this system was not 
due to a block in theT cell response to endogenous EL-2 but 
rather, due to a lack of YLr2 production following CD28 
costimulation. The effect of wortmannin on other aspects of 
T cell function, namely purified T cell proliferation 
induced by PM A and ionomycin (Fig. 5c) and IL-2-driven 
proliferation of T lymphoblasts (Fig. 5d) was also meas­
ured. Surprisingly, there was no inhibition of proliferation 
due to the presence of wortmannin in either of these assays. 
Whilst performing these experiments, it was noted that 
incubation of wortmannin for 1 h in cell culture media prior 
to the addition of T cells, resulted in loss of inhibition by 
wortmannin of OKT3/CHO-B7+-induced T cell prolifera­
tion (Fig. 5e).This correlated with the loss of inhibition by 
wortmannin of PI 3;kina^e activity in p85, and, CD28 
immunoprecipitates -as determined by in vitro lipid kinase 
assays (data not shown): These in vitro lipid kinase assays 
revealed that the inhibitory* action of wortmannin on PI 
3-kinase was unstable and abolished after as little as 30-min 
incubation of wortmannin' with cell culture medium at 
37°C : " ’
■ • •: • ■i/.r'! • 1 t
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4  D iscussion
The data presented in this report demonstrate the activa­
tion of PI 3-kinase following ;CD28 stimulation and the 
inhibition of this pathway by the PI 3-kinase inhibitor 
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Figure 5. Effect of wortmannin on T cell proliferation and IL-2 
production. Purified T cells (5 x 104) (a, b, c and e) were pre­
incubated for 10 min with wortmannin (0.001-10 pM).  Cells were 
stimulated with: (a and e) 1 pg/ml OKT3 plus 2 x 104 CHO-B7+ 
cells (O), or 1 pg/ml OKT3 plus parental 2 x 104 CHO-B7-  cells 
( • ) ;  (b) 1 pg/ml OKT3 plus 2 x 104 CHO-B7+ cells; (c) 100 ng/ml 
PMA and 500 ng/ml ionomycin (O) or vehicle ( • ) .  (b) Superna­
tants fromT cells stimulated as described were collected at 72 h. 
These supernatants were assayed for IL-2 production by incubation 
with 5 x  104 CTLL for 24 h and comparison with IL-2 standards. 
CTLL proliferative responses were determined following addition 
of [3H] thymidine for the final 4 h of incubation as described in 
Sect. 2.3 (d) IL-2-dependent T lymphoblasts (1 x 105) were pre­
incubated for 10 min with vehicle ( • )  or 10 pM wortmannin (O) 
followed by the addition of 1-50 U/ml IL-2. (e) Wortmannin was 
incubated for 1 h at 37 °C in cell culture medium followed by the 
addition of purified T cells and the appropriate stimuli as stated. 
Purified T cells (a, c, and e) and T lymphoblasts (d) were harvested 
at 72 h after pulsing with [3H] thymidine as described in Sect. 2.3. 
The data represents triplicate' Samples from a single experiment 
representative of at leasf tHreeTbthers I-1
i n •' I ' . ■ ' ' 6tl « ■ iv • •
r 1 ‘i.; .$$£}££• Hfe! : . .
previous reports [28-32] of a direct and rapid association of 
CD28 with PL3-kitiase following.stimulation. The associa­
tion between CD28 and PI 3-kinase appears to involve 
interactions between theYXXMiinotif and both the p85 bl­
and C-terihinal SH2 domains [29/ 31]. Since SH2 domains 
have specificity for phosphotyrosine residues [12, 15], this 
implies that phosphorylation of the GD28 molecule follow­
ing hgation by B7 must occur/at:least in part, on tyrosine 
173: Accordingly, several gfoiipsrusing anti-phosphotyro- 
sine mAb have detected tyrosine phosphorylation of immu­
noprecipitated, GD28 following ligation [31, 32].
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The major outstanding question regarding the CD28 asso­
ciation with and activation of PI 3-kinase, is the biological 
relevance of this interaction. To address this question, we 
have used the PI 3-kinase inhibitor wortmannin. This 
compound, whilst reportedly non-specific at micromolar 
concentrations [16-18], has been shown to specifically 
inhibit PI 3-kinase at nanomolar concentrations in nume­
rous cells [16-18]. Accordingly, wortmannin inhibited the 
PI 3-kinase activity associated with p85 immunoprecipi­
tates as well as the increases of both PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 following ligation of CD28 by B7. Howev­
er, wortmannin did not affect Ptdlns 4-kinase activity 
present in Jurkat cell lysates. Moreover, micromolar con­
centrations of wortmannin did not affect activation of 
phospholipase C and calcium mobilization mechanisms as 
determined by the lack of effect of wortmannin on UCHT1- 
induced PtdIns(4,5)P2 metabolism as well as UCHT1- and 
CD28-induced [Ca2+]j elevation.
Having established that wortmannin was indeed able to 
inhibit PI 3-kinase inT cells, the effects of this compound in 
assays of CD28-dependent T cell function were determined 
using naive T cells, activated T lymphoblasts and Jurkat 
cells. CD28 was found to associate with PI 3-kinase in naive 
T cells and T lymphoblasts after ligation by B7, in a similar 
manner to that reported in Jurkat (unpublished observa­
tions). As such, theseT cells provide a system with which to 
analyze the functional significance of CD28 coupling to PI 
3-kinase. In Jurkat cells, wortmannin inhibited the eleva­
tion of D-3 phosphoinositides following CD28 activation 
and this action may be responsible for the potent inhibition 
by wortmannin of B7-dependent T cell proliferation. The 
observed effects of wortmannin do not appear to be due to 
toxic effects o f wortmannin, since incubation with wort­
mannin had no effect on cell viability (unpublished obser­
vations) and high concentrations of wortmannin did not 
abolish T cell proliferation induced by phorbol esters and 
ionomycin. It is significant that the B7-induced co-associa­
tion of PI 3-kinase with CD28 was unaffected by wortman­
nin pre-treatment, such that the effect of wortmannin on 
CD28 signalling would appear to be primarily on the 
enzymatic activity of PI 3-kinase and not the ability of 
CD28 to recruit PI 3-kinase. Indeed, the site of action of 
wortmannin is believed to be the ATP binding site on the 
p i 10 catalytic subunit [17].
The observation that wortmannin abrogated IL-2 produc­
tion induced by CD28 ligation is an important finding. In 
the primary T cell system used in this study, it has previous­
ly been demonstrated [8, 21] that the regulation of IL-2 
production and proliferation are both functions of CD28 
costimulation. Clearly, the abrogation of IL-2 production 
by wortmannin is highly consistent with a primary blockade 
of the CD28 signaling pathway and not later events such as 
responses mediated by IL-2. The lack of IL-2 production as 
determined using the IL-2-dependent CTLL cell line, 
seems unlikely to be explained by a direct effect of 
wortmannin on the CTLL cultures, since our data indicates 
that the ability of wortmannin to inhibit PI 3-kinase as 
determined by in vitro lipid kinase assays, is completely 
abolished after approximately 30 min incubation under cell 
culture conditions.
Interestingly, certain T cell responses were insensitive to 
wortmannin. Firstly, wortmannin had no effect on the
response of T lymphoblasts to exogenous IL-2. This was 
surprising in view of the fact that PI 3-kinase has previously 
been shown to associate with the IL-2 receptor [33] and D-3 
phosphoinositides are elevated upon IL-2 stimulation of 
T cells [34]. These observations may be due to coupling of 
the IL-2 receptor to a recently described wortmannin- 
insensitive PI 3-kinase isoform [35]. Alternatively, these 
observations may also relate to the instability of wortman­
nin under culture conditions and the use of T lymphoblasts. 
Wortmannin is known to irreversibly inhibit PI 3-kinase 
[17] but it is inactivated rapidly during the first few hours of 
cell culture. T lymphoblasts are highly metabolically active 
which may eventually result in the de novo  synthesis of new 
pools of PI 3-kinase that are no longer exposed to 
functional.wortmannin.Thus, at the time at which prolifer­
ative responses to IL-2 are measured (72 h), wortmannin 
appears to have little effect. Further biochemical studies of 
IL-2 receptor signaling will be needed to address this issue. 
Another alternative is that the IL-2 receptor may be able to 
invoke multiple signaling pathways such that PI 3-kinase is 
not critical to IL-2 receptor signaling.
The second wortmannin-insensitive response was observed 
in PMA- and ionomycin-stimulated T cells. These experi­
ments were performed in freshly isolated, purified, resting 
T cells which were not synthetically active and therefore 
de n ovo  synthesis of PI 3-kinase may not explain this 
particular wortmannin-insensitive response. A possible 
explanation for this finding is that either PMA or ionomy­
cin act individually or in combination, at a point distal to 
the generation of D-3 phosphoinositides and their subse­
quent target molecules. This is interesting since one candi­
date target for PtdIns(3,4,5)P3 is the t, isoform of PKC [36]. 
However, this enzyme has been reported to be phorbol 
ester insensitive [37].
In addition to CD28 [10] and the IL-2 receptor [33, 34], 
other T cell molecules such as the TcR and CD4 are known 
to associate with PI 3-kinase via interactions with the src 
family kinases fyn  [38] and lek [39-41], respectively. 
Moreover, both the TcR [26] and CD7 [42] also induce D-3 
phosphoinositide production following ligation, albeit at 
much reduced levels compared to CD28-mediated 
increases (unpublished observations). It is unclear there­
fore, why activation of this pathway, which is clearly coupled 
to and activated by multipleT cell surface receptors, should 
be a critical event in T cell costimulation when specifically 
activated by CD28. In this respect, heterogeneity of (i) PI 
3-kinase isoforms [35, 43, 44], (ii) receptor coupling to PI 
3-kinase (either tyrosine kinase-regulated or G protein- 
regulated mechanism) [43], (iii) PI 3-kinase substrate 
specificity [35], or (iv) magnitude of receptor-induced D-3 
phosphoinositide formation, may determine distinct func­
tions for different T cell surface receptors. This may explain 
the critical role of CD28-activated PI 3-kinase but not for 
instance, TcR-activated PI 3-kinase [26], at least with 
respect to T cell costimulation.
Observations from this and other recent studies have 
implicated PI 3-kinase as an important enzyme in CD28 
function [10, 28-32]. The data presented here show that 
abrogation of the generation of D-3 phosphoinositides 
resulting from CD28 activation, prevents CD28-mediated 
costimulation and implies that the coupling of CD28 to PI 
3-kinase and subsequent signaling represents a critical
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physiological signal. Clearly, at some point signals gener­
ated via this pathway must converge with those generated 
by the TcR pathway in order for the observed potent 
synergy to occur. Recent evidence has demonstrated that 
the protein kinase JNK is a likely point at which signal 
integration occurs since simultaneous activation of TcR and 
CD28 results in JNK activation [45]. Interestingly, JNK is a 
novel member of the MAP kinase group [46], activation of 
which requires complex protein kinase cascades which have 
been postulated to involve regulation by PtdIns[3,4,5)P3
[11]. However, the events distal to PI 3-kinase activation 
and ultimately D-3 phosphoinositide elevation remain 
unclear [11].
We are grateful to Richard Parry for assistance with HPLC 
separations.
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B7/CD28 but not LFA-3/CD2 interactions can provide ‘third-party* 
co-stimulation for human T-cell activation
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SUMMARY
The requirement for co-stimulation in T-cell activation has become firmly established, whilst the 
precise identity of the molecules involved remains uncertain. Some of the major co-stimulatory 
molecules include ICAM-1, LFA-3 and B7. We have investigated the abilities of both LFA-3 and B7 
to co-stimulate T-cell proliferation under a number of conditions using transfected Chinese hamster 
ovary cells. Using anti-CD3 antibodies we observed that B7 but not LFA-3 transfectants were 
capable of co-stimulating proliferation in purified peripheral blood T cells. In addition, both LFA-3 
and B7 could induce proliferation in response to phytohaemagglutinin (PHA) and we obtained 
additive effects using both B7 and LFA-3 together. Using the superantigen staphylococcal 
enterotoxin B (SEB), we observed that presentation to purified T cells required the presence of class 
II-positive transfectants and that sensitivity to antigen was increased approximately 100-fold by the 
co-transfection of either B7 or LFA-3. However, when co-stimulatory molecules were provided by 
cells separate from those engaging the T-cell receptor (TcR), only B7 was capable of enhancing 
proliferation. Kinetic studies which investigated the time dependence for co-stimulation revealed that 
T cells responding to anti-CD3 antibodies required the B7 co-stimulation within the first few hours, 
for proliferation to be effective. Our data differentiate between the co-stimulatory abilities of B7 and 
LFA-3 and support the concept of a pivotal role for B7 in T-cell proliferation.
INTRODUCTION
The activation of T lymphocytes within the immune system is of 
fundamental importance in generating both cell-mediated and 
| humoral responses. Increasing evidence suggests that this 
process requires at least two signals, one delivered by the a//? 
T-cell receptor (TcR) as well as a second delivered by a co- 
stimulatory molecule.1 The absence of co-stimulation during 
TcR engagement is increasingly implicated in leading to a state 
of unresponsiveness (clonal anergy)2*3 or possibly to pro­
grammed cell death (apoptosis).0  Evidence from murine sys­
tems suggests that T cells may be rescued from clonal anergy by 
the delivery of a co-stimulatory signal by a ‘third-party* cell 
which cannot engage the TcR.6 This situation demands that any 
potential candidates for such co-stimulatory function be able to 
deliver signals from a cell different to that providing TcR 
engagement. Although there are several molecules reported to 
possess co-stimulatory activity, most have not been tested on 
third-party cells. Recently, interest in co-stimulation has 
focused on the molecule B7 and its T-cell ligand CD28.
B7 is a 44,000-54,000 MW glycoprotein first identified on 
the surface of activated B cells by the antibody BB17 and
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subsequently found on monocytes,1 dendritic cells9 and some 
repeatedly activated T cells.10 B7 binds to the T-cell surface 
molecule CD28 on the majority of T lymphocytes, and modula­
tion of CD28 has important effects on T-cell stimulation, 
including the augmentation of proliferation with anti-CD3 
antibodies, alloantigens and lectins.1112 The enhancement of 
these responses appears to be effected by an increase in 
production of interleukin-2 (IL-2) brought about by accumu­
lation and stabilization of IL-2 mRNA and direct up-regulation 
of the IL-2 enhancer.13-15 It has also recently been established 
that the pathway by which CD28 signals is independent of the 
TcR and results in tyrosine phosphorylation.16 Whilst data have 
accumulated which suggest the potential involvement of B7/ 
CD28 interactions as co-stimulators, there is little evidence as to 
whether this form of co-stimulation is consistent with the effects 
observed in reversing clonal anergy, in particular whether B7 is 
effective as a ‘third-party* co-stimulator in T-cell activation. In 
this study we have used Chinese hamster ovary cell transfectants 
to test whether B7-expressing cells can provide effective co­
stimulation to cells expressing a ligand for the T-cell receptor 
only. Our data show that B7/CD28 but not LFA-3/CD2 
interactions can deliver co-stimulation from a separate cell to 
that engaging the TcR. In addition, this interaction is time 
dependent in that the delivery of the B7 co-stimulatory signal is 
only effective within the first 24 hr following TcR engagement.
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These results provide strong support for the role of B7 as a 
critical co-stimulator of T-cell activation, which may well act as 
a switch between activation and anergy.
MATERIALS AND METHODS
Transfectants
Chinese hamster ovary (CHO) K1 cells were transfected with 
human cDNAs, encoding LFA-3, B7 and HLA-DR A and DR 
B1 *0401. The DR genes were established under the control of a 
human cytomegalovirus immediate early promoter in the vector 
pEE6 hCMV. Cassettes containing DR4 genes were then sub­
cloned into the vector pSVLGS. 1, containing glutamine synthe­
tase (GS) as a selectable marker (these vectors were a gift from 
Dr C. Bebbington, Celltech, Slough, U.K.). This construct was 
transfected by calcium phosphate precipitation into CHO cells 
and the cells selected using the GS inhibitor L-methionine 
sulphoximine (Sigma, Poole, U.K.) at 1 mM. Cells expressing 
high levels of DR molecules were cloned by limiting dilution. 
Subsequent expression of accessory molecules was achieved 
using the pEE6 expression vector transfected into DR-positive 
clones by electroporation. Selection of LFA-3 was based on 
G418,500 pg/ml, and for B7 hygromycin was used at 250 pg/ml. 
All transfectants were grown in Dulbecco’s minimal essential 
medium (DM EM) without glutamine, containing 10% fetal calf 
serum (FCS) and antibiotics with appropriate selection. The 
transfectants were routinely screened and sorted for expression 
by FACS and levels of expression were comparable between 
transfectants.
Monoclonal antibodies
The following monoclonal antibodies (mAb) were used: L243 
(anti-DR) and TS2/9 (anti-LFA-3), obtained from ATCC 
(Rockville, MD); BB1 (anti-B7), obtained from Dr E. Clark 
(University of Washington, WA); BUI 2 (CD 19), obtained from 
Professor I. MacLennan (University of Birmingham, U.K.); 
UCHM1 (CD 14) and UCHT1 (CD3), obtained from Professor 
P. Beverley (ICRF, London, U.K.); CD25 antibody, obtained 
from Becton Dickinson (Mountain View, CA). For FACS 
analysis antibodies were used as undiluted culture supernatants, 
except BB1 and BU12 which were used as ascites diluted 1/2000 
and 1/1000, respectively. In stimulation assays UCHT1 was 
used as dialysed 50% ammonium sulphate precipitate diluted to 
10 ng/ml.
Antigen presentation assays
Transfectants were trypsinized and washed in RPMI-1640 
containing 10% FCS prior to use. The cells were resuspended in 
1 ml of complete medium up to 107 per ml and treated with 
mitomycin (100 /xg/ml) for 2 hr at 37° or fixed with 0 025% 
glutaraldehyde for 2 min after pulsing with staphylococcal 
enterotoxin B (SEB) for 3 hr. After washing twice the cells were 
plated in 96-well flat-bottomed plates at 2-5 x 1 Orwell for use as 
antigen-presenting cells (APC). In the kinetic experiments T 
cells were purified as detailed below and added at 5 x 1 Orwell 
with anti-CD3 antibody at 10 pg/ml with or without co­
stimulation. B7-transfected CHO cells were glutaraldehyde 
fixed and added at 2 x  UP/well as co-stimulators at the time- 
points indicated post-stimulation. Cells were pulsed at equiva­
lent time-points and frozen until counting. All samples were 
issayed in triplicate with standard errors routinely less than
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Figure 1. Co-stimulation of anti-CD3-induced activation by LFA-3 and 
B7 transfectants. UCHTI (10 /ig/ml) induces proliferation in un­
separated (PBMC) but not in purified T cells (T cells). The ability to 
proliferate is restored by B7 co-stimulation but not by LFA-3 or control 
CHO cells.
10%. The data shown are representative of at least three 
independent experiments.
T-cell purification
Heparinized blood samples were separated on a histopaque 
(1-077) density gradient. Mononuclear cells recovered from the 
gradient were washed twice in phosphate-buffered saline (PBS) 
and used as responder cells without further fractionation at 10s 
cells/well. In experiments involving purified T cells, cells were 
isolated from peripheral blood mononuclear cells (PBMC) by 
negative selection. Briefly, after plastic adherence for 1 hr at 37° 
in FCS-containing medium, non-adherent cells were subjected 
to magnetic bead separation (Dynal-M450) using anti-DR 
(L243), anti-B cell (BUI2) and anti-monocyte (UCHMI) anti­
bodies. The resulting T cells were greater than 95% CD3 
positive and used at 5 x 1 Orwell with SEB or phytohaemagglu- 
tinin (PHA) at the concentrations shown. T-cell proliferation 
was measured at 72-96 hr by adding I pC\ of tritiated 
thymidine/well for the last 8-24 hr of culture, followed by 
harvesting cells onto filters, and counting by liquid scintillation.
RESULTS
B7- but not LFA-3-expressing transfectants co-stimulate anti- 
CD3 antibodies
In the first series of experiments, B7- and LFA-3-expressing 
transfectants were tested for their ability to provide co­
stimulation to purified resting peripheral blood T cells stimu­
lated using anti-CD3 antibodies. It is known that in the absence 
of co-stimulators anti-CD3 is insufficient to induce proliferation. 
As shown in Fig. 1, unseparated PBMC responded vigorously to 
anti-CD3 antibodies added to the culture but the purification of 
T cells resulted in complete abrogation of the response. This loss 
of responsiveness is thought to reflect the removal of FcR- 
bearing cells which may cross-link the antibody but which also 
provide the co-stimulatory signals necessary for proliferation. 
Using this system we therefore investigated the ability of CHO 
transfectants expressing either B7 or LFA-3 molecules to 
provide this co-stimulatory requirement. This experiment 
(Fig. 1) demonstrated that B7 but not LFA-3 transfectants 
stimulated responses comparable to those obtained using 
unseparated cells. This confirmed that B7 is a major co-








Figure 2. Co-stimulation o f PHA-induced activation by LFA-3 and B7 
transfectants. (a) PHA 1 ng/ml is incapable o f inducing proliferation in 
purified T cells co-stimulated with CHO controls cells, whereas both B7 
and LFA-3 transfectants induce a proliferative response, (b) PHA- 
treated Tcells are responsive to exogenous IL-2 and both B7 and LFA-3 
augment this response, (c) B7 and LFA-3 synergize in PHA responses. T 
cells were stimulated with PHA and B7 cells with the addition o f further 
CHO, CHO-B7 or CHO-LFA-3 transfectants. This shows that the 
presence o f both LFA-3 and B7 on separate cells results in increased 
responses to PHA.
stimulatory molecule in the induction of proliferative responses 
in resting T cells and demonstrated that LFA-3 was not effective 
in this situation.
Both LFA-3 and B7 can co-stimulate PHA-stimulated T cells
In order to further assess the abilities of both B7- and LFA-3- 
expressing transfectants in providing co-stimulation, the trans­
fectants were added to T cells co-cultured with PHA as a 
stimulus. This Experiment (Fig. 2) clearly demonstrated that, 
whilst purified T cells were incapable of responding to PHA 
alone, the addition of B7 and LFA-3 transfectants but not 
control CHO cells induced the T cells to proliferate strongly. 
Thus both the LFA-3 and B7 molecules expressed on the 
transfectants were functionally competent and capable of co­
stimulation with PHA. In addition, the experiment was repeated 
with the addition of exogenous IL-2 to observe whether the 
PHA treatment had resulted in responsiveness to IL-2 in the 
absence of proliferation. The addition of IL-2 to the PHA- 
stimulated T cells (Fig. 2b) showed that the cells were responsive 
to IL-2 without further co-stimulation. Thus PHA stimulation 
of purified T cells allowed up-regulation of the IL-2 receptor but 
was insufficient to allow proliferation. However, where the T 
cells had been co-stimulated with PHA and either the B7 or 
LFA-3 transfectants, proliferation was further enhanced by 
IL-2 additions. In particular, responses to the LFA-3 transfec- 
tant were enhanced over three-fold, suggesting that signalling 
through CD2 might be affecting the level of expression of the 
IL-2 receptor. Since it is known that a major feature of CD28 
engagement by B7 is an increase in IL-2 production we 
postulated that LFA-3 and B7 together would augment the 
response of purified T cells to PHA stimulation. As shown in 
Fig. 2c this proved to be the case. The addition of CHO or of 
further B7 cells to the PHA stimulation did not result in 
enhanced responses and indeed reduced the level of prolifera­
tion compared to optimized cell numbers. However, when both 
B7 and LFA-3 transfectants were added together they produced 
a considerable increase in proliferation despite supra-optimal 
numbers of transfectants being present. Together these data 
clearly demonstrate the ability of both B7 and LFA-3 to 
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Figure 3. Effect o f transfected accessory molecules LFA-3 and B7 on 
responses o f purified T cells to SEB. Purified T cells are unable to 
respond to SEB in the absence o f APC (O). However, responses were 
obtained by the addition o f DR4 (O)-expressing CHO cells. DR4 cells 
co-transfected with either B7 (a ) or LFA-3 (■) were used to assess the 
effect o f  these co-stimulatory molecules in response to a range o f  SEB 
concentrations.
B7 but not LFA-3 transfectants provide ‘third-party’ co-stimula­
tion of SEB-induced proliferation
Whilst the initial experiments established that B7 was a potent 
co-stimulator of T cells with anti-CD3, and that both B7 and 
LFA-3 molecules could co-stimulate PHA-induced prolifera­
tion, they did not allow us to conclude which of the interactions 
were required on the same surface as the TcR and which, if any, 
could take place through more remote interactions not involved 
in increasing adhesion between the T cell and its target. To 
address this issue, TcR and co-stimulatory signals were deli­
vered separately to T cells by using transfectants expressing 
DR4 molecules coated with SEB as the TcR target and the co­
stimulatory molecules B7 or LFA-3 as separate co-stimulators. 
Initially, experiments were performed to evaluate the ability of 
peripheral blood T cells to respond to SEB in the absence of 
APCs (Fig. 3). As expected, the purified T cells failed to respond, 
but the addition of transfectants expressing DR4 alone, DR4- 
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Figure 4. ‘Third-party’ co-stimulation is provided by B7 but not by 
LFA-3. DW4 transfectants were pulsed with 1 /rg/ml SEB and used to 
stimulate purified T cells. Different numbers o f  CHO (O), CHO-LFA-3 
(I) and CHO-B7 (□) cells were added to assess the ability o f B7 and 
LFA-3 to provide co-stimulation from a ‘third-party’ cell. B7 (a ) and 
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Figure 5. Kinetics o f B7 co-stimulation with anti-CD3 antibodies. 
Purified T cells were stimulated with UCHT1 at 10 /rg/ml. Fixed CHO 
(G) or CHO-B7 (a ) cells were added at times indicated after the start o f  
the assay. Samples were harvested for counting after pulsing with 
iritiated thymidine overnight.
both LFA-3 and B7 could function as potent co-stimulators 
when present on the same cell as the TcR ligand. Subsequently, 
the experiments were repeated with B7 and LFA-3 co-stimula­
tion provided by cells separate from those engaging the TcR 
(Fig. 4). In this situation only B7 proved capable of enhancing 
proliferation in resting T cells. This enhancement was dependent 
on TcR stimulation since B7 transfectants alone were unable to 
induce proliferation and thus clearly demonstrated co-stimula- 
lion by B7 but not LFA-3 on a third-party cell. These results are 
consistent with the observations that CD28 has a separate 
signalling pathway and that LFA-3/CD2 apparently requires 
CD3 stimulation for signalling.
Hie delivery of B7 co-stimulation is time dependent '
Having demonstrated that B7 but not LFA-3 is capable of 
Fulfilling a major requirement for co-stimulatory; function, we 
next addressed whether the signal delivered by B7 was time 
iependent (as predicted by experiments capable of anergy 
prevention). We therefore used B7 or control CHO cells as co- 
itimulators of anti-CD3-induced proliferation and investigated
the effects of delayed addition of the B7 co-stimulation. In these 
experiments purified T cells were treated with anti-CD3 at the 
start of the experiment and B7 or control CHO cells add^d at 
the times indicated (Fig. 5). The results from this experiment 
showed that for co-stimulation to be effective the signal must be 
delivered within the first 24 hr of TcR engagement. The addition 
of cytokines such as IL-1 and IL-6, as well as control CHO cells, 
in these experiments did not result in any co-stimulation.
DISCUSSION
The activation of T cells is thought to require at least two 
distinct signals, an antigen-specific signal delivered through the 
TcR (Signal 1), as well as a co-stimulatory signal (Signal 2) 
which enables the cell to proceed to IL-2 production and 
proliferation. A number of studies indicate that the delivery of 
Signal 1 in the absence of Signal 2 results not only in the absence 
of proliferation but also in a state of unresponsiveness with 
respect to the antigen providing Signal 1. This scenario is 
attractive also because it potentially explains a number of in vivo 
findings regarding tolerance.17-19 However, to date the nature of 
the co-stimulatory signal(s) remains uncertain. Several mole­
cules are known to provide some degree of co-stimulation for T- 
cell proliferation.I3-20-22 Of these, the best candidate appears to 
be B7 which has been shown in several studies to up-regulate the 
production of IL-2 by T cells. This cytokine has been suggested 
to play a key role in overcoming or preventing anergy. In this 
study we have established that B7 can co-stimulate T-cell 
proliferation in a way which is distinguishable from another 
important co-stimulatory molecule, LFA-3. In particular we 
have shown that B7 can fulfil the predictions for co-stimulatory 
function made by Jenkins et al.,6 which include: (1) the ability to 
provide co-stimulation from a cell not providing Signal 1; (2) the 
ability to provide a signal which can synergize with CD3, 
resulting in proliferation; and (3) the ability to generate a signal 
which is time dependent in its ability to induce proliferation. The 
differences observed between B7 and LFA-3 do not appear to 
relate to levels of expression since these are comparable by 
FACS analysis. In addition, in functional analyses (using SEB) 
both B7 and LFA-3 molecules are capable of considerable 
functional effects.
Recently the ability of B7 to provide third-party co­
stimulation has been addressed in the mouse by Liu and 
Janeway.23 In this study, however, the authors concluded that 
third-party co-stimulation was limited when using anti-CD3 
bound by FcR on one cell and providing co-stimulation via 
LPS-treated B cells or transfectants expressing B7. There may be 
several reasons for the discrepancies between our data. First, the 
mouse system may indeed be different in its ability to receive 
third-party co-stimulation. In this regard it is interesting that 
mouse T cells do not express class II molecules when activated, 
in contrast to human T cells which express both class II and B7 
on some T-cell blasts. This may reflect a difference in the abilities 
of human and mouse T cells to receive B7 engagement of CD28 
from other cells. Second, in our experiments we used SEB as an 
antigen for the TcR; this may have different co-stimulatory 
requirements to stimulation via CD3. It has recently been shown 
that stimulation via SEB may give different signals compared to 
normal antigenic stimulation.24 Third, the levels of B7 ex­
pression on the co-stimulator cells may differ thereby affecting 
the ability of the third-party cells to co-stimulate. However, our
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data are consistent with those of Liu and Janeway in other 
respects. We also find the expression of both ligands on the same 
cell to be a more potent stimulus for proliferation and that B7 is 
capable of direct stimulation of T cell blasts but not resting T 
cells (data not shown).
The ability of LFA-3 to co-stimulate PHA but not anti-CD3 
antibodies is also an interesting finding. These experiments 
suggest that LFA-3 is not a co-stimulatory ligand for CD2 by 
itself and may require other signals from the same cell surface as 
the TcR. The fact that pairs of antibodies are required to 
stimulate through CD2 is consistent with this possibility.25 In 
our experiments with SEB presentation by DR4-LFA-3 trans­
fectants, LFA-3 may be serving to provide adhesion rather than 
co-stimulation, thereby providing increased sensitivity to anti­
gen. Previously, however, we have noted, using SEA, that 
LFA-3 has the potential to enhance IFN-y production, suggest­
ing some signalling capacity although perhaps insufficient to 
generate a proliferative response.26 It is also possible that CD2 
stimulation rigorously requires the engagement of CD3 on the 
same surface, as would be provided by our DR4-LFA-3 co- 
transfectants, and that this results in an enhanced proliferative 
signal. In the experiments where PHA was present it appears 
that the lectin provides an additional ligand for CD2 which is 
capable of synergy with LFA-3, resulting in a more potent 
stimulus for T-cell proliferation. Recently, two new ligands for 
CD2 have been identified27’28 and of particular interest is the 
report that mouse CD2 binds to the CD48/Blast-1 antigen. 
Given the restricted expression of the Blast-1 molecule on cells 
involved in the immune response,29 this may provide the 
necessary signalling for proliferation in association with LFA-3.
Whilst our experiments have not directly tested the induc­
tion of anergy in peripheral blood T cells, it is clear that the use 
of anti-CD3 requires a co-stimulus to induce proliferation in 
these cells. Our data suggest that this co-stimulation can be 
provided by B7 but not LFA-3 and that the delivery of co­
stimulation is restricted to the first few hours after TcR 
engagement. Clearly our data support the involvement of B7 as 
a major co-stimulatory molecule required for the proliferation 
of T cells and are consistent with a role in the prevention of 
T-cell anergy.
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Induction of Activator Protein (AP)-1 and Nuclear Factor-icB 
by CD28 Stimulation Involves Both Phosphatidylinositol 
3-Kinase and Acidic Sphingomyelinase Signals1
Christine E. Edmead, Yusuf I. Patel, Anne Wilson, George Boulougouris, Nicolas D. Hall, 
Steven G. Ward, and David M. Sansom2
A major obstacle in understanding the signaling events that follow CD28 receptor ligation arises from the fact that CD28 acts 
as a costimulus to TCR engagement, making it difficult to assess the relative contribution of CD28 signals as distinct from those 
of the TCR. To overcome this problem, we have exploited the observation that activated human T cell blasts can be stimulated 
via the CD28 surface molecule in the absence of antigenic challenge; thus, we have been able to observe the response of normal 
T cells to CD28 activation in isolation. Using this system, w e observed that CD28 stimulation by B7-transfected CHO cells 
induced a proliferative response in T cells that was not accompanied by measurable IL-2 production. However, subsequent 
analysis of transcription factor generation revealed that B7 stimulation induced both activator protein-1 (AP-1) and nuclear 
factor-icB (NF-kB) complexes, but not NF-AT. In contrast, engagement of the TCR by class II MHC/superantigen, either with or 
without C 028 ligation, resulted in the induction of NF-AT, AP-1, and NF-kB as well as IL-2 production. Using selective inhib­
itors, we investigated the signaling pathways involved in the CD28-mediated induction of AP-1 and NF-kB. This revealed that 
NF-kB generation was sensitive to chloroquine, an inhibitor of acidic sphingomyelinase, but not to the phosphatidylinositol 
3-kinase inhibitor, wortmannin. In contrast, AP-1 generation was inhibited by wortmannin and was also variably sensitive to 
chloroquine. These data suggest that in activated normal T cells, CD28-derived signals can stimulate proliferation at least in part 
via NF-kB and AP-1 generation, and that this response uses both acidic sphingomyelinase and phosphatidylinositol 3-kinase- 
linked pathways. The Journal o f Immunology, 1996, 157: 3290-3297 .
A ctivation of T lymphocytes is central to the efficient 
functioning of the immune system. In addition to stim­
ulation of the TCR by foreign Ags, the activation of 
resting T cells requires additional signals, which can be provided 
by the co-ordinated engagement of the CD28 molecule (1, 2). 
While CD28 has been known for some time to be a major co- 
stimulatory molecule, the signaling events associated with its en­
gagement are still poorly characterized, especially in normal T 
cells. Recent progress has identified a number of receptor proximal 
events that appear to be triggered following ligation of CD28 ei­
ther by its natural ligand B7-1 (CD80) or by activating anti-CD28 
Abs. In particular, ligation of CD28 has been shown to result in the 
generation of 3' phosphoinositides following the recruitment and 
activation of the enzyme PI3K3 (3). This interaction is mediated 
via binding of the PI3K p85 subunit SH2 domains to the phos- 
phorylated Tyr Met Asn Met (YMXM) motif in the cytoplasmic
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domain of CD28 (4). The importance of PI3K in CD28 signaling 
has been investigated by use of the 3-kinase inhibitor, wortmannin, 
which blocks the enzymatic activity of the kinase, but not its re­
cruitment by CD28 (5). These studies have demonstrated that in 
normal resting T cells, wortmannin blocks both proliferation and 
IL-2 production in response to CD28 costimulation, but contrasts 
to the limited inhibitory effects seen using wortmannin in activated 
cells, such as Jurkat cells. Thus, the relative contributions of PI3K 
to CD28-induced proliferation and IL-2 production are currently 
unclear. One possible explanation for the difference in the effects 
of PI3K inhibition is the existence of alternative CD28-driven sig­
naling pathways, which in activated cells may be capable of pro­
viding the necessary costimulatory signals. The recent discovery of 
the involvement of the acidic sphingomyelinase pathway in CD28 
signaling (6) has, therefore, provided a second mechanism through 
which CD28 could exert its costimulatory actions.
The sphingomyelinase signaling pathway is a second messenger 
system that appears to be associated with a diverse range of surface 
receptors, including CD28, TNF (7-9), and Fas (10). Two different 
forms of the sphingomyelinase enzyme have been described: a 
membrane-bound neutral sphingomyelinase and an acidic form 
that is thought to be sequestered in lysosomes (11). Activation of 
the acidic form is sensitive to inhibition by lysosomotropic agents 
such as chloroquine (7), which affect lysosomal pH, and it is this 
acidic form that is activated by CD28. Activation of the sphingo­
myelinase enzyme results in the generation of phosphorylcholine 
and ceramide; the^  latter is the active signaling entity. Several 
downstream targets of ceramide have been identified to date, in­
cluding activation of the Ras/Raf pathway (12), JNK (13), and 
PKC£ (14). PKC£ has been reported to be responsible for the in­
duction of NF-kB via mechanisms involving phosphorylation and
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subsequent degradation of IkB, the inhibitory subunit of the 
NF-kB complex (15). Degradation of IkB allows free translocation 
of the NF-kB to the nucleus, where it participates in gene regula­
tion. The activation of acidic sphingomyelinase by CD28 ligation 
may, therefore, provide a link to the regulation of NF-kB.
While the downstream effects of CD28 signals are still under 
investigation, it is clear that a major outcome of CD28 costimu­
lation is the regulation of cytokine genes at both the transcriptional 
and post-transcriptional levels (16, 17). Previous reports have sug­
gested that CD28 may affect transcription factors that bind to the 
IL-2 and other cytokine promoters (18); however, many of these 
studies have been performed in Jurkat cells using anti-CD28 Abs 
in addition to mitogenic stimuli (such as PMA and ionomycin), 
making it difficult to interpret the precise effect of the CD28 
stimulation.
In the present study, we have used normal activated T cells to 
investigate the regulation by CD28 of transcription factors known 
to bind to the IL-2 promoter. Exploiting the observation that su­
perantigen-driven T cell blasts respond to CD28 stimulation in the 
absence of TCR engagement, we have used CHO transfectants 
expressing B7 to stimulate CD28 responses. Given that both PI3K 
and acidic sphingomyelinase pathways have been implicated in 
CD28 signaling, we have used this system to determine which 
transcription factors can be influenced by CD28 stimulation and 
which proximal signaling events influence their generation. Our 
results demonstrate that in activated T cells, CD28 ligation results 
in both proliferation and the induction of NF-kB and AP-1 com­
plexes. Furthermore, using inhibitors of PI3K and acidic sphingo­
myelinase, we demonstrate that both of these signaling pathways 
are involved in the induction of these transcription factors 
by CD28.
Materials and Methods
Preparation of T cell blasts and purified T cells
Heparinized peripheral blood was diluted 1/1 with PBS, layered onto a 
Lymphoprep (Nycomed, Oslo, Norway) gradient (density, 1.077 g/ml), and 
centrifuged at 300 X g for 30 min. The mononuclear cells (PBMCs) were 
harvested aid washed twice in medium. To generate T cell blasts, PBMCs 
were placed in a tissue culture flask at a density of 3 to 5 X 106/ml and 
stimulated with the superantigen SEA (10 ng/ml). The cells were then 
expanded in IL-2 as required. After 8 to 10 days, the blasts were restim­
ulated with SEA Ag fixed onto DR4/B7 transfectants, and the cells were 
expanded in IL-2 for an additional 8 to 14 days before use.
Purified T cells were prepared as previously described (19). Briefly, 
PBMCs were subjected to plastic adherence for 1 h. Nonadherent cells 
were recovered and depleted by negative immunomagnetic selection of 
CD 14-, CD19-, and HLA-DR-expressing cells. Cell purity was assessed by 
FACS, and populations were at least 95% CD3+.
Transfectints
CHO cell transfectants were generated as previously described (19) by 
expressing the appropriate cDNAs downstream of a CMV promoter in 
pEE6 or pcDNA-3 expression vectors. Transfectants were cloned and 
sorted by FACS, and the expression levels o f the relevant Ags were rou­
tinely moni.ored by FACS analysis. All the transfectant cells were cultured 
in glutamire-free DMEM containing 10% FCS and penicillin/streptomy­
cin. For use in stimulation assays, transfectants were washed in PBS, fixed 
in 0.025% glutaraldehyde for 2 min, and extensively washed in complete 
medium before use.
Proliferatbn assays
Routinely, 7 cell proliferation in response to various stimuli was measured 
using 5 X 104 T cells/well in a flat-bottom 96-well plate in combination 
with 2 X 104 glutaraldehyde-fixed transfectants. Monoclonal Abs were 
added at 1 /tg/ml in soluble form unless otherwise stated, and each treat­
ment was conducted in triplicate. Assays were incubated for 72 h at 37°C. 
Aliquots of supernatant were then removed from each well and assayed for 
IL-2 production using a CTLL bioassay, as described previously (5). To 
measure proliferation, 1 p.Ci of [3H]thymidine was added to each well, and
incubation was conducted for an additional 8 h. After this time, the cells 
were harvested onto Whatman GFC glass fiber filters (Clifton, NJ), and the 
incorporation of radioactivity was assessed using liquid scintillation 
counting.
FACS analysis
The following Abs were used as staining reagents at 1 p.g/ml: OKT11 
(anti-CD2), UCHT1 (anti-CD3), E2H10 (anti-CD4), 8784 (anti-CD25), 9.3 
(anti-CD28), and L243 (anti-HLA-DR). Staining was detected by the ad­
dition of FITC-conjugated anti-mouse polyvalent Igs (Sigma Chemical 
Co., St. Louis, MO), and 5000 cells were analyzed by flow cytometry on 
a Becton Dickinson FACStar Plus (Mountain View, CA). Abs against 
CD2, CD25, and DR were obtained from American Type Culture Collec­
tion (Rockville, MD), 9.3 was a gift from Dr. P. Linsley, and UCHT1 and 
E2H10 were obtained from Prof. P. Beverley.
Preparation o f  nuclear extracts
Cells (6 X 107) were washed, resuspended at 3 X 106/ml, and stimulated 
at 37°C for 4 h. Transfectants were used as stimulators at a ratio of 1:5 
transfectants to T cells. For experiments involving enzyme inhibitors, the 
T cells were preincubated for 1 h before stimulation.
After stimulation, cells were washed in cold PBS, pelleted, and resus­
pended in 400 /d of hypotonic buffer 1 (10 mM HEPES, pH 7.8; 1.5 mM 
MgCl2; 10 mM KC1; 0.5 mM DTT; 0.2 mM PMSF; leupeptin E64; and 
pepstatin) supplemented with 0.2% Nonidet P-40 on ice for 15 min. Nuclei 
were pelleted by gentle centrifugation in a microcentrifuge. The pellet was 
gently washed in 1 ml of buffer 1 supplemented with 8.5% sucrose and 
recovered by centrifugation as described above. Nuclei were resuspended 
in 400 fil o f buffer 2 (20 mM HEPES pH 7.8; 25% glycerol; 0.42 M NaCl; 
1.5 mM MgCl2; 0.2 mM EDTA; 0.5 mM DTT; and protease inhibitors as 
described above) and incubated on ice for 20 min. Lysates were centrifuged 
for 30 min, and ammonium sulfate (0.33 g/ml) was added to precipitate 
proteins. The protein pellet was resuspended in 50 /d of buffer 3 (20 mM 
HEPES, pH 7.8; 20 mM KC1; 1 mM MgCl2; 2 mM DTT; 17% glycerol; 
and 0.2 mM PMSF) and assayed for protein content using a colorimetric 
assay. Aliquots were stored at -80°C  until use.
Electromobility gel shift assay
Fifteen micrograms nuclear extract were incubated for 10 min with 1 fig 
poIy(dl-dC), in 7.5% (v/v) glycerol, 38 mM KC1, and 0.6 mM MgCl2. 
Oligonucleotides corresponding to the binding sites for NF-AT, NF-kB, 
and AP-1 were end labeled using T4 polynucleotide kinase. Incubation was 
performed at room temperature for 20 min before loading onto a 5% non­
denaturing polyacrylamide gel. Following electrophoresis, the gel was 
dried and exposed by autoradiography.
The oligonucleotides used were as follows: NF-AT, 5' GGA GGA 
AAA ACT GTT TCA TAC AGA AGG CGT 3'; NF-kB, 5' AGT TGA 
GGG GAC TTT CCC AGG C 3'; and AP-1, 5' CGC AAG TGA CTC 
AGC GCG 3'.
Acidic sphingomyelinase assay
T cell blasts (6 X 106) were incubated for 1 h with either 1 mM chloroquine 
or a PBS vehicle control. Cells were then stimulated at 37°C for the indi­
cated time points with fixed B7 transfectants at a 1:3 ratio of transfectants 
to T cells. Reactions were stopped by immersion in liquid nitrogen and 
subsequently pelleted in a microfuge. Pellets were lysed in 200 fil o f 0.5% 
Nonidet P-40 (containing protease inhibitors as described above), and the 
supernatants were recovered. Protein (30-50 fig) was then incubated in a 
50-/U.1 reaction containing 250 mM sodium acetate and 1 mM EDTA, pH 
5.0, containing 1.1 pCi/ml (14C]sphingomyelin. After incubation for 2 h at 
37°C, the reaction was phase separated by the addition of 200 fil HzO and 
800 p.1 of chloroform/methanol (2/1). The aqueous phase was then mea­
sured by scintillation counting. The procedure at each time point was con­
ducted in triplicate, and the data were normalized relative to the zero time 
control as 100%. A minimum of three experiments were conducted in 
each case.
Results
CD28 stimulates proliferation in activated, but not resting, T 
cells
The requirement for CD28 costimulation in T cell activation has 
been established in numerous experiments, using both stimulatory 
and inhibitory reagents (1, 19, 20). In general, most investigations
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FIGURE t .  T cell blasts proliferate in response to B7 stimulation 
only. A, Purified peripheral blood T cells were stimulated with soluble  
anti-CD3 (mAb OKT3, 1 /xg/ml), alone or in the presence of glutaral- 
dehyde-fixed CHO or CHO-B7-transfected cells or with CHO-B7 cells 
alone in 96-w ell plates for 72 h. B, Day 8 SEA-T cell blasts were 
incubated in medium or with fixed CHO or CHO-B7 cells for 72 h. 
[3H|Thymidine (1 p,Ci/well) was added, and the cells w ere harvested 
after an additional 18 h. Proliferation was measured by scintillation 
counting.
have provided information on the requirements for CD28 costimu­
lation in initiating the proliferation in resting T cells, but little is 
known concerning the role played by CD28 in maintaining this 
response. We were interested in establishing whether CD28 stim­
ulation played a part in sustaining proliferation in normal T cells. 
Using transfectants expressing the CD28 ligand B7-1 (CD80) as a 
source of costimulation, we compared the effects of CD28 engage­
ment in both resting and activated T cells to determine whether 
CD28 ligation could further stimulate previously activated cells. 
Consistent with previous findings, we observed that CD28 co­
stimulation was absolutely required to achieve optimal prolifera­
tive responses to anti-CD3 Abs in resting T cells (Fig. 1A) and that 
neither anti-CD3 nor B7 stimulation alone was sufficient to stim­
ulate a response. In contrast, in experiments using T cells previ­
ously activated by superantigen stimulation (T cell blasts), a clear
B
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FIGURE 2. Kinetics of B7 responses in T cell blasts. SEA-stimulated 
T cell blasts were taken from culture at the the times shown post- 
antigenic stimulation, washed, and incubated in fresh medium alone 
(UNSTIM) in the presence of fixed CHO or CHO-B7 transfectants or 
with PMA (0.3 ng/ml) and ionomycin (1 /aM) for 24 h (P+l). Prolifer­
ation w as measured by [3H]thymidine incorporation (A). Aliquots of 
supernatant w ere removed from the proliferation cultures and ana­
lyzed for IL-2 by CTLL bioassay (B).
proliferative response was observed following CD28 stimulation 
alone (Fig. IB). This experiment demonstrated that CD28 was ca­
pable of transmitting proliferative signals to activated T cells, but 
not to T cells in a resting state. This finding was similar to that of 
Linsley et al., who also observed the ability of B7 to directly stim­
ulate PHA blasts (1). To determine whether these responses by T 
cell blasts were down-regulated as the T cells became more qui­
escent, responses were investigated at various time points follow­
ing antigenic stimulation. This experiment (Fig. 2) demonstrated 
that the response to B7 stimulation by activated T cells was de­
pendent upon the state of activation. Up to 8 days following an­
tigenic stimulation, CD28 engagement induced a substantial pro­
liferative response; however, as the cells became more quiescent, 
the CD28 response diminished, causing minimal proliferation by 
day 12 (Fig. 2A). In the course of these experiments we also ob­
served that by day 12 T cells were no longer responsive to either 
CD3 or CD28 alone and had reestablished the requirement for both 
signals to induce proliferation. This, therefore, established that 
substantial differences existed in the responses of resting and ac­
tivated T cells to CD28 engagement, but that these differences
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FIGURE 3. FACS analysis of  the T cell populations used. T cells were 
analyzed on day 0 (A), day 6 after SEA stimulation (B), and day 12 after 
stimulation (C) and stained for the markers shown.
w ere transient, and ultim ately, T  ce lls returned to having the ac­
tivation requirements o f  resting T  cells. In addition to investigating  
the proliferative response o f  B7-stim ulated T cell blasts, the effect 
on IL-2 production was studied. Surprisingly, w e w ere unable to 
detect any significant levels o f  IL-2 production in the B 7-stim u- 
lated T  cell blasts measured by CTLL bioassay (Fig. 2B)  despite 
the induction o f  substantial proliferation. To ensure that this lack 
o f  IL-2 production was not associated with either an incapacity to 
m ake IL-2 or a lack o f  cellular viab ility , T ce lls  w ere fully restim ­
ulated with PM A and ionom ycin and assessed  for both prolifera­
tion and IL-2 production on day 12 (Fig. 2, A and B ). S ince these 
responses were fully intact, our data suggested  that normal acti­
vated T  ce lls  could respond to C D 28 stim ulation in isolation for a 
period o f  tim e follow ing antigenic stim ulation, and that w hile this 
response was not characterized by significant IL-2 production, the 
cells  could  generate proliferative responses. N otably, both IL-2 
and proliferative responses could  readily be stim ulated by subse­
B
FIGURE 4. Detection of transcription factor com plexes in day 6 \ 
cell blasts. SEA-activated T cells were analyzed for the presence of 
NF-AT and AP-1 6 days following SEA stimulation. The cells were 
unstimulated (U), stimulated with PMA and ionomycin (P/I), or stim­
ulated with CHO-B7 expressing transfectants (B7). Nuclear extracts 
were prepared, and the com plexes w ere separated on a 5% acrvl 
am ide gel and visualized by autoradiography.
quent full activation, suggesting that a limited set o f  signals was 
provided by C D 28 under these conditions, which could  stim ulate 
proliferation but not the large am ounts o f  IL-2 seen when fully 
activating the cells.
The surface phenotype o f  the T ce lls used in these experim ents 
w as also established by FACS analysis at various lim e points 
T hese data (Fig. 3) show ed that the resting T ce lls w ere predom ­
inately C D 3 ' C D 25 and H L A -D R  (Fig. 3 A ). consistent with 
their resting status. In contrast, activation with superantigens re­
sulted in a significant up-regulation m easured on day 6 o f  C D 2. 
C D 25 , and H LA -D R  m olecu les, as expected  (Fig. 3 B).  and by day 
12, as the ce lls  becam e more quiescent, it w'as evident that acti­
vation markers, in particular C D 25, w ere dow n-regulated (Fig  
3C ). In addition to these markers, w e exam ined T cells for the 
presence o f  C T L A -4 and C D 80 expression , but we did not detect 
either o f  these markers on our activated T cells.
C D 28 stim ulation directly results in the generation o f  NF-k B 
and  AP-1, but not NF-AT
F ollow in g  the observation that B7 engagem ent w as sufficient to 
stim ulate proliferation in T  cell blasts, w e sought to establish  
w hich signaling events, such as the generation o f  transcription fac­
tor com p lexes, might be involved . W e, therefore, m easured the 
induction o f  transcription factors known to be important in T cell 
proliferation (N F-A T . A P-1, and N F -kB) using electrophoretic 
m obility  shift assays (gel shift assays). T hese experim ents revealed  
a number o f  interesting features. Initially, w e noted that our T cell 
blasts w ere highly active (up to day 6, as evidenced  by prolifera­
tion assays), and that there w ere high levels o f  transcription fac­
tors, including N F-A T  and A P -1, found in T cell blasts at this time, 
m aking m easurem ent o f  responses to B7 stim ulation difficult (Fig  
4). At these early time points, w e were unable to detect increases 
in transcription factors in response to either PMA and ionom ycin
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FIGURE 5. Induction of transcription factors in su 
per antigen and B7-stimulated T cell blasts. Day 10 
SEA F cell blasts were stimulated with fixed CHO 
< rlls. CHO DR4 cells, or CHO-DR4/B7 cells pulsed 
with SEA or CHO-B7 cells alone for 4 h Nuclear 
extracts were prepared and incubated with ' P la­
beled oligonucleotides representing consensus NF 
Ar. AP-1, and NF-kB binding sites. Com plexes were 
separated on a 5% acrylamide gel and visualized bv 
autoradiography
m xviih B7. Therefore, to study the induction of transcription fac­
to rs  in response to B7 stim ulation, w e allow ed the I ce lls to qui 
e s c e  further, and experim ents were routinely performed on day 10 
post-SE A  stim ulation. By using T cell blasts at later time points, 
we observed substantially lower levels o f  transcription factors in 
unsiim ulated cells
At these later time points (Fig. 5). w e observed that stim ulation  
nl 1 cells with either D R -4 or D R 4-B 7 transfectants pulsed with 
SEA resulted in substantial up-regulation o f  all three factors m ea­
sured (N F-A T, A P-1. and N F-kB ). Firstly, this clearly dem on­
strated a requirement for TCR stim ulation in the induction o f  
N F-A T in this system , and furthermore, m easurem ents o f  IL-2 
production from the sam e experim ent (Fig. 6) show ed a strong 
correlation between the ability o f  T  ce lls to make IL-2 and the 
induction o f  NF-AT. Thus, superantigen stim ulation o f  the TCR  
alone was sufficient to induce both proliferation and 1 1 2  produc­
tion in T cell blasts. H ow ever, C D 28 costim ulation in addition to 
superantigen stim ulation considerably augm ented IL-2 production, 
dem onstrating that additional costim ulation had indeed occurred.
In addition to the above events, w e observed that T ce lls  chal­
lenged with B 7-expressing transfectants alone responded by the 
up-regulation o f  both AP I and N F -kB; how ever, stim ulation by 
B7 alone did not stim ulate the generation o f  either N F -A T  or IL-2. 
These data dem onstrated that N F -k B and AP I were downstream  
targets o f C D 28 stim ulation and that w hile these transcription fac­
tors were not exclu sive  to C D 28 signaling. N F -kB and AP-1 were 
significant targets o f  C D 28 signaling. Furthermore, our data co n ­
firmed previous observations on the involvem ent o f  TCR pathways 
in the induction o f  N F-A T  and IL-2.
C D  28  signaling  in v o lv e s  b o th  PIJK a n d  a c id ic  
s p h in g o m y e lin a se  a c tiv a tio n
T w o pathways that have been suggested  to be involved  in C D 28  
signaling are those via PI3K and acid ic sph ingom yelinase W e,
therefore, sought to establish w bother either o f  these pathw ays w as 
being used fo llow ing B7 stim ulation o f  the T cell blasts. W e have 
previously  dem onstrated that in response to B7 stim ulation. PI3K  
is both recruited and activated by C D 28 (5): using a sim ilar ap­
proach in this system , we observed that B7 stim ulation resulted in 
PI3K recruitment by C D2S (data not show n). To establish whether 
C D 2 8  stim ulation could a lso  activate the acidic sphingom yelinase  
pathw ay in T cell blasts, as previously reported, the effect o f  B7 
stim ulation on this pathway wav also measured (Fig. 1) This anal 
y sis revealed that fo llow ing B7 engagem ent there was a rapid el 
e  vat ion in sphingom yelinase activity in B 7 -stim ulated, but not 
control, lysates, indicating that C D 28 ligation in these T cell blasts 
could  lead to the activation o f  sphingom yelinase activity Further 
m ore, this activity could be inhibited by the use o f  chloroquine. 
w hich  is reported to inhibit the activation o f  acidic sphingom y e l i ­
nase. Thus, w e had evidence that both P13K and acidic sph ingo­
m yelinase pathways were being activated fo llow in g  the en gage­
m ent o f  C D 28 in isolation in our T cell blasts.
H aving demonstrated that both acidic sphingom yelinase and 
PI3K  pathw ays were activated by C D 28 in the absence o f  TCR  
engagem ent, gel shift experim ents were performed using ch loro­
quine and wortmannin to investigate whether these pathw ays were 
invo lved  in N F-kB and AP I generation. These results revealed  
that pretreatment o f  the T cell blasts with wortmannin produced  
substantial, but not com plete, inhibition o f  AP I generation (Fig  
8A ). In addition, in som e experim ents chloroquine had an effect on 
AP-1 induction, but this effect varied betw een cultures (com pare 
Fig. 8, A and B ), raising the possibility  that AP I may be a d ow n ­
stream target o f  both PI3K and acidic sph ingom yelinase pathways. 
In contrast, N F-kB induction was not inhibited by wortm annin. in 
fact, it show ed a slight increase com pared with that in the B7 
control. T his observation is interesting in light o f  the fact that 
wortm annin has been suggested to result in increased IL-2 pro­
duction  from som e T cells i 2 11. and this may be on e possib le
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FIGURE 6. Corresponding IL-2 production in T cell blasts stimulated 
as shown lor the gel shift assay (Fig. 5). Stimulated cell aliquots (5 x 
104) w ere removed before preparation of the nuclear extracts and in­
cubated in 96-well plates for an additional 24 h. Supernatants were 
removed, and IL-2 production was assessed by CTLL assay
FIGURE 8. Effects of wortmannin and chloroquine on B7-induced 
transcription factor generation. Day 10 T cell blasts were incubated in 
medium alone or in the presence of wortmannin (100 nM) or chloro­
quine (50 /xM) for 1 h before a 4-h stimulation with fixed CHO or 
CHO-B7 transt'ectants. Nuclear extracts were prepared and analyzed 
for AP-1 -binding activity in two different experiments (A and B).
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FIGURE 7. Effect of chloroquine on acidic sphingom yelinase activ­
ity in B7-stimulated T cell blasts. Day 10 T cell blasts were preincu­
bated for 1 h in medium (closed symbols) or with 1 mM chloroquine 
(open symbols). After washing, the cells were stimulated with fixed 
CHO (triangles) or CHO-B7 (squares) cells for the time specified. Cy­
toplasmic cell extracts were prepared and analyzed for enzymatic ac­
tivity on [‘JC|sphingomyelin. Results are shown as the percentage of 
activity at time zero.
FIGURE 9. Etfects of wortmannin and chloroquine on NF-kB. Day 
10 SEA blasts were treated with 100 nM wortmannin (B7 + W) or 50 
/xM chloroquine (B7 + CQ) for 1 h before a 4-h stimulation with fixed 
CHO or CHO-B7 transfectants. Nuclear extracts were prepared and 
analyzed as described in M aterials and  M ethods.
m echanism . In contrast, chloroquine com p letely  inhibited the in­
duction of N F -kB in response to C D 28 stim ulation (Fig. 9), pro­
viding a strong indication that C D 28 induction o f  N F -kB may be 
m ediated via acidic sph ingom yelinase.
O verall, therefore, these results suggested  that both the PI3K 
and acidic sphingom yelinase pathways w ere activated by C D 28  
stim ulation, and inhibition o f  either o f  these pathways could  affect 
the generation o f  N F -kB and AP I transcription factor com plexes.
Discussion
C D 28  costim ulation is a critical event in T  ce ll activation. In its 
absence, resting T cells do not fully enter the ce ll cy c le  or prolif­
erate in response to TCR engagem ent, and T  ce lls  may enter either 
anergic or apoptotic states (2 2 -2 4 ) . W e have studied a system  in 
w hich activated T cells w ere found to be responsive to C D 28 stim ­
ulation alone, and we have used this system  to better characterize
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CD28 signals as distinct from those provided by TCR stimuli or 
mitogenic agents. The proliferative effects of B7 (CD80) stimula­
tion were detectable in T cell blasts up to 8 days following anti­
genic challenge. This response was not due to the persistence of 
TCR stimulation by Ag in our cultures, since we were unable to 
observe either NF-AT or IL-2 production in response to B7 alone, 
whereas both were demonstrable following TCR engagement with 
superantigen. This indicated that the signals arising from the CD28 
ligation resulted directly in the generation of the transcription fac­
tors AP-1 and NF-kB.
The observation that generation of NF-AT required TCR en­
gagement and correlated with the production of IL-2 suggests that 
this model of T cell stimulation is compatible with that in previous 
studies (25, 26) and confirms the critical role of TCR stimulation 
in EL-2 production. Somewhat surprisingly, NF-AT, IL-2 produc­
tion, and proliferation were observed in experiments using DR4- 
SEA complexes alone, in contrast to our experience of prolifera­
tive responses to anti-CD3 that require CD28 costimulation. Taken 
in conjunction with the observation that MHC-superantigen com­
plexes can also stimulate proliferation in resting T cells (19), this 
indicates that superantigens may be more capable of providing 
costimulatory signals, in line with previous suggestions (27). Fur­
thermore, the up-regulation of both NF-kB and AP-1 by DR4-SEA 
stimulation implies activation of costimulatory pathways, since ac­
tivation of these factors has been linked to ceramide (14) and JNK 
pathways (28), neither of which results directly from TCR stimu­
lation alone, and both of which can now be linked to costimulatory 
pathways such as CD28.
The present data also confirm that considerable differences exist 
in the interpretation of CD28 signals by resting and activated T 
cells. In particular, while CD28 ligation alone is capable of stim­
ulating proliferation in activated T cells, this response is not ob­
served in resting cells despite the fact that both PI3K and acidic 
sphingomyelinase interactions have been observed (5,6). This pre­
sumably indicates that in resting T cells the pathways activated by 
the TCR are critical in allowing proliferation to proceed, and these 
pathways remain open in activated T cells for some time, thus 
allowing CD28 signals to induce proliferation. Perhaps more sur­
prisingly, we also noted that B7-induced proliferation in T cell 
blasts was not associated with IL-2 production. This is in contrast 
to the significant amounts of IL-2 observed following CD28 co­
stimulation of the TCR and indicates that IL-2 production is strin­
gently regulated and correlates well with NF-AT production. Fur­
thermore, our data indicate that T cells can respond by 
proliferation in the absence of detectable EL-2 when given subop- 
timal stimuli such as CD28 alone. However, we did observe a 
B7-dependent increase in IL-2 output when T cells were stimu­
lated with DR4/B7-SEA compared with DR4-SEA, demonstrating 
that costimulation was provided by B7 in these circumstances. 
Since transcription factor levels induced by DR4/B7-SEA com­
pared with those induced by DR4-SEA were indistinguishable, the 
additional IL-2 production observed in the presence of B7 may, 
therefore, reflect increased transcriptional activity or mRNA sta­
bilization by CD28, as has been reported previously (17).
One transcription factor complex reported to be induced by 
CD28 is the CD28 response complex (CD28RC) (18), which binds 
to a conserved DNA sequence within the IL-2 promoter. More 
recent investigations of this complex, however, have shown that it 
can be induced in the absence of CD28 receptor engagement by 
mitogenic agents (29), and that the complex comprises members of 
the Rel family of NF-KB-related proteins (30, 31). Consistent with 
this is the fact that in the presence of PMA, CD28 has been re­
ported to have an effect on NF-kB induction via the down-regu- 
lation of its cytoplasmic inhibitor, I k B  (29, 32). Our data are con­
sistent with these reports, in that we found NF-kB to be a target of 
CD28 costimulation. Furthermore, this response was sensitive to 
inhibition by chloroquine, but not by wortmannin, indicating that 
NF-kB may be primarily downstream of acidic sphingomyelinase 
in CD28 signaling. In line with this finding, previous reports have 
shown that other receptors, such as TNF, that activate sphingomy­
elinase can also induce NF-kB (6, 7).
We have also identified AP-1 as a downstream target of CD28 
signaling. AP-1 generation has previously been shown to involve 
the activation of c-jun kinase (JNK) following TCR and CD28 
receptor stimulation (28). However, while Su et al. demonstrated a 
requirement for both TCR and CD28 signals in JNK activation, our 
observation that CD28 could induce AP-1 activity in the absence 
of TCR engagement may be explained by the fact that our work 
was performed in activated T cell blasts compared with Jurkat 
cells. Currently, the receptor proximal events that are triggered by 
CD28 in the activation of JNK are unclear. However, since the 
acidic sphingomyelinase and PDK pathways have both been 
shown to be associated with CD28 signaling, the involvement of 
one or possibly both of these pathways is implicated in the CD28- 
mediated activation of JNK.
Previously, we identified activation of the PDK pathway in re­
sponse to CD28 engagement (5). However, while recruitment and 
activation of this enzyme by CD28 are unequivocal, there are dis­
crepancies concerning the importance of this pathway in stimulat­
ing IL-2 production (5, 33,34). In resting T cells, blocking of PDK 
activity by wortmannin results in inhibition of both proliferation 
and IL-2 production, whereas in activated cells such as Jurkat 
cells, no inhibition is seen, and there may be an increase in IL-2 
output (21), implying a negative regulatory role for PDK. Further­
more, while PDK has been suggested to be involved in the induc­
tion of JNK and AP-1 via the small GTPases, Racl and Cdc42 (35, 
36), the inability of wortmannin to completely inhibit AP-1 induc­
tion in our studies indicates that additional pathways may be in­
volved. Interestingly, we also observed during these studies that 
chloroquine had variable inhibitory effects on AP-1 expression, 
raising the possibility that activation of acidic sphingomyelinase 
provides an alternative route to AP-1 following CD28 stimulation 
in some circumstances. This possibility would explain the inability 
of wortmannin to completely inhibit AP-1 generation as well as the 
effects of chloroquine on AP-1. Furthermore, such a hypothesis is 
consistent with data indicating that other receptors linked to acidic 
sphingomyelinase/ceramide pathways, including TNF, can acti­
vate JNK (13, 37).
Since it appears that both AP-1 and NF-kB might be activated 
via the acidic sphingomyelinase pathway, what then is the role of 
PDK? Recent reports have implicated PDK in the activation of the 
signaling molecule PKB (38) and the cell cycle regulator S6 kinase 
(39). Interestingly, S6 kinase has also been shown to be activated 
by CD28 and is wortmannin sensitive. Thus, one major role for 
PDK may be in the promotion of cell cycle progression or, pos­
sibly, T cell survival. Evidence that PDK may prevent apoptosis 
has been suggested in other cell systems (40) and may play a role 
in T cells. This would be consistent with the functional role of 
CD28 in preventing anergy and apoptosis in response to TCR en­
gagement (23, 41).
The requirement for CD28 in the activation of T cells has been 
repeatedly demonstrated; however, the signals that mediate these 
effects are less well defined. The present studies indicate that both 
AP-1 and NF-kB are direct targets for CD28 signals and that both 
PDK and acidic sphingomyelinase activation are involved in their 
generation. While it is likely that there are other effects mediated 
by the recruitment of tyrosine kinases to CD28, such as lek, fyn,
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and itk (42-44), our data establish an important role for both acidic 
sphingomyelinase and PI3K in CD28 signaling.
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